<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002823.pub2" GROUP_ID="MUSKEL" ID="574500020411102040" MERGED_FROM="" MODIFIED="2009-11-12 14:08:16 +0100" MODIFIED_BY="Elizabeth Tanjong Ghogomu" REVIEW_NO="C094-R" REVMAN_SUB_VERSION="5.0.22" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.2">
<COVER_SHEET MODIFIED="2009-11-12 08:04:33 -0500" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-02-20 11:38:26 -0500" MODIFIED_BY="[Empty name]">Transcutaneous electrostimulation for osteoarthritis of the knee</TITLE>
<CONTACT>
<PERSON ID="55AAB96B82E26AA2000F11BC5E70C1F3" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Anne</FIRST_NAME>
<MIDDLE_INITIALS>WS</MIDDLE_INITIALS>
<LAST_NAME>Rutjes</LAST_NAME>
<SUFFIX/>
<POSITION>Senior research fellow</POSITION>
<EMAIL_1>arutjes@ispm.unibe.ch</EMAIL_1>
<EMAIL_2>a.rutjes@crc-cesi.org</EMAIL_2>
<URL>http://www.ispm.ch/ and http://www.crc-cesi.org/</URL>
<MOBILE_PHONE>+39 389 999 36 50</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Finkenhubelweg 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP>3012</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 (0)31 631 33 28</PHONE_1>
<PHONE_2>+39 389 999 36 50</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2009-11-12 08:03:35 -0500" MODIFIED_BY="Elizabeth Tanjong Ghogomu">
<PERSON ID="55AAB96B82E26AA2000F11BC5E70C1F3" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Anne</FIRST_NAME>
<MIDDLE_INITIALS>WS</MIDDLE_INITIALS>
<LAST_NAME>Rutjes</LAST_NAME>
<SUFFIX/>
<POSITION>Senior research fellow</POSITION>
<EMAIL_1>arutjes@ispm.unibe.ch</EMAIL_1>
<EMAIL_2>a.rutjes@crc-cesi.org</EMAIL_2>
<URL>http://www.ispm.ch/ and http://www.crc-cesi.org/</URL>
<MOBILE_PHONE>+39 389 999 36 50</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Finkenhubelweg 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP>3012</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 (0)31 631 33 28</PHONE_1>
<PHONE_2>+39 389 999 36 50</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6701E84582E26AA201880571E7219167" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Eveline</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Nüesch</LAST_NAME>
<SUFFIX/>
<POSITION>Research Fellow</POSITION>
<EMAIL_1>enueesch@ispm.unibe.ch</EMAIL_1>
<EMAIL_2/>
<URL>www.ispm.unibe.ch</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Finkenhubelweg 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP>3012</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 (0) 31 631 33 28</PHONE_1>
<PHONE_2/>
<FAX_1>+ 41 (0) 31 631 35 20</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="E4898B6082E26AA200F94DADC4F681AF" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Rebekka</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Sterchi</LAST_NAME>
<SUFFIX/>
<POSITION>Research Fellow</POSITION>
<EMAIL_1>rsterchi@ispm.unibe.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Finkenhubelweg 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP>3012</ZIP>
<REGION>Bern</REGION>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 31 631 33 28</PHONE_1>
<PHONE_2/>
<FAX_1>+41 31 301 90 10</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="BA1D422982E26AA2016BE8A0F243D18C" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Leonid</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Kalichman</LAST_NAME>
<SUFFIX/>
<POSITION>Senior lecturer</POSITION>
<EMAIL_1>kalihman@zahav.net.il</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Physical Therapy, Recanati School for Community Health Professions, Faculty of Health Sciences</DEPARTMENT>
<ORGANISATION>Ben-Gurion University of the Negev</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Beer Sheva</CITY>
<ZIP>84105</ZIP>
<REGION/>
<COUNTRY CODE="IL">Israel</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14227" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Erik</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hendriks</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>erik.hendriks@epid.unimaas.nl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Epidemiology Department</DEPARTMENT>
<ORGANISATION>Maastricht University</ORGANISATION>
<ADDRESS_1>P.O. Box 616</ADDRESS_1>
<ADDRESS_2/>
<CITY>Maastricht</CITY>
<ZIP>NL-6200 MD</ZIP>
<REGION/>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<PHONE_1>+31 43 3881428</PHONE_1>
<PHONE_2/>
<FAX_1>+31 43 3884128</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14977" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Manathip</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Osiri</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor, Division of Rheumatology</POSITION>
<EMAIL_1>Manathip.O@chula.ac.th</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>Faculty of Medicine</ORGANISATION>
<ADDRESS_1>Chulalongkorn University</ADDRESS_1>
<ADDRESS_2>1873 Rama IV Road, Pathumwan</ADDRESS_2>
<CITY>Bangkok</CITY>
<ZIP>10330</ZIP>
<REGION/>
<COUNTRY CODE="TH">Thailand</COUNTRY>
<PHONE_1>+662-256-4526 ext: 14</PHONE_1>
<PHONE_2/>
<FAX_1>+662-252-8467</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="9058" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Lucie</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Brosseau</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor</POSITION>
<EMAIL_1>Lucie.Brosseau@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Rehabilitation Sciences, Faculty of Health Sciences</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>451 Smyth Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1H 8M5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613-562-5800 ext: 8015</PHONE_1>
<PHONE_2/>
<FAX_1>+1 613-562-5428</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="BA21A0D082E26AA2016BE8A0E778565A" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Stephan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Reichenbach</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Research Associate</POSITION>
<EMAIL_1>rbach@ispm.unibe.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department for Rheumatology, Clinical Immunology, and Allergology</DEPARTMENT>
<ORGANISATION>University Hospital</ORGANISATION>
<ADDRESS_1>Inselspital</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+1 617-418-3368</PHONE_1>
<PHONE_2>+41 31 631 33 78</PHONE_2>
<FAX_1>+41 31 631 35 20</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="10779" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Jüni</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>Head of Division</POSITION>
<EMAIL_1>juni@ispm.unibe.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Finkenhubelweg 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 31 631 33 78</PHONE_1>
<PHONE_2/>
<FAX_1>+41 31 631 35 20</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2009-10-08 06:35:28 -0400" MODIFIED_BY="Anne Rutjes">
<UP_TO_DATE>
<DATE DAY="2" MONTH="2" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="5" MONTH="8" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="7" MONTH="10" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2009-11-12 08:04:33 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-10-08 09:41:25 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="10" YEAR="2009"/>
<DESCRIPTION>
<P>Number needed to treat for function were corrected</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-07-02 05:58:55 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>CMSG ID C094-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-11-12 08:04:33 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-11-12 08:04:33 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="7" YEAR="2009"/>
<DESCRIPTION>
<P>14 additional trials included</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2009-11-12 08:04:26 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="7" YEAR="2009"/>
<DESCRIPTION>
<P>Change in authors and conclusions. Updated search and wider selection criteria, which resulted in 14 additional trials; more detailed quality assessment of component trials; exclusion of results from cross-over trials if treatment phases could not be distinguished; use of end of trial estimates to calculate SMDs; detailed exploration of sources of variation between trials, including concealment of allocation, blinding, intention-to-treat analysis, characteristics of electrostimulation, and investigations of funnel plots; use of a random-effects model.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-08-04 07:25:31 -0400" MODIFIED_BY="Jenny Bellorini">
<DATE DAY="30" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-12-22 06:43:39 -0500" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2008-12-22 06:42:56 -0500" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-12-22 06:42:56 -0500" MODIFIED_BY="[Empty name]">
<NAME>Institute of Social and Preventive Medicine, University or Bern</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION>
<P>Intramural grants</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2008-12-22 06:43:39 -0500" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-12-22 06:43:39 -0500" MODIFIED_BY="[Empty name]">
<NAME>Swiss National Science Foundation</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION>
<P>National Research Program 53 on musculoskeletal health (grant numbers 4053-40-104762/3 and 3200-066378)</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-10-08 09:42:18 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-10-08 09:08:08 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-08-12 15:12:40 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;From Hulme review, need to check whether still applies&lt;/p&gt;" NOTES_MODIFIED="2009-08-12 15:12:40 -0400" NOTES_MODIFIED_BY="[Empty name]">Transcutaneous electrostimulation for osteoarthritis of the knee</TITLE>
<SUMMARY_BODY MODIFIED="2009-10-08 09:08:08 -0400" MODIFIED_BY="[Empty name]">
<P>This summary of a Cochrane review presents what we know from research about the effect of transcutaneous electrostimulation on osteoarthritis of the knee.</P>
<P>
<B>The review shows that in people with osteoarthritis:</B>
</P>
<P>- We are uncertain whether transcutaneous electrostimulation affects pain or your ability to use your knee because of the very low quality of the evidence.  <BR/>- Transcutaneous electrostimulation may not have any side effects. We often do not have precise information about side effects and complications. This is particularly true for rare but serious side effects. </P>
<P>
<B> </B>
</P>
<P>
<B>What is osteoarthritis and what is transcutaneous electrostimulation?</B>
</P>
<P>Osteoarthritis (OA) is a disease of the joints, such as your knee. When the joint loses cartilage, the bone grows to try and repair the damage. Instead of making things better, however, the bone grows abnormally and makes things worse. For example, the bone can become misshapen and make the joint painful and unstable.  This can affect your physical function or ability to use your knee.<BR/>
<BR/>
</P>
<P>Transcutaneous electrostimulation, such as TENS, is a kind of pain relief typically using electrical currents applied to the skin. Transcutaneous electrostimulation machines are typically small, battery-operated machines with 2 electrodes attached.  Electrodes are wires that send the electrical current.  Usually, you connect two electrodes from the machine to your skin on the painful area. Your doctor or physiotherapist will show you how to use it, and most machines can be used at home.</P>
<P> </P>
<P>
<B>Best estimate of what happens to people with osteoarthritis who use transcutaneous electrostimulation up to 4 weeks after using it:</B>
</P>
<P>
<B>Pain</B>
</P>
<P>- People who used electrostimulation had an improvement in their pain of about 2 on a scale from 0 (no pain) to 10 (extreme pain) 4 weeks after using it.</P>
<P>- People who used a fake electrostimulation machine or just took their usual treatments had an improvement in their pain of about 2 on a scale from 0 (no pain) to 10 (extreme pain) 4 weeks after using it.</P>
<P>- People had no more average improvement when using electrostimulation, and no more people responded to treatment with electrostimulation compared with people who used a fake electrostimulation machine or just took their usual treatments (difference of 0%).</P>
<P> </P>
<P>
<B>Physical Function</B>
</P>
<P>- People who used electrostimulation had an improvement in their physical function of about 2 on a scale from 0 (no disability) to 10 (extreme disability) 4 weeks after using it.</P>
<P>- People who used a fake electrostimulation machine or just took their usual treatments had an improvement in their physical function of about 1 on a scale from 0 (no disability) to 10 (extreme disability) 4 weeks after using it.</P>
<P>- People using electrostimulation had 1 unit more improvement in their knee function when compared to people who used a fake electrostimulation machine or just took their usual treatments.</P>
<P>Another way of saying this is:</P>
<P>- 29 people out of 100 who used electrostimulation respond to treatment (29%).</P>
<P>- 26 people out of 100 who used a fake electrostimulation machine or just took their usual treatments respond to treatment (26%).</P>
<P>- 3 more people respond to treatment with electrostimulation compared with people who used a fake electrostimulation machine or just took their usual treatments (difference of 3%).</P>
<P>
<B> </B>
</P>
<P>
<B>Dropouts or withdrawals from the trial because of side effects</B>
</P>
<P>- 2 people out of 100 who used electrostimulation dropped out or withdrew from the trial because of side effects (2%).</P>
<P>- 2 people out of 100 who used a fake electrostimulation machine or just took their usual treatments dropped out of the trial because of side effects (2%).</P>
<P>- There was no difference in the number of people who dropped out of the trial because of side effects (difference of 0%). This could be the result of chance.</P>
<P>
<B> </B>
</P>
<P>
<B>Side effects</B>
</P>
<P>- 15 people out of 100 who used electrostimulation experienced side effects (15%).</P>
<P>- 15 people out of 100 who used a fake electrostimulation machine or just took their usual treatments experienced side effects (15%).</P>
<P>- There was no difference in the number of people who experience side effects (difference of 0%). This could be the result of chance.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-08-12 15:12:38 -0400" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-08-12 15:12:19 -0400" MODIFIED_BY="[Empty name]">
<P>Osteoarthritis is the most common form of joint disease and the leading cause of pain and physical disability in the elderly. Transcutaneous electrical nerve stimulation (TENS), interferential current stimulation and pulsed electrostimulation are used widely to control both acute and chronic pain arising from several conditions, but some policy makers regard efficacy evidence as insufficient.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-08-12 15:12:21 -0400" MODIFIED_BY="[Empty name]">
<P>To compare transcutaneous electrostimulation with sham or no specific intervention in terms of effects on pain and withdrawals due to adverse events in patients with knee osteoarthritis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-08-12 15:12:25 -0400" MODIFIED_BY="[Empty name]">
<P>We updated the search in CENTRAL, MEDLINE, EMBASE, CINAHL and PEDro up to 5 August 2008, checked conference proceedings and reference lists, and contacted authors.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-08-12 15:12:28 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised or quasi-randomised controlled trials that compared transcutaneously applied electrostimulation with a sham intervention or no intervention in patients with osteoarthritis of the knee. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-08-12 14:21:16 -0400" MODIFIED_BY="[Empty name]">
<P>We extracted data using standardised forms and contacted investigators to obtain missing outcome information. Main outcomes were pain and withdrawals or dropouts due to adverse events. We calculated standardised mean differences (SMDs) for pain and relative risks for safety outcomes and used inverse-variance random-effects meta-analysis. The analysis of pain was based on predicted estimates from meta-regression using the standard error as explanatory variable.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-08-12 15:12:38 -0400" MODIFIED_BY="[Empty name]">
<P>In this update we identified 14 additional trials resulting in the inclusion of 18 small trials in 813 patients. Eleven trials used TENS, four interferential current stimulation, one both TENS and interferential current stimulation, and two pulsed electrostimulation. The methodological quality and the quality of reporting was poor and a high degree of heterogeneity among the trials (I<SUP>2</SUP> = 80%) was revealed. The funnel plot for pain was asymmetrical (P &lt; 0.001). The predicted SMD of pain intensity in trials as large as the largest trial was -0.07 (95% CI -0.46 to 0.32), corresponding to a difference in pain scores between electrostimulation and control of 0.2 cm on a 10 cm visual analogue scale. There was little evidence that SMDs differed on the type of electrostimulation (P = 0.94). The relative risk of being withdrawn or dropping out due to adverse events was 0.97 (95% CI 0.2 to 6.0).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-08-12 14:27:34 -0400" MODIFIED_BY="[Empty name]">
<P>In this update, we could not confirm that transcutaneous electrostimulation is effective for pain relief. The current systematic review is inconclusive, hampered by the inclusion of only small trials of questionable quality. Appropriately designed trials of adequate power are warranted.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-10-08 09:42:18 -0400" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-08-12 15:13:26 -0400" MODIFIED_BY="[Empty name]">
<P>Osteoarthritis is an age-related condition, occurring more frequently in women than in men. Its prevalence, causal associations and outcomes vary markedly according to the joint site affected (<LINK REF="REF-J_x00fc_ni-2006" TYPE="REFERENCE">Jüni 2006</LINK>). Osteoarthritis is characterised by focal areas of loss of articular cartilage in synovial joints, accompanied by subchondral bone changes, osteophyte formation at the joint margins, thickening of the joint capsule and mild synovitis (<LINK REF="REF-Solomon-1997" TYPE="REFERENCE">Solomon 1997</LINK>). The objectives of management of knee osteoarthritis are to relieve pain and to maintain or improve function. Different modalities in physiotherapy have been suggested to improve the clinical course of knee osteoarthritis, with potentially fewer adverse effects than medical treatment (<LINK REF="REF-Bjordal-2007" TYPE="REFERENCE">Bjordal 2007</LINK>; <LINK REF="REF-Jamtvedt-2008" TYPE="REFERENCE">Jamtvedt 2008</LINK>), but some policy makers consider the evidence for effectiveness to be insufficient (<LINK REF="REF-Gezondheidsraad-1999" TYPE="REFERENCE">Gezondheidsraad 1999</LINK>).</P>
<P>Transcutaneous electrostimulation, the application of any electrical current through the skin with the aim of pain modulation, is a frequently used modality in knee osteoarthritis (<LINK REF="REF-Carroll-2001" TYPE="REFERENCE">Carroll 2001</LINK>; <LINK REF="REF-Osiri-2000" TYPE="REFERENCE">Osiri 2000</LINK>). It is based on the 'Gate-Control Theory' of pain perception as described by Melzack and Wall (<LINK REF="REF-Melzack-1965" TYPE="REFERENCE">Melzack 1965</LINK>). The theory suggests that the stimulation of large diameter, (A-beta) primary sensory afferent cutaneous fibres activates inhibitory interneurons in the spinal cord dorsal horn and, thereby, may attenuate the transmission of nociceptive signals from small diameter A-delta and C fibres. Other suggested mechanisms include a stimulation of &#946; endorphin production (<LINK REF="REF-Andersson-1976" TYPE="REFERENCE">Andersson 1976</LINK>; <LINK REF="STD-Grimmer-1992" TYPE="STUDY">Grimmer 1992</LINK>; <LINK REF="REF-Mayer-1989" TYPE="REFERENCE">Mayer 1989</LINK>) and even the potential for articular cartilage repair (<LINK REF="STD-Fary-2008" TYPE="STUDY">Fary 2008</LINK>; <LINK REF="REF-Haddad-2007" TYPE="REFERENCE">Haddad 2007</LINK>).</P>
<P>Several types of electrostimulation are available. Conventional transcutaneous electrical nerve stimulation (TENS), in its narrow sense, uses moderate to high frequency current of 40 to 150 Hz and 50 to 100 µsec pulse width, typically at a low intensity, to stimulate sensory fibres. Several other types of TENS were subsequently developed, which differ in intensity, pulse width or frequency. Acupuncture-like TENS (AL TENS) uses a low frequency current of 0.5 to 10 Hz and a pulse width of &gt; 150 µsec at a high intensity to stimulate both motor and sensory fibres. The stimulation may be painful, and the intensity of the current will depend on the patient's individual pain tolerance. Burst TENS was developed to minimise patients' discomfort, as experienced with AL TENS. It uses short bursts of high frequency current of typically 80 to 100 Hz, which are repetitively applied at low intensity and a burst frequency of around 5 Hz, to stimulate motor and sensory fibres. The intensity used is slightly higher than used with conventional TENS. Brief TENS uses a high frequency current of more than 100 Hz and 150 to 250 µsec pulse width at the maximal intensity tolerated by the patient to stimulate not only motor and sensory, but also nociceptor fibres. Modulation TENS combines several of the modalities above, typically using alternations of low and high frequency currents (<LINK REF="REF-Brosseau-2004" TYPE="REFERENCE">Brosseau 2004</LINK>; <LINK REF="REF-Sluka-2003" TYPE="REFERENCE">Sluka 2003</LINK>). Classical interferential current stimulation simultaneously uses two non-modulated biphasic pulsed currents applied with two sets of electrodes with four electrical poles; one current is fixed at approximately 4000 Hz and the other ranging typically from 4000 to 4100 Hz. The superimposition of the two currents results in a new frequency with a range from 1 to 100 Hz (<LINK REF="REF-Wadsworth-1980" TYPE="REFERENCE">Wadsworth 1980</LINK>). Modulated interferential current stimulation uses directed currents between two electrical poles and vectorially sums currents in the tissue, with a carrier frequency typically set at 4000 Hz, a beat frequency at 80 Hz, and a modulation frequency set between 0 to 150 Hz. The effective frequency is defined by the sum of beat and modulation frequency and varies between 80 and 230 Hz. The high frequency of the carrier currents in inferential current stimulation leads to a considerably lower impedance of skin and subcutaneous tissue as compared with conventional TENS and minimises patients' discomfort. Lastly, pulsed electrostimulation applies high frequency current of 100 Hz and a pulse width of 640 to 1800 µsec, typically using knee garments with flexible, embedded electrodes and a small battery-operated generator, allowing application times of several hours rather than 15 to 60 minutes, as is the case for any other of the modalities described above.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-08-12 15:13:28 -0400" MODIFIED_BY="[Empty name]">
<P>We set out to compare transcutaneous electrostimulation with sham or no specific intervention in terms of effects on pain and function and safety outcomes in patients with knee osteoarthritis and to explore whether potential variation between trials could be explained by characteristics of the electrostimulation, by biases affecting individual trials or by publication bias.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-08-12 16:03:47 -0400" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-08-12 15:13:56 -0400" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-08-12 15:13:31 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised or quasi-randomised controlled trials with a control group receiving a sham intervention or no intervention. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-08-12 15:13:32 -0400" MODIFIED_BY="[Empty name]">
<P>Studies including at least 75% of patients with clinically and/or radiologically confirmed osteoarthritis of the knee.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-08-12 15:13:34 -0400" MODIFIED_BY="[Empty name]">
<P>Any type of transcutaneous electrostimulation with electrodes set to stimulate nerves supplying the knee joint area aiming at pain relief. We did not consider transcutaneous electrostimulation aiming at muscle strength enhancement, such as neuromuscular electrostimulation, and electrostimulation not directly aimed at stimulating nerves of the knee joint area, such as transcranial applications or transcutaneous spinal electroanalgesia. There were no restrictions related to the type of electrode used.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-08-12 15:13:56 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Main outcomes</HEADING>
<P>Main outcomes were pain intensity as the effectiveness outcome (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>; <LINK REF="REF-Pham-2004" TYPE="REFERENCE">Pham 2004</LINK>) and withdrawals or drop-outs because of adverse events as the safety outcome. If data on more than one pain scale were provided for a trial, we referred to a previously described hierarchy of pain-related outcomes (<LINK REF="REF-J_x00fc_ni-2006" TYPE="REFERENCE">Jüni 2006</LINK>; <LINK REF="REF-Reichenbach-2007" TYPE="REFERENCE">Reichenbach 2007</LINK>) and extracted data on the pain scale that is highest on this hierarchy:</P>
<OL>
<LI>Global pain</LI>
<LI>Pain on walking</LI>
<LI>WOMAC osteoarthritis index pain subscore</LI>
<LI>Composite pain scores other than WOMAC</LI>
<LI>Pain on activities other than walking</LI>
<LI>Rest pain or pain during the night</LI>
<LI>WOMAC global algofunctional score</LI>
<LI>Lequesne osteoarthritis index global score</LI>
<LI>Other algofunctional scale</LI>
<LI>Patient's global assessment</LI>
<LI>Physician's global assessment</LI>
</OL>
<P>If pain outcomes were reported at several time points, we extracted the estimate at the end of the treatment period.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>Secondary outcomes were function, the number of patients experiencing any adverse event and patients experiencing any serious adverse events. We defined serious adverse events as events resulting in hospitalisation, prolongation of hospitalisation, persistent or significant disability, congenital abnormality/birth defect of offspring, life-threatening events or death.</P>
<P>If data on more than one function scale were provided for a trial, we extracted data according to the hierarchy presented below.</P>
<OL>
<LI>Global disability score</LI>
<LI>Walking disability</LI>
<LI>WOMAC disability subscore</LI>
<LI>Composite disability scores other than WOMAC</LI>
<LI>Disability other than walking</LI>
<LI>WOMAC global scale</LI>
<LI>Lequesne osteoarthritis index global score</LI>
<LI>Other algofunctional scale</LI>
<LI>Patient&#8217;s global assessment</LI>
<LI>Physician&#8217;s global assessment</LI>
</OL>
<P>If function outcomes were reported at several time points, we extracted the estimate at the end of the treatment period. For safety outcomes, we extracted end of trial data.</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-08-12 15:14:00 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Electronic searches</HEADING>
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2008, issue 3), MEDLINE and EMBASE through the Ovid platform (<A HREF="http://www.ovid.com">www.ovid.com</A>), CINAHL through EBSCOhost, Physiotherapy Evidence Database (PEDro, <A HREF="http://www.pedro.fhs.usyd.edu.au/">http://www.pedro.fhs.usyd.edu.au/</A>, from 1929 onwards), all from implementation to 5 August 2008, using a combination of keywords and text words related to electrostimulation combined with keywords and text words related to osteoarthritis and a validated filter for controlled clinical trials (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>). The search strategy is presented in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> and <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Searching other sources</HEADING>
<P>We manually searched conference proceedings, used Science Citation Index to retrieve reports citing relevant articles, contacted content experts and trialists and screened reference lists of all obtained articles, including related reviews. Finally, we searched several clinical trial registries (<A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>, <A HREF="http://www.controlled-trials.com">www.controlled-trials.com</A>, <A HREF="http://www.actr.org.au">www.actr.org.au</A>, <A HREF="http://www.umin.ac.jp/ctr">www.umin.ac.jp/ctr</A>) to identify ongoing trials.</P>
<P>The last update of the manual search was on 2 February 2009.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-08-12 16:03:47 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Selection of studies</HEADING>
<P>Two review authors evaluated independently all titles and abstracts for eligibility (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We resolved disagreements by discussion. We applied no language restrictions. If multiple reports described the same trial, we considered all.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data collection</HEADING>
<P>Two review authors (AR and EN, RS or LK) extracted trial information independently using a standardised, piloted data extraction form accompanied by a codebook. We resolved disagreements by consensus or discussion with a third author (SR or PJ). We extracted the type of electrostimulation, including the mode of function (types of stimulator and electrode), the pulse form (intensity, rate and width), the electrode placement site and the frequency and duration of treatment. Other data extracted included the type of control intervention used, patient characteristics (gender, average age, duration of symptoms, type of joint), characteristics of pain, function and safety outcomes, design, trial size, trial duration (defined as time from randomisation until end of follow up), type and source of financial support and publication status. When necessary, we approximated means and measures of dispersion from figures in the reports. For cross-over trials, we extracted data from the first period only. Whenever possible, we used results from an intention-to-treat analysis. If effect sizes could not be calculated, we contacted the authors for additional data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality assessment</HEADING>
<P>Two review authors (AR and EN, RS or LK) independently assessed randomisation, blinding, selective outcome reporting and handling of incomplete outcome data in the analyses (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>; <LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>). We resolved disagreements by consensus or discussion with a third author (SR or PJ). We assessed two components of randomisation: generation of allocation sequences and concealment of allocation. We considered generation of sequences adequate if it resulted in an unpredictable allocation schedule; mechanisms considered adequate included random-number tables, computer-generated random numbers, minimisation, coin tossing, shuffling of cards and drawing of lots. Trials using an unpredictable allocation sequence were considered randomised; trials using potentially predictable allocation mechanisms, such as alternation or the allocation of patients according to date of birth, were considered quasi-randomised. We considered allocation concealment adequate if the investigators responsible for patient selection were unable to suspect before allocation which treatment was next; methods considered adequate included central randomisation and sequentially numbered, sealed, opaque envelopes. We considered blinding of patients adequate if a sham intervention was used that was identical in appearance from the control intervention. Transcutaneous electrostimulation generally does not allow blinding of therapists, whereas pain as the main effectiveness outcome is patient-reported by definition. Therefore, we did not assess blinding of therapists and outcome assessors. We considered handling of incomplete outcome data adequate if all randomised patients were included in the analysis (intention-to-treat principle). Finally, we used GRADE to describe the quality of the overall body of evidence (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>; <LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>), defined as the extent of confidence in the estimated treatment benefits and harms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data synthesis</HEADING>
<P>We summarised continuous outcomes using standardised mean differences (SMD), with the differences in mean values at the end of treatment across treatment groups divided by the pooled standard deviation. If differences in mean values at the end of the treatment were unavailable, we used differences in mean changes. If some of the required data were unavailable, we used approximations as previously described (<LINK REF="REF-Reichenbach-2007" TYPE="REFERENCE">Reichenbach 2007</LINK>). A SMD of -0.20 standard deviation units can be considered a small difference between experimental and control group, a SMD of -0.50 a moderate difference, and -0.80 a large difference (<LINK REF="REF-Cohen-1988" TYPE="REFERENCE">Cohen 1988</LINK>; <LINK REF="REF-J_x00fc_ni-2006" TYPE="REFERENCE">Jüni 2006</LINK>). SMDs can also be interpreted in terms of the percent of overlap of the experimental group's scores with the scores of the control group. A SMD of -0.20 indicates an overlap in the distributions of pain or function scores in about 85% of cases, a SMD of -0.50 in approximately 67% and a SMD of -0.80 in about 50% of cases (<LINK REF="REF-Cohen-1988" TYPE="REFERENCE">Cohen 1988</LINK>; <LINK REF="REF-J_x00fc_ni-2006" TYPE="REFERENCE">Jüni 2006</LINK>). On the basis of a median pooled SD of 2.5 cm found in large-scale osteoarthritis trials that assessed pain using a 10 cm visual analogue scale (VAS) (<LINK REF="REF-Nuesch-2009" TYPE="REFERENCE">Nuesch 2009</LINK>), SMDs of -0.20, -0.50 and -0.80 correspond to approximate differences in pain scores between experimental and control groups of 0.5, 1.25 and 2.0 cm on a 10 cm VAS. SMDs for function were back transformed to a standardised WOMAC disability score (<LINK REF="REF-Bellamy-1995" TYPE="REFERENCE">Bellamy 1995</LINK>) ranging from 0 to 10 on the basis of a median pooled SD of 2.1 units observed in large-scale osteoarthritis (<LINK REF="REF-Nuesch-2009" TYPE="REFERENCE">Nuesch 2009</LINK>). We expressed binary outcomes as relative risks.</P>
<P>We used standard inverse-variance random-effects meta-analysis (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>) to combine trials overall and stratified according to gross categories of electrostimulation (TENS, interferential current stimulation or pulsed electrostimulation). We quantified heterogeneity between trials using the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>), which describes the percentage of variation across trials that is attributable to heterogeneity rather than to chance and the corresponding &#967;<SUP>2</SUP> test. I<SUP>2</SUP> values of 25%, 50% and 75% may be interpreted as low, moderate and high between-trial heterogeneity, although the interpretation of I<SUP>2 </SUP>depends on the size and number of trials included (<LINK REF="REF-Rucker-2008" TYPE="REFERENCE">Rucker 2008</LINK>). The association between trial size and treatment effects was investigated in funnel plots, plotting effect sizes on the vertical axis against their standard errors on the horizontal axis. We assessed asymmetry by the asymmetry coefficient: the difference in effect size per unit increase in standard error (<LINK REF="REF-Sterne-2001" TYPE="REFERENCE">Sterne 2001</LINK>), which is mainly a surrogate for sample size, and used uni-variable meta-regression analysis to predict treatment effects in trials as large as the largest trials included in the meta-analysis, using the standard error as the explanatory variable (<LINK REF="REF-Shang-2005" TYPE="REFERENCE">Shang 2005</LINK>). In view of the biased nature of the predominantly small trials included in the meta-analysis of pain intensity, we considered the predicted estimates of effectiveness more reliable than the pooled estimates. For the analysis on the effectiveness outcomes pain and function, we differentiated between TENS, interferential current stimulation and pulsed electrostimulation. Then, we performed effectiveness analyses stratified by the following trial characteristics: concealment of allocation, use of a sham intervention in the control group, blinding of patients, analysis in accordance with the intention-to-treat principle, trial size, difference in the use of analgesic cointerventions, specific type of electrostimulation, duration of stimulation per session, number of sessions per week, duration of electrostimulation per week as an overall measure of treatment intensity, and duration of treatment period. A cut-off of 200 patients was used to distinguish between small and large trials; a sample size of 100 patients per group will yield more than 80% power to detect a small to moderate SMD of -0.40 at a two-sided P of 0.05. For the analysis according to specific type of stimulation, we distinguished between high frequency TENS, burst TENS, modulation TENS, low frequency TENS, interferential current stimulation or pulsed electrostimulation. We classified conventional TENS and brief TENS as high frequency TENS. Cut-offs of 20 and 60 minutes were used for the duration of electrostimulation per session, corresponding to the typical treatment duration in physical therapy, and the optimum stimulation duration suggested by <LINK REF="STD-Cheing-2003" TYPE="STUDY">Cheing 2003</LINK>. A cut-off of four weeks was used for the overall duration of the treatment period (time from randomisation to last session), in line with the previous version on this review. Cut-offs of three and seven were used for the number of sessions per week; one and five hours for the duration of electrostimulation per week, corresponding to the distribution of tertiles. We used uni-variable random-effects meta-regression models to determine whether treatment effects were affected by these factors (<LINK REF="REF-Thompson-1999" TYPE="REFERENCE">Thompson 1999</LINK>). Then, we converted SMDs of pain intensity and function to odds ratios (<LINK REF="REF-Chinn-2000" TYPE="REFERENCE">Chinn 2000</LINK>) to derive numbers needed to treat (NNT) to cause one additional treatment response on pain or function as compared with control, and numbers needed to harm (NNH) to cause one additional adverse outcome. We defined treatment response as a 50% improvement in scores (<LINK REF="REF-Clegg-2006" TYPE="REFERENCE">Clegg 2006</LINK>), which corresponds to an average decrease of 1.2 standard deviation units. Based on the median standardised pain intensity at baseline of 2.4 standard deviation units and the median standardised decrease in pain scores of 0.72 standard deviation units observed in large osteoarthritis trials (<LINK REF="REF-Nuesch-2009" TYPE="REFERENCE">Nuesch 2009</LINK>), we calculated that a median of 31% of patients in the control group would achieve an improvement of pain scores of 50% or more. This percentage was used as the control group response rate to calculate NNTs for treatment response on pain. Based on the median standardised WOMAC function score at baseline of 2.7 standard deviation units and the median standardised decrease in function scores of 0.58 standard deviation units (<LINK REF="REF-Nuesch-2009" TYPE="REFERENCE">Nuesch 2009</LINK>), 26% of patients in the control group would achieve a reduction in function of 50% or more. Again, this percentage was used as the control group response rate to calculate NNTs for treatment response on function. We used median risks of 150 patients with adverse events per 1000 patient-years, four patients with serious adverse events per 1000 patient-years and 17 drop-outs due to adverse events per 1000 patient-years observed in placebo groups in large osteoarthritis trials (<LINK REF="REF-Nuesch-2009" TYPE="REFERENCE">Nuesch 2009</LINK>) to calculate NNHs for safety outcomes. We performed analyses in RevMan version 5 (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>) and STATA version 10.1 (StataCorp, College Station, Texas). All P values are two-sided.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-10-08 09:42:18 -0400" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-08-12 15:15:31 -0400" MODIFIED_BY="[Empty name]">
<P>We identified 1697 references to articles and considered 85 to be potentially eligible (Figure 1). Twenty-two reports describing 18 completed trials in 813 patients and two protocols describing uncompleted trials (<LINK REF="STD-Fary-2008" TYPE="STUDY">Fary 2008</LINK>; <LINK REF="STD-Palmer-2007" TYPE="STUDY">Palmer 2007</LINK>) met our inclusion criteria. Six trials evaluated high frequency TENS (<LINK REF="STD-Bal-2007" TYPE="STUDY">Bal 2007</LINK>; <LINK REF="STD-Cetin-2008" TYPE="STUDY">Cetin 2008</LINK>; <LINK REF="STD-Cheing-2002" TYPE="STUDY">Cheing 2002;</LINK> <LINK REF="STD-Cheing-2003" TYPE="STUDY">Cheing 2003;</LINK> <LINK REF="STD-Law-2004a" TYPE="STUDY">Law 2004a;</LINK> <LINK REF="STD-Smith-1983" TYPE="STUDY">Smith 1983</LINK>), one high frequency and burst TENS (<LINK REF="STD-Grimmer-1992" TYPE="STUDY">Grimmer 1992</LINK>), one high frequency TENS and interferential current stimulation (<LINK REF="STD-Adedoyin-2005" TYPE="STUDY">Adedoyin 2005</LINK>), one low frequency, high frequency and modulation TENS with alternating low and high frequency current (<LINK REF="STD-Law-2004" TYPE="STUDY">Law 2004</LINK>), one burst TENS (<LINK REF="STD-Fargas_x002d_Babjak-1989" TYPE="STUDY">Fargas-Babjak 1989</LINK>), two low frequency TENS (<LINK REF="STD-Ng-2003" TYPE="STUDY">Ng 2003;</LINK> <LINK REF="STD-Yurtkuran-1999" TYPE="STUDY">Yurtkuran 1999</LINK>), four interferential current stimulation (<LINK REF="STD-Adedoyin-2002" TYPE="STUDY">Adedoyin 2002</LINK>; <LINK REF="STD-Defrin-2005" TYPE="STUDY">Defrin 2005</LINK>; <LINK REF="STD-Itoh-2008" TYPE="STUDY">Itoh 2008</LINK>; <LINK REF="STD-Quirk-1985" TYPE="STUDY">Quirk 1985</LINK>), and three evaluated pulsed electrostimulation (<LINK REF="STD-Fary-2008" TYPE="STUDY">Fary 2008</LINK>; <LINK REF="STD-Garland-2007" TYPE="STUDY">Garland 2007</LINK>; <LINK REF="STD-Zizic-1995" TYPE="STUDY">Zizic 1995</LINK>). The protocol of <LINK REF="STD-Palmer-2007" TYPE="STUDY">Palmer 2007</LINK> did not specify which type of TENS would be used.</P>
<P>The description of the uncompleted trials can be found in the '<LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>' table. Of the completed trials, 17 trials used a parallel group and one a 2 x 2 factorial design (<LINK REF="STD-Itoh-2008" TYPE="STUDY">Itoh 2008</LINK>). Twelve trials used a sham intervention in the control group, five used no intervention (<LINK REF="STD-Adedoyin-2005" TYPE="STUDY">Adedoyin 2005</LINK>; <LINK REF="STD-Cetin-2008" TYPE="STUDY">Cetin 2008</LINK>; <LINK REF="STD-Itoh-2008" TYPE="STUDY">Itoh 2008</LINK>; <LINK REF="STD-Quirk-1985" TYPE="STUDY">Quirk 1985</LINK>; <LINK REF="STD-Ng-2003" TYPE="STUDY">Ng 2003</LINK>) and one trial had both a sham and a no intervention control (<LINK REF="STD-Cheing-2002" TYPE="STUDY">Cheing 2002</LINK>). Standardised co-interventions, provided in both experimental and control groups, were used in five trials with no intervention controls (<LINK REF="STD-Adedoyin-2005" TYPE="STUDY">Adedoyin 2005</LINK>; <LINK REF="STD-Cetin-2008" TYPE="STUDY">Cetin 2008</LINK>; <LINK REF="STD-Cheing-2002" TYPE="STUDY">Cheing 2002</LINK>; <LINK REF="STD-Ng-2003" TYPE="STUDY">Ng 2003</LINK>; <LINK REF="STD-Quirk-1985" TYPE="STUDY">Quirk 1985</LINK>) and in two trials with a sham intervention (<LINK REF="STD-Adedoyin-2002" TYPE="STUDY">Adedoyin 2002</LINK>; <LINK REF="STD-Bal-2007" TYPE="STUDY">Bal 2007</LINK>). <LINK REF="STD-Cetin-2008" TYPE="STUDY">Cetin 2008</LINK> used hot packs and exercise, <LINK REF="STD-Adedoyin-2002" TYPE="STUDY">Adedoyin 2002</LINK> dietary advice and exercise, <LINK REF="STD-Quirk-1985" TYPE="STUDY">Quirk 1985</LINK>, <LINK REF="STD-Cheing-2002" TYPE="STUDY">Cheing 2002</LINK> and <LINK REF="STD-Adedoyin-2005" TYPE="STUDY">Adedoyin 2005</LINK> exercise, <LINK REF="STD-Bal-2007" TYPE="STUDY">Bal 2007</LINK> used infra-red therapy and <LINK REF="STD-Ng-2003" TYPE="STUDY">Ng 2003</LINK> an educational pamphlet. In addition, <LINK REF="STD-Itoh-2008" TYPE="STUDY">Itoh 2008</LINK> assigned 50% of patients to acupuncture using a factorial design.</P>
<P>Characteristics of the currents varied considerably, even within a specific type of electrostimulation. In the three trials evaluating low frequency TENS, pulse width and pulse frequency ranged from 200 &#956;sec and 2 Hz to 1000 &#956;sec and 4 Hz, with intensities set to reach a comfortable level in one (<LINK REF="STD-Law-2004" TYPE="STUDY">Law 2004</LINK>), and resulting in muscle contraction in two trials (<LINK REF="STD-Ng-2003" TYPE="STUDY">Ng 2003</LINK>; <LINK REF="STD-Yurtkuran-1999" TYPE="STUDY">Yurtkuran 1999</LINK>). In trials of high frequency TENS, pulse width and pulse frequency ranged from 80 &#956;sec and 32 Hz (<LINK REF="STD-Smith-1983" TYPE="STUDY">Smith 1983</LINK>) to 200 &#956;sec and 100 Hz (<LINK REF="STD-Cheing-2003" TYPE="STUDY">Cheing 2003</LINK>), with the majority of intensities described as strong but comfortable. In trials of burst TENS, <LINK REF="STD-Fargas_x002d_Babjak-1989" TYPE="STUDY">Fargas-Babjak 1989</LINK> used a pulse frequency of 200 Hz, a train length of 125 &#956;sec and a repetition frequency of 4 Hz with intensity increased up to the patients' limits of tolerability, while <LINK REF="STD-Grimmer-1992" TYPE="STUDY">Grimmer 1992</LINK> used a pulse frequency of 80 Hz, an unclear train length and pulse width and a repetition frequency of 3 Hz, with the intensity resulting in a strong, tolerable tingling sensation and visible, but comfortable muscle contraction. In the five trials of interferential current stimulation, the beat frequency ranged from 30 to 130 Hz and intensities resulted typically in tingling sensations in four trials (<LINK REF="STD-Adedoyin-2002" TYPE="STUDY">Adedoyin 2002</LINK>; <LINK REF="STD-Adedoyin-2005" TYPE="STUDY">Adedoyin 2005</LINK>; <LINK REF="STD-Itoh-2008" TYPE="STUDY">Itoh 2008</LINK>; <LINK REF="STD-Quirk-1985" TYPE="STUDY">Quirk 1985</LINK>), and pain in one (<LINK REF="STD-Defrin-2005" TYPE="STUDY">Defrin 2005</LINK>). The two trials of pulsed electrostimulation were the only ones to use intensities below the sensory threshold (<LINK REF="STD-Garland-2007" TYPE="STUDY">Garland 2007</LINK>; <LINK REF="STD-Zizic-1995" TYPE="STUDY">Zizic 1995</LINK>). The trials used the same device, which produces monophasic, spike-shaped pulses in a frequency of 100 Hz. The intensity of the current was initially increased until a tingling sensation was felt and subsequently reduced until this sensation disappeared.</P>
<P>The trials differed in type, number and localisation of electrodes used (see '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'). The median duration of electrostimulation per session was 25 minutes (range 15 minutes to 8.2 hours), with a duration of 15 to 20 minutes in 10 trials (<LINK REF="STD-Adedoyin-2005" TYPE="STUDY">Adedoyin 2005</LINK>; <LINK REF="STD-Adedoyin-2002" TYPE="STUDY">Adedoyin 2002</LINK>; <LINK REF="STD-Cetin-2008" TYPE="STUDY">Cetin 2008</LINK>; <LINK REF="STD-Cheing-2003" TYPE="STUDY">Cheing 2003</LINK>; <LINK REF="STD-Defrin-2005" TYPE="STUDY">Defrin 2005</LINK>; <LINK REF="STD-Itoh-2008" TYPE="STUDY">Itoh 2008</LINK>; <LINK REF="STD-Quirk-1985" TYPE="STUDY">Quirk 1985</LINK>; <LINK REF="STD-Ng-2003" TYPE="STUDY">Ng 2003</LINK>; <LINK REF="STD-Smith-1983" TYPE="STUDY">Smith 1983</LINK>; <LINK REF="STD-Yurtkuran-1999" TYPE="STUDY">Yurtkuran 1999</LINK>), 30 to 40 minutes in six (<LINK REF="STD-Bal-2007" TYPE="STUDY">Bal 2007</LINK>; <LINK REF="STD-Cheing-2003" TYPE="STUDY">Cheing 2003</LINK>; <LINK REF="STD-Fargas_x002d_Babjak-1989" TYPE="STUDY">Fargas-Babjak 1989;</LINK> <LINK REF="STD-Grimmer-1992" TYPE="STUDY">Grimmer 1992;</LINK> <LINK REF="STD-Law-2004a" TYPE="STUDY">Law 2004a;</LINK> <LINK REF="STD-Law-2004" TYPE="STUDY">Law 2004</LINK>) and 60 minutes or more in 4 trials (<LINK REF="STD-Cheing-2002" TYPE="STUDY">Cheing 2002;</LINK> <LINK REF="STD-Cheing-2003" TYPE="STUDY">Cheing 2003;</LINK> <LINK REF="STD-Garland-2007" TYPE="STUDY">Garland 2007;</LINK> <LINK REF="STD-Zizic-1995" TYPE="STUDY">Zizic 1995</LINK>). The median number of treatment sessions per week was 3.5 (range 1 to 14), with up to three sessions per week in eight trials (<LINK REF="STD-Adedoyin-2002" TYPE="STUDY">Adedoyin 2002</LINK>; <LINK REF="STD-Adedoyin-2005" TYPE="STUDY">Adedoyin 2005</LINK>; <LINK REF="STD-Cetin-2008" TYPE="STUDY">Cetin 2008</LINK>; <LINK REF="STD-Defrin-2005" TYPE="STUDY">Defrin 2005</LINK>; <LINK REF="STD-Grimmer-1992" TYPE="STUDY">Grimmer 1992</LINK>; <LINK REF="STD-Itoh-2008" TYPE="STUDY">Itoh 2008</LINK>; <LINK REF="STD-Quirk-1985" TYPE="STUDY">Quirk 1985</LINK>; <LINK REF="STD-Smith-1983" TYPE="STUDY">Smith 1983</LINK>), four to six in seven (<LINK REF="STD-Bal-2007" TYPE="STUDY">Bal 2007</LINK>; <LINK REF="STD-Cheing-2002" TYPE="STUDY">Cheing 2002</LINK>; <LINK REF="STD-Cheing-2003" TYPE="STUDY">Cheing 2003</LINK>; <LINK REF="STD-Law-2004" TYPE="STUDY">Law 2004</LINK>; <LINK REF="STD-Law-2004a" TYPE="STUDY">Law 2004a</LINK>; <LINK REF="STD-Ng-2003" TYPE="STUDY">Ng 2003</LINK>; <LINK REF="STD-Yurtkuran-1999" TYPE="STUDY">Yurtkuran 1999</LINK>) and seven or more in three trials (<LINK REF="STD-Fargas_x002d_Babjak-1989" TYPE="STUDY">Fargas-Babjak 1989;</LINK> <LINK REF="STD-Garland-2007" TYPE="STUDY">Garland 2007;</LINK> <LINK REF="STD-Zizic-1995" TYPE="STUDY">Zizic 1995</LINK>). This resulted in a median duration of electrostimulation of 1.5 hours per week (range 15 minutes to 57.4 hours). The median length of the treatment period was four weeks (range one day to 12 weeks).</P>
<P>All but one trial explicitly included patients with knee osteoarthritis only, with the diagnosis based on clinical and/or radiographic evidence. <LINK REF="STD-Fargas_x002d_Babjak-1989" TYPE="STUDY">Fargas-Babjak 1989</LINK> included patients with either knee or hip osteoarthritis, and failed to report the percentage of patients with knee osteoarthritis, but it was considered likely that this percentage was above 75%. The majority of patients had a clinical severity requiring simple non-surgical treatments (<LINK REF="REF-J_x00fc_ni-2006" TYPE="REFERENCE">Jüni 2006</LINK>). In one trial of pulsed electrostimulation, the majority of patients (41 out of 58) were candidates for total knee arthroplasty, however (<LINK REF="STD-Garland-2007" TYPE="STUDY">Garland 2007</LINK>). The description of patient characteristics was generally poor. Only four trials (<LINK REF="STD-Bal-2007" TYPE="STUDY">Bal 2007;</LINK> <LINK REF="STD-Garland-2007" TYPE="STUDY">Garland 2007</LINK>; <LINK REF="STD-Law-2004a" TYPE="STUDY">Law 2004a</LINK>; <LINK REF="STD-Yurtkuran-1999" TYPE="STUDY">Yurtkuran 1999</LINK>) reported the average disease duration, which ranged from two to 8.4 years.</P>
<P>Four cross-over trials could not be included because of incomplete reporting, which did not allow the distinction between treatment phases (<LINK REF="STD-Lewis-1984" TYPE="STUDY">Lewis 1984;</LINK> <LINK REF="STD-Lewis-1985" TYPE="STUDY">Lewis 1985;</LINK> <LINK REF="STD-Lewis-1994" TYPE="STUDY">Lewis 1994</LINK>; <LINK REF="STD-Taylor-1981" TYPE="STUDY">Taylor 1981</LINK>). All but <LINK REF="STD-Lewis-1985" TYPE="STUDY">Lewis 1985</LINK> were included in the previous version of this review (<LINK REF="REF-Osiri-2000" TYPE="REFERENCE">Osiri 2000</LINK>). Three other trials were excluded because of an active control intervention using another type of electrostimulation (<LINK REF="STD-Burch-2008" TYPE="STUDY">Burch 2008</LINK>; <LINK REF="STD-Jensen-1991" TYPE="STUDY">Jensen 1991;</LINK> <LINK REF="STD-Volklein-1990" TYPE="STUDY">Volklein 1990</LINK>). Detailed reasons for exclusion are displayed in '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'.<BR/>
</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-08-12 15:16:01 -0400" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> summarises the methodological characteristics and source of funding of included trials. One trial reported both adequate sequence generation and adequate concealment of allocation (<LINK REF="STD-Garland-2007" TYPE="STUDY">Garland 2007</LINK>), five trials reported only adequate sequence generation (<LINK REF="STD-Itoh-2008" TYPE="STUDY">Itoh 2008</LINK>; <LINK REF="STD-Law-2004" TYPE="STUDY">Law 2004</LINK>; <LINK REF="STD-Law-2004a" TYPE="STUDY">Law 2004a</LINK>; <LINK REF="STD-Ng-2003" TYPE="STUDY">Ng 2003</LINK>; <LINK REF="STD-Smith-1983" TYPE="STUDY">Smith 1983</LINK>) and one trial reported adequate concealment, but provided insufficient detail on the generation of allocation sequence (<LINK REF="STD-Grimmer-1992" TYPE="STUDY">Grimmer 1992</LINK>). Two trials were quasi-randomised, one used alternation to allocate patients to experimental and control intervention (<LINK REF="STD-Adedoyin-2002" TYPE="STUDY">Adedoyin 2002</LINK>), the other allocated patients according to hospital registration number (<LINK REF="STD-Bal-2007" TYPE="STUDY">Bal 2007</LINK>). In the remaining nine trials, low quality of reporting hampered any judgement regarding sequence generation and concealment of allocation.</P>
<P>Six trials (<LINK REF="STD-Fargas_x002d_Babjak-1989" TYPE="STUDY">Fargas-Babjak 1989</LINK>; <LINK REF="STD-Garland-2007" TYPE="STUDY">Garland 2007</LINK>; <LINK REF="STD-Grimmer-1992" TYPE="STUDY">Grimmer 1992</LINK>; <LINK REF="STD-Law-2004" TYPE="STUDY">Law 2004</LINK>; <LINK REF="STD-Law-2004a" TYPE="STUDY">Law 2004a</LINK>; <LINK REF="STD-Zizic-1995" TYPE="STUDY">Zizic 1995</LINK>) were described as double-blind. Thirteen trials used sham interventions, all using identical devices in experimental and control groups (<LINK REF="STD-Adedoyin-2002" TYPE="STUDY">Adedoyin 2002</LINK>; <LINK REF="STD-Bal-2007" TYPE="STUDY">Bal 2007</LINK>; <LINK REF="STD-Cheing-2002" TYPE="STUDY">Cheing 2002</LINK>; <LINK REF="STD-Cheing-2003" TYPE="STUDY">Cheing 2003</LINK>; <LINK REF="STD-Defrin-2005" TYPE="STUDY">Defrin 2005</LINK>; <LINK REF="STD-Fargas_x002d_Babjak-1989" TYPE="STUDY">Fargas-Babjak 1989</LINK>; <LINK REF="STD-Garland-2007" TYPE="STUDY">Garland 2007</LINK>; <LINK REF="STD-Grimmer-1992" TYPE="STUDY">Grimmer 1992</LINK>; <LINK REF="STD-Law-2004a" TYPE="STUDY">Law 2004a</LINK>; <LINK REF="STD-Law-2004" TYPE="STUDY">Law 2004</LINK>; <LINK REF="STD-Smith-1983" TYPE="STUDY">Smith 1983</LINK>; <LINK REF="STD-Yurtkuran-1999" TYPE="STUDY">Yurtkuran 1999</LINK>; <LINK REF="STD-Zizic-1995" TYPE="STUDY">Zizic 1995</LINK>). In 10 out of 13 trials, sham devices had broken leads so that no current could pass, whereas the indicator light or digital display of intensity control functioned normally. In the two pulsed electrostimulation trials, all patients were instructed to increase the intensity until a tingling sensation was felt, after which they were asked to reduce intensity just below the perception (sensory) level. Pulsed electrostimulation sham devices were adapted with an automatic shut-off as soon as the amplitude was reduced (<LINK REF="STD-Garland-2007" TYPE="STUDY">Garland 2007;</LINK> <LINK REF="STD-Zizic-1995" TYPE="STUDY">Zizic 1995</LINK>). Only the sham device used in <LINK REF="STD-Defrin-2005" TYPE="STUDY">Defrin 2005</LINK> was not considered to lead to adequate patient blinding, as the sham device was described as shut off. Only the two trials of pulsed electrostimulation, however, which used currents below the sensory threshold, were deemed to have fully credible blinding of patients (<LINK REF="STD-Garland-2007" TYPE="STUDY">Garland 2007</LINK>; <LINK REF="STD-Zizic-1995" TYPE="STUDY">Zizic 1995</LINK>).</P>
<P>Sixteen out of 18 completed trials contributed to the analysis of pain outcomes. Of these, only three trials (<LINK REF="STD-Adedoyin-2002" TYPE="STUDY">Adedoyin 2002</LINK>; <LINK REF="STD-Bal-2007" TYPE="STUDY">Bal 2007;</LINK> <LINK REF="STD-Grimmer-1992" TYPE="STUDY">Grimmer 1992</LINK>), which had analysed all randomly assigned patients, were considered to have an intention-to-treat analysis of pain outcomes at end of treatment. In three trials (<LINK REF="STD-Cetin-2008" TYPE="STUDY">Cetin 2008;</LINK> <LINK REF="STD-Defrin-2005" TYPE="STUDY">Defrin 2005;</LINK> <LINK REF="STD-Ng-2003" TYPE="STUDY">Ng 2003</LINK>) it was unclear whether exclusions of randomised patients from the analysis had occurred, in five trials (<LINK REF="STD-Fargas_x002d_Babjak-1989" TYPE="STUDY">Fargas-Babjak 1989;</LINK> <LINK REF="STD-Garland-2007" TYPE="STUDY">Garland 2007;</LINK> <LINK REF="STD-Law-2004" TYPE="STUDY">Law 2004;</LINK> <LINK REF="STD-Law-2004a" TYPE="STUDY">Law 2004a;</LINK> <LINK REF="STD-Yurtkuran-1999" TYPE="STUDY">Yurtkuran 1999</LINK>) exclusions were reported, but their percentage remained unclear and in the remaining six trials the median reported exclusion rate was 7% in the experimental and 11.5% in the control groups (range 0% to 25% in both experimental and control groups). Two out of nine trials contributing to the analysis of function outcomes were considered to have an intention-to-treat analysis (<LINK REF="STD-Bal-2007" TYPE="STUDY">Bal 2007;</LINK> <LINK REF="STD-Quirk-1985" TYPE="STUDY">Quirk 1985</LINK>). In one trial (<LINK REF="STD-Cetin-2008" TYPE="STUDY">Cetin 2008</LINK>) it was unclear whether exclusions of randomised patients from the analysis had occurred, in three trials (<LINK REF="STD-Garland-2007" TYPE="STUDY">Garland 2007;</LINK> <LINK REF="STD-Law-2004a" TYPE="STUDY">Law 2004a;</LINK> <LINK REF="STD-Yurtkuran-1999" TYPE="STUDY">Yurtkuran 1999</LINK>) exclusions were reported, but their percentage remained unclear and in the remaining three trials the median reported exclusion rate was 11.5% in experimental and 12% in control groups (range 0% to 25% in experimental, and 11% to 25% in control groups, respectively).</P>
<P>Only three trials explicitly specified primary outcomes (<LINK REF="STD-Adedoyin-2002" TYPE="STUDY">Adedoyin 2002;</LINK> <LINK REF="STD-Itoh-2008" TYPE="STUDY">Itoh 2008;</LINK> <LINK REF="STD-Zizic-1995" TYPE="STUDY">Zizic 1995</LINK>), although one of these specified more than two (<LINK REF="STD-Zizic-1995" TYPE="STUDY">Zizic 1995</LINK>). Only one trial reported a sample size calculation (<LINK REF="STD-Adedoyin-2005" TYPE="STUDY">Adedoyin 2005</LINK>). None of the trials had a sufficient sample size of at least 200 patients overall to achieve sufficient power for detecting a small to moderate SMD. Only three trials reported their source of funding: one was supported by a non-profit organisation and a commercial body (<LINK REF="STD-Fargas_x002d_Babjak-1989" TYPE="STUDY">Fargas-Babjak 1989</LINK>), the other two by a commercial body only (<LINK REF="STD-Garland-2007" TYPE="STUDY">Garland 2007;</LINK> <LINK REF="STD-Zizic-1995" TYPE="STUDY">Zizic 1995</LINK>).</P>
<P>For the effectiveness outcomes pain and function, the quality of the evidence (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>) was classified as very low in view of the risk of bias in the included, predominantly small trials of questionable quality, the large heterogeneity between trials, the potential for selective reporting of function outcomes and the exploratory nature of the model used to predict SMDs of pain in trials as large as the largest trials ('<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>'). For the safety outcomes, the quality of the evidence (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>) was classified as moderate to low, again because of the predominantly small trials of questionable quality, the small number of trials reporting the outcomes and the small number of events resulting in imprecise estimates.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-10-08 09:42:18 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Knee pain</HEADING>
<P>Sixteen trials with 18 comparisons (726 patients) contributed to the meta-analysis of pain outcomes (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). The analysis suggested an overall large SMD of -0.86 (95% CI -1.23 to -0.49), which corresponds to a difference in pain scores of 2.1 cm on a 10 cm VAS between electrostimulation and control, favouring electrostimulation. Within the types of electrostimulation, a very large effect was found for interferential current stimulation (SMD -1.20, 95% CI -1.99 to -0.42), a large effect in TENS (SMD -0.85, 95% CI -1.36 to -0.34) and a moderate effect in pulsed electrostimulation (SMD -0.41, 95% CI -0.77 to -0.05). However, interaction tests provided little evidence for differences between different types. Pooling all types of electrostimulation, an I<SUP>2</SUP> of 80% indicated a high degree of between-trial heterogeneity (P for heterogeneity &lt; 0.001), which was not substantially reduced when pooling types of electrostimulation separately. Four trials (<LINK REF="STD-Cheing-2003" TYPE="STUDY">Cheing 2003;</LINK> <LINK REF="STD-Defrin-2005" TYPE="STUDY">Defrin 2005</LINK>; <LINK REF="STD-Law-2004" TYPE="STUDY">Law 2004;</LINK> <LINK REF="STD-Law-2004a" TYPE="STUDY">Law 2004a</LINK>) showed unrealistically large SMDs of twice to three times the magnitude of what would be expected for total joint replacement (<LINK REF="REF-J_x00fc_ni-2006" TYPE="REFERENCE">Jüni 2006</LINK>). The funnel plot appeared asymmetrical (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>, P for asymmetry &lt; 0.001) and the corresponding asymmetry coefficient was -7.6 (95% CI -10.6 to -4.5). This coefficient indicates that the bene&#64257;t of electrostimulation increases by 7.6 standard deviation units for each unit increase in the standard error of the SMD, which is mainly a surrogate for sample size. The predicted SMD in trials as large as the largest trial (<LINK REF="STD-Zizic-1995" TYPE="STUDY">Zizic 1995</LINK>, n = 71, standard error = 0.24) was -0.07 (95% CI -0.46 to 0.32), which corresponds to a difference in pain scores of 0.2 cm on a 10 cm VAS between electrostimulation and control. Referring to a median pain intensity of 6.1 cm in placebo groups at baseline, this corresponds to a difference of 4% improvement (95% CI -13% to +20%) between electrostimulation and control ('<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>').</P>
<P>
<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> presents results from stratified analyses. Estimates of SMD varied to some degree depending on concealment of allocation, adequacy of patient blinding, use of analgesic cointerventions and characteristics of electrostimulation, but 95% CIs of SMDs were wide and tests of interaction and tests for trend not statistically significant. There was little evidence to suggest that SMDs depended on the type of electrostimulation used (P for interaction = 0.94). Contrary to what would be expected in the presence of relevant placebo effects, we found some evidence towards larger benefits of electrostimulation in trials with a sham intervention as compared with trials without (P for interaction = 0.12). In addition, there was some evidence for larger benefits of electrostimulation associated with short durations of the overall treatment period of less than four weeks as compared with four weeks or more (P for interaction = 0.14). The analysis could not be stratified according to sample size, because none of included trials reached the pre-specified sample size of 200 patients to be considered as adequately sized.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Withdrawals or drop-outs because of adverse events</HEADING>
<P>Eight trials (348 patients) contributed to the meta-analysis of patients withdrawn or dropped out because of adverse events (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). Of these, four TENS trials and one interferential current stimulation trial reported that no withdrawals or drop-outs due to adverse events had occurred, neither in experimental nor in control groups, therefore relative risks could not be estimated. In the remaining three trials, there was no evidence that transcutaneous electrostimulation is unsafe (relative risk 0.97), but 95% confidence intervals were wide and ranged from 0.16 to 6.00. Pooling all types of electrostimulation, an I<SUP>2</SUP> of 20% indicated a low degree of between-trial heterogeneity (P for heterogeneity = 0.29).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Function</HEADING>
<P>Nine trials (407 patients) contributed to the meta-analysis of function. The analysis suggested a small SMD of -0.34 (95% CI -0.54 to -0.14, <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>), which corresponds to a difference in function scores of 0.7 units on a standardised WOMAC disability scale ranging from 0 to 10, favouring electrostimulation. Referring to a median function score of 5.6 units in placebo groups at baseline, this corresponds to a difference of 20% improvement (95% CI +11% to +29%) between electrostimulation and control ('<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>'). The estimated difference in the percentage of treatment responders between patients allocated to electrostimulation and patients allocated to placebo of 3% translated into an NNT to cause one additional treatment response on function of 10 (95% CI 7 to 22) ('<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>'). Differences between types of electrostimulation were not statistically significant. An I<SUP>2</SUP> of 0% suggested no between-trial heterogeneity (P for heterogeneity = 0.57). The funnel plot did not appear asymmetrical (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>, P for asymmetry = 0.52). The corresponding asymmetry coefficient was 1.4 (95% CI, -3.5 to 6.3).</P>
<P>
<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> presents results from stratified analyses. Estimates of SMD varied to some degree depending on type of control intervention, adequacy of patient blinding, characteristics of electrostimulation and overall treatment period, but 95% CIs of SMDs were wide and tests for interaction and tests for trend not statistically significant. There was little evidence to suggest that SMDs depended on the type of electrostimulation used (P for interaction = 0.32). Again, the analysis could not be stratified according to sample size, because none of included trials reached the pre-specified sample size of 200 patients to be considered as adequately sized.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other safety outcomes</HEADING>
<P>Three trials (175 patients) contributed to the meta-analysis of patients experiencing any adverse event (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>) and four trials (195 patients) to the meta-analysis of patients experiencing any serious adverse event (<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>). In general, there was no evidence to suggest that electrostimulation is unsafe, but 95% CIs were wide and results inconclusive.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-08-12 15:17:13 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2009-08-12 15:16:49 -0400" MODIFIED_BY="[Empty name]">
<P>Our systematic review of trials comparing any type of transcutaneous electrostimulation with a sham or non-intervention control revealed a lack of adequately sized, methodologically sound and appropriately reported trials and a moderate to high degree of heterogeneity between trials, which made the interpretation of results difficult, particularly for joint pain as the primary therapeutic target of transcutaneous electrostimulation. In an attempt to minimise biases associated with small trials of questionable quality, we used meta-regression to predict effects of transcutaneous electrostimulation on pain and found the predicted effect sizes for pain negligibly small. The rates of withdrawals or drop-outs due to adverse events were comparable in experimental and control groups, but 95% CIs were wide and therefore inconclusive.</P>
</SUMMARY_OF_RESULTS>
<QUALITY_OF_EVIDENCE MODIFIED="2009-08-12 15:16:56 -0400" MODIFIED_BY="[Empty name]">
<P>An inspection of funnel plots and a formal analysis of asymmetry indicated asymmetry for knee pain, but not for function, which suggested the presence of biases associated with small sample size particularly when estimating the effects of electrostimulation on knee pain. Asymmetrical funnel plots should be seen not only as an indication of publication bias, but as a generic tool for examination of small study effects: the tendency for the smaller studies to show larger treatment effects, possibly due to a combination of publication bias, selective reporting of outcomes and methodological problems particularly in small trials (<LINK REF="REF-Nuesch-2009a" TYPE="REFERENCE">Nuesch 2009a</LINK>; <LINK REF="REF-Sterne-2000" TYPE="REFERENCE">Sterne 2000</LINK>). If reporting is inadequate, as was the case in our systematic review, then the standard error as a proxy for study size may be a more precise measure of trial quality than formal assessments of methodological quality. When modelling effects expected in trials as large as the largest trial included in our systematic review, we found effects on pain near null -0.07 (95% CI -0.46 to 0.32), which were clearly smaller than the pooled SMD actually found for pain in the meta-analysis -0.86 (95% CI -1.23 to -0.49). The effect of electrostimulation on function was small, but potentially clinically relevant, and the accumulated evidence appeared less affected by biases associated with small sample size.</P>
<P>The methodological quality and the quality of reporting was poor. Insufficient information was noted in several randomised controlled trials about the treatment assignment procedure and concealment of allocation. Primary outcomes were specified in only three trials. Although several studies reported blinding of patients, complete blinding is difficult to achieve due to the sensory differences between treatment and placebo, as well as unintended communication between patient and evaluator (<LINK REF="REF-Deyo-1990" TYPE="REFERENCE">Deyo 1990</LINK>). Only <LINK REF="STD-Grimmer-1992" TYPE="STUDY">Grimmer 1992</LINK> and <LINK REF="STD-Bal-2007" TYPE="STUDY">Bal 2007</LINK> mentioned the inclusion of patients to be restricted to those without prior TENS experience; another two trials were likely to have achieved adequate blinding of patients with currents below the sensory threshold used in the experimental group, which were likely to be indistinguishable from the sham intervention also for patients with treatment experience (<LINK REF="STD-Garland-2007" TYPE="STUDY">Garland 2007</LINK>, <LINK REF="STD-Zizic-1995" TYPE="STUDY">Zizic 1995</LINK>). The majority of papers did not provide adequate information regarding withdrawals, drop-outs and losses to follow up, nor indicated whether patients with incomplete clinical data were included in the data analysis. Several trials omitted to describe adverse events, which is of concern.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2009-08-12 15:16:57 -0400" MODIFIED_BY="[Empty name]">
<P>Our review is based on a broad literature search, and it seems unlikely that we missed relevant trials. Trial selection and data extraction, including quality assessment, were done independently by two authors to minimise bias and transcription errors. Components used for quality assessment are validated and reported to be associated with bias (<LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>).</P>
<P>As with any systematic review, our study is limited by the quality of included trials. As indicated above, trials generally suffered from poor methodological quality, inadequate reporting and small sample size. Some trials (<LINK REF="STD-Cheing-2003" TYPE="STUDY">Cheing 2003</LINK>; <LINK REF="STD-Defrin-2005" TYPE="STUDY">Defrin 2005</LINK>; <LINK REF="STD-Law-2004a" TYPE="STUDY">Law 2004a</LINK>) showed unrealistically large SMDs of twice to three times the magnitude of what would be expected for total joint replacement (<LINK REF="REF-J_x00fc_ni-2006" TYPE="REFERENCE">Jüni 2006</LINK>). Including these trials in the meta-analysis is likely to result in an overestimation of the benefits of transcutaneous electrostimulation.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2009-08-12 15:17:13 -0400" MODIFIED_BY="[Empty name]">
<P>Interestingly, there are nearly as many systematic reviews and meta-analyses on transcutaneous electrostimulation in osteoarthritis as randomised trials. Here, we will focus mainly on the similarities and differences between ours and the previous version of this review (<LINK REF="REF-Osiri-2000" TYPE="REFERENCE">Osiri 2000</LINK>), which included seven transcutaneous electrical nerve stimulation (TENS) trials. We updated the search and used broader selection criteria, which resulted in 14 additional trials; 11 trials used TENS as the experimental treatment, four interferential current stimulation, one both TENS and interferential current stimulation, and two pulsed electrostimulation. As in the review of <LINK REF="REF-Osiri-2000" TYPE="REFERENCE">Osiri 2000</LINK>, both parallel group and cross-over RCTs were included. For the cross-over studies, we only collected data from the first intervention phase in order to eliminate carry-over effects, whereas Osiri and colleagues included pooled data over all phases. We excluded three previously included cross-over trials, because the investigators were unable to provide data from the first phase only. In this update, we performed a more detailed quality assessment of component trials, followed by a detailed exploration of sources of variation between trials, including concealment of allocation, blinding, intention-to-treat analysis, characteristics of electrostimulation, and the investigation of funnel plots. To analyse continuous data, Osiri and colleagues used weighted mean differences or SMDs of the change from baseline scores, whereas we used SMDs of end of treatment scores and based our conclusions on treatment effects on pain predicted in uni-variable meta-regression models by using the standard error as the explanatory variable. In addition, fixed-effect models were used in the previous version unless there was statistically significant heterogeneity between trials based on &#967;<SUP>2</SUP> testing. Model selection based on the mechanistic application of heterogeneity tests should be avoided, however. Here, we used random-effects models, which will generally be more conservative in terms of the estimated precision, but will be more affected by small study effects than a fixed-effect model, which makes an exploration of sources of variation, including different types of bias, mandatory. Results from the previous and current versions are therefore not directly comparable. Nevertheless, pooled SMDs for pain were favourable in our and the previous review (<LINK REF="REF-Osiri-2000" TYPE="REFERENCE">Osiri 2000</LINK>), with us reporting a pooled SMD of -0.86 (95% CI -1.23 to -0.49), whereas <LINK REF="REF-Osiri-2000" TYPE="REFERENCE">Osiri 2000</LINK> reported a SMD of -0.45 (95% CI -0.70 to -0.19), with confidence intervals overlapping widely. Although both Osiri and we acknowledge the risk of bias in summary estimates, Osiri concluded that transcutaneous electrostimulation is "shown to be effective in pain control over placebo". We disagree with these conclusions: when modelling effects expected in trials as large as the largest trial included, we found the SMD of pain near null and clinically irrelevant (-0.07, 95% CI -0.46 to 0.32). <LINK REF="REF-Osiri-2000" TYPE="REFERENCE">Osiri 2000</LINK> recorded function separately for the outcomes 'stiffness of the knee', '50-foot walking time', 'quadriceps muscle strength' and 'knee flection' with only one trial contributing to each of the categories. We choose a different approach, using a hierarchy developed to minimise the impact of selective reporting of outcomes and to allow for a synthesis of evidence across different studies using divergent definitions of function. Our effect sizes and conclusion concerning function are less favourable compared to those made by <LINK REF="REF-Osiri-2000" TYPE="REFERENCE">Osiri 2000</LINK>. In this version, we also summarised safety data and found no evidence to suggest that electrostimulation is unsafe. Finally, unlike <LINK REF="REF-Osiri-2000" TYPE="REFERENCE">Osiri 2000</LINK>, we also included trials of interferential current stimulation and pulsed electrostimulation. One of the two trials of pulsed electrostimulation (<LINK REF="STD-Zizic-1995" TYPE="STUDY">Zizic 1995</LINK>) is covered in another Cochrane Review by <LINK REF="REF-Hulme-2002" TYPE="REFERENCE">Hulme 2002</LINK> on electromagnetic fields, even though the device used (BioniCare BIO-1000) does not generate electromagnetic fields, but electric currents (<LINK REF="REF-Regence-Medical-Policy-2009" TYPE="REFERENCE">Regence Medical Policy 2009</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-08-12 15:17:20 -0400" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-08-04 08:24:11 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Despite more than 20 years of clinical research, there is a lack of adequate evidence to support the use of any type of transcutaneous electrostimulation in patients with knee osteoarthritis. The effects on both knee pain and function are potentially clinically relevant and deserve further clinical evaluation.<BR/>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-08-12 15:17:20 -0400" MODIFIED_BY="[Empty name]">
<P>The current systematic review is inconclusive, hampered by the inclusion of only small trials of questionable quality (<LINK REF="REF-Nuesch-2009a" TYPE="REFERENCE">Nuesch 2009a</LINK>). Adequately sized randomised parallel-group trials in about 2 x 100 patients with knee osteoarthritis are necessary to determine whether a specific type of transcutaneous electrostimulation is indeed associated with a clinically relevant benefit on pain. A sample size of 2 x 100 patients will yield more than 80% power to detect a small to moderate SMD of -0.40 at a two-sided P of 0.05, which corresponds to a difference of 1 cm on a 10 cm visual analogue scale (VAS) between experimental and control intervention. The trials should enrol patients without prior experience of any type of transcutaneous electrostimulation or evaluate success of blinding at the end of trial, use adequate concealment of allocation, experimental and sham interventions that are close to indistinguishable and an intention-to-treat analysis. Transcutaneous electrical nerve stimulation (TENS) devices are marketed as small, inexpensive, easy-to-use home units, but in the majority of trials TENS was administered by a therapist in a practice or hospital setting. Future research may focus on the effectiveness of self-administered TENS, with accurate recording of the duration of electrostimulation per day to assess compliance and enable the exploration of possible dose-effect relationships.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-08-12 15:17:22 -0400" MODIFIED_BY="[Empty name]">
<P>We thank the Cochrane Musculoskeletal editorial team and Henk van Zutphen for valuable comments, and Malcolm Sturdy for database support. The authors are grateful to Serpil Bal, Gladys Cheing and Pearl Law for providing additional information concerning design and outcome data. We thank Beverly Lewis, Daniel Lewis and Mark Hallett who replied to our queries and attempted to locate files of trials published approximately 20 years ago, but were unable to provide additional outcome data.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-08-12 15:17:24 -0400" MODIFIED_BY="[Empty name]">
<P>None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-08-12 15:17:24 -0400" MODIFIED_BY="[Empty name]">
<P>Study conception: Rutjes, Jüni<BR/>Protocol development: Rutjes, Nüesch, Hendriks, Kalichman, Reichenbach, Jüni<BR/>Acquisition of data: Rutjes, Nüesch, Sterchi, Kalichman, Hendriks, Osiri, Brosseau, Reichenbach, Jüni<BR/>Analysis and interpretation of data: Rutjes, Nüesch, Sterchi, Hendriks, Kalichman, Osiri, Brosseau, Reichenbach, Jüni<BR/>Drafting of the manuscript: Rutjes<BR/>Critical revision of the manuscript for important intellectual content: Rutjes, Nüesch, Sterchi, Hendriks, Kalichman, Reichenbach, Jüni<BR/>Statistical analysis: Nüesch, Jüni, Rutjes<BR/>Obtained funding: Reichenbach, Jüni</P>
<P>Dr Rutjes and Mrs Nüesch contributed equally to this article.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-08-12 15:17:31 -0400" MODIFIED_BY="[Empty name]">
<P>Before embarking on this review, we generated a standard protocol for this and all other Cochrane Reviews performed by our group. The protocol was approved by the Editorial Board of the Cochrane Musculoskeletal Review Group (CMSG), but, as an update, did not result in a specific publication in the Cochrane database. We deviated from the standard protocol with respect to the selection of main outcomes and analysis. The main outcomes specified in the protocol were pain and function, as recommended for osteoarthritis trials. After approval of the standard protocol, the Editorial Board of CMSG reconvened several times to establish common views on how to conduct systematic reviews, and it was decided that the main outcomes of future reviews should reflect both effectiveness <I>and</I> safety. CMSG further agreed to recommend the use of a maximum of two main outcomes. Therefore, the CMSG Editorial Board and the authors of this review agreed to specify pain intensity and the number of drop-outs or withdrawals due to adverse events as main outcomes for this update. Function was specified as one of the secondary outcomes. The protocol specified that our main analysis would be based on standardised mean differences (SMDs) derived from inverse-variance random-effects meta-analysis. In view of the high degree of heterogeneity, the predominance of small trials of low methodological quality and the skewed funnel plot for pain intensity as one of the main outcomes, we refrained from presenting the SMD of pain as primary result in main body of text and summary of findings table, but reported results from uni-variable meta-regression analysis used to predict treatment effects in trials as large as the largest trials included in the meta-analysis with the standard error as the explanatory variable. We acknowledge that this analysis is exploratory, however. In addition, we used 'Risk of bias' tables to present the methodological quality of included trials and a 'Summary of findings' table to present results.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2008-12-29 06:14:43 -0500" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-08-13 10:28:21 -0400" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-08-13 10:28:21 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-08-12 15:52:09 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Adedoyin-2002" MODIFIED="2009-08-12 15:31:15 -0400" MODIFIED_BY="[Empty name]" NAME="Adedoyin 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-08-12 15:31:15 -0400" MODIFIED_BY="[Empty name]" NOTES="Accession Number: 2002170966. Language: English. Entry Date: 20021206. Revision Date: 20040123. Publication Type: journal article; clinical trial; research; tables/charts. Journal Subset: Allied Health; Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; UK &amp;amp; Ireland. Special Interest: Pain and Pain Management; Physical Therapy. No. of Refs: 41 ref. NLM UID: 0401223. Email: radedoyi@yahoo.com.0031-9406" NOTES_MODIFIED="2009-08-12 15:31:15 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adedoyin RA, Olaogun MOB, Fagbeja OO</AU>
<TI>Effect of interferential current stimulation in management of osteo-arthritic knee pain</TI>
<SO>Physiotherapy</SO>
<YR>2002</YR>
<VL>88</VL>
<NO>8</NO>
<PG>493-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Adedoyin-2005" MODIFIED="2008-12-22 23:32:58 -0500" MODIFIED_BY="[Empty name]" NAME="Adedoyin 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-08 08:48:23 -0500" MODIFIED_BY="[Empty name]" NOTES="Accession Number: 2009090357. Language: English. Entry Date: 20060512. Publication Type: journal article; clinical trial; research; tables/charts. Journal Subset: Allied Health; Asia; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed. Special Interest: Physical Therapy. Instrumentation: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). No. of Refs: 44 ref. NLM UID: 100908968. Email: radedoyi@yahoo.com.1013-7025" NOTES_MODIFIED="2008-12-08 08:48:23 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adedoyin RA, Olaogun MOB, Oyeyemi AL</AU>
<TI>Transcutaneous electrical nerve stimulation and interferential current combined with exercise for the treatment of knee osteoarthritis: a randomised controlled trial</TI>
<SO>Hong Kong Physiotherapy Journal</SO>
<YR>2005</YR>
<VL>23</VL>
<PG>13-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bal-2007" MODIFIED="2009-08-12 15:52:09 -0400" MODIFIED_BY="[Empty name]" NAME="Bal 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-12 15:52:09 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bal S, Turan Y, Grgan A</AU>
<TI>The effectiveness of transcutaneous electrical nerve stimulation in patients with knee osteoarthritis</TI>
<SO>Osteoporosis International</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>suppl. 3</NO>
<PG>S94</PG>
<IDENTIFIERS MODIFIED="2008-12-09 03:33:43 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-09 03:33:43 -0500" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Expert contact"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-08-04 08:57:20 -0400" MODIFIED_BY="Jenny Bellorini" NOTES="TurkishDiz osteoartritli hastalarda transkutan elektriksel sinir stimulasyonunun etkinligiJournal: Article" NOTES_MODIFIED="2009-08-04 08:57:20 -0400" NOTES_MODIFIED_BY="Jenny Bellorini" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bal S, Turan Y, Gurgan A</AU>
<TI>The effectiveness of transcutaneous electrical nerve stimulation in patients with knee osteoarthritis</TI>
<SO>Journal of Rheumatology and Medical Rehabilitation</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>1</NO>
<PG>1-5</PG>
<IDENTIFIERS MODIFIED="2009-08-04 08:57:20 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cetin-2008" MODIFIED="2009-02-03 09:15:42 -0500" MODIFIED_BY="[Empty name]" NAME="Cetin 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-02-03 09:15:42 -0500" MODIFIED_BY="[Empty name]" NOTES="United States" NOTES_MODIFIED="2009-02-03 09:15:42 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cetin N, Aytar A, Atalay A, Akman MN, Cetin Nuri, Aytar Aydan, et al</AU>
<TI>Comparing hot pack, short-wave diathermy, ultrasound, and TENS on isokinetic strength, pain, and functional status of women with osteoarthritic knees: a single-blind, randomized, controlled trial</TI>
<SO>American Journal of Physical Medicine &amp; Rehabilitation</SO>
<YR>2008</YR>
<VL>87</VL>
<NO>6</NO>
<PG>443-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheing-2002" MODIFIED="2009-08-12 15:31:54 -0400" MODIFIED_BY="[Empty name]" NAME="Cheing 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-12-08 08:44:03 -0500" MODIFIED_BY="[Empty name]" NOTES="England" NOTES_MODIFIED="2008-12-08 08:44:03 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cheing GL, Hui-Chan CW, Chan KM, Cheing Gladys LY, Hui-Chan Christina WY, Chan KM</AU>
<TI>Does four weeks of TENS and/or isometric exercise produce cumulative reduction of osteoarthritic knee pain?</TI>
<SO>Clinical Rehabilitation</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>7</NO>
<PG>749-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-08-12 15:31:54 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheing GL, Hui-Chan CW, Cheing Gladys LY, Hui-Chan Christina WY</AU>
<TI>Would the addition of TENS to exercise training produce better physical performance outcomes in people with knee osteoarthritis than either intervention alone?</TI>
<SO>Clinical Rehabilitation</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>5</NO>
<PG>487-97</PG>
<IDENTIFIERS MODIFIED="2008-12-09 03:28:21 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-08-04 08:57:37 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheing GLY, Hui-Chan CWY, Chan KM</AU>
<TI>Does four weeks of TENS and/or isometric exercise produce cumulative reduction of osteoarthritic knee pain?</TI>
<SO>Pain Reviews</SO>
<YR>2002</YR>
<VL>9</VL>
<NO>3/4</NO>
<PG>141-51</PG>
<IDENTIFIERS MODIFIED="2009-08-04 08:57:37 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheing-2003" MODIFIED="2009-08-12 15:32:16 -0400" MODIFIED_BY="[Empty name]" NAME="Cheing 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-12 15:32:16 -0400" MODIFIED_BY="[Empty name]" NOTES="Sweden" NOTES_MODIFIED="2009-08-12 15:32:16 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheing GL, Tsui AY, Lo SK, Hui-Chan CW, Cheing Gladys LY, Tsui Amy YY, et al</AU>
<TI>Optimal stimulation duration of TENS in the management of osteoarthritic knee pain</TI>
<SO>Journal of Rehabilitation Medicine</SO>
<YR>2003</YR>
<VL>35</VL>
<NO>2</NO>
<PG>62&#8211;8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Defrin-2005" MODIFIED="2009-08-12 15:32:33 -0400" MODIFIED_BY="[Empty name]" NAME="Defrin 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-08-12 15:32:33 -0400" MODIFIED_BY="[Empty name]" NOTES="Netherlands" NOTES_MODIFIED="2009-08-12 15:32:33 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Defrin R, Ariel E, Peretz C</AU>
<TI>Segmental noxious versus innocuous electrical stimulation for chronic pain relief and the effect of fading sensation during treatment</TI>
<SO>Pain</SO>
<YR>2005</YR>
<VL>115</VL>
<NO>1-2</NO>
<PG>152&#8211;60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fargas_x002d_Babjak-1989" MODIFIED="2009-03-05 07:14:58 -0500" MODIFIED_BY="[Empty name]" NAME="Fargas-Babjak 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-03-05 07:14:48 -0500" MODIFIED_BY="[Empty name]" NOTES="United states" NOTES_MODIFIED="2009-03-05 07:14:48 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fargas-Babjak A, Rooney P, Gerecz E, Fargas-Babjak A, Rooney P, Gerecz E</AU>
<TI>Randomized trial of Codetron for pain control in osteoarthritis of the hip/knee</TI>
<SO>Clinical Journal of Pain</SO>
<YR>1989</YR>
<VL>5</VL>
<NO>2</NO>
<PG>137-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-05 07:14:58 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fargas-Babjak AM, Pomeranz B</AU>
<TI>Acupuncture-like stimulation with Codetron for rehabilitation of patients with chronic pain syndrome and osteoarthritis</TI>
<SO>Acupuncture &amp; Electro-Therapeutics Research</SO>
<YR>1992</YR>
<VL>17</VL>
<PG>95-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garland-2007" MODIFIED="2009-08-12 15:32:48 -0400" MODIFIED_BY="[Empty name]" NAME="Garland 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-12 15:32:48 -0400" MODIFIED_BY="[Empty name]" NOTES="England" NOTES_MODIFIED="2009-08-12 15:32:48 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garland D, Holt P, Harrington JT, Caldwell J, Zizic T, Cholewczynski J, et al</AU>
<TI>A 3-month, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a highly optimized, capacitively coupled, pulsed electrical stimulator in patients with osteoarthritis of the knee</TI>
<SO>Osteoarthritis &amp; Cartilage</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>6</NO>
<PG>630-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grimmer-1992" MODIFIED="2009-08-12 15:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Grimmer 1992" YEAR="1992">
<REFERENCE MODIFIED="2009-08-12 15:33:19 -0400" MODIFIED_BY="[Empty name]" NOTES="7/10 [Eligibility criteria: Yes; Random allocation: Yes; Concealed allocation: No; Baseline comparability: Yes; Blind subjects: Yes; Blind therapists: No; Blind assessors: Yes; Adequate follow-up: Yes; Intention-to-treat analysis: No; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*EnglishDownloaded from PEDro http://www.pedro.fhs.usyd.edu.au" NOTES_MODIFIED="2009-08-12 15:33:19 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grimmer K</AU>
<TI>A controlled double blind study comparing the effects of strong burst mode TENS and high rate TENS on painful osteoarthritic knees</TI>
<SO>Australian Journal of Physiotherapy</SO>
<YR>1992</YR>
<VL>38</VL>
<NO>1</NO>
<PG>49-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Itoh-2008" MODIFIED="2009-08-12 15:33:32 -0400" MODIFIED_BY="[Empty name]" NAME="Itoh 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-08-12 15:33:32 -0400" MODIFIED_BY="[Empty name]" NOTES="England" NOTES_MODIFIED="2009-08-12 15:33:32 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Itoh K, Hirota S, Katsumi Y, Ochi H, Kitakoji H</AU>
<TI>A pilot study on using acupuncture and transcutaneous electrical nerve stimulation (TENS) to treat knee osteoarthritis (OA)</TI>
<SO>Chinesische Medizin</SO>
<YR>2008</YR>
<VL>3</VL>
<PG>2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Law-2004" MODIFIED="2009-08-12 15:33:50 -0400" MODIFIED_BY="[Empty name]" NAME="Law 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-08-12 15:33:50 -0400" MODIFIED_BY="[Empty name]" NOTES="Sweden" NOTES_MODIFIED="2009-08-12 15:33:50 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Law PP, Cheing GL</AU>
<TI>Optimal stimulation frequency of transcutaneous electrical nerve stimulation on people with knee osteoarthritis</TI>
<SO>Journal of Rehabilitation Medicine</SO>
<YR>2004</YR>
<VL>36</VL>
<NO>5</NO>
<PG>220&#8211;5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Law-2004a" MODIFIED="2009-08-12 15:34:05 -0400" MODIFIED_BY="[Empty name]" NAME="Law 2004a" YEAR="2004">
<REFERENCE MODIFIED="2009-08-12 15:34:05 -0400" MODIFIED_BY="[Empty name]" NOTES="8/10 [Eligibility criteria: Yes; Random allocation: Yes; Concealed allocation: Yes; Baseline comparability: Yes; Blind subjects: Yes; Blind therapists: No; Blind assessors: Yes; Adequate follow-up: Yes; Intention-to-treat analysis: No; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*EnglishDownloaded from PEDro http://www.pedro.fhs.usyd.edu.au" NOTES_MODIFIED="2009-08-12 15:34:05 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Law PPW, Cheing GLY, Tsui AYY</AU>
<TI>Does transcutaneous electrical nerve stimulation improve the physical performance of people with knee osteoarthritis?</TI>
<SO>Journal of Clinical Rheumatology</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>6</NO>
<PG>295&#8211;9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ng-2003" MODIFIED="2009-08-12 15:34:21 -0400" MODIFIED_BY="[Empty name]" NAME="Ng 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-12 15:34:21 -0400" MODIFIED_BY="[Empty name]" NOTES="United States" NOTES_MODIFIED="2009-08-12 15:34:21 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ng MM, Leung MC, Poon DM, Ng MML, Leung Mason CP, Poon DMY</AU>
<TI>The effects of electro-acupuncture and transcutaneous electrical nerve stimulation on patients with painful osteoarthritic knees: a randomized controlled trial with follow-up evaluation</TI>
<SO>Journal of Alternative &amp; Complementary Medicine</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>5</NO>
<PG>641&#8211;9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quirk-1985" MODIFIED="2009-08-12 15:34:40 -0400" MODIFIED_BY="[Empty name]" NAME="Quirk 1985" YEAR="1985">
<REFERENCE MODIFIED="2009-08-12 15:34:40 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quirk AS, Newman RJ, Newman KJ</AU>
<TI>An evaluation of interferential therapy, shortwave diathermy and exercise in the treatment of osteoarthrosis of the knee</TI>
<SO>Physiotherapy</SO>
<YR>1985</YR>
<VL>71</VL>
<PG>55-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1983" MODIFIED="2009-02-03 09:18:34 -0500" MODIFIED_BY="[Empty name]" NAME="Smith 1983" YEAR="1983">
<REFERENCE MODIFIED="2009-02-03 09:18:34 -0500" MODIFIED_BY="[Empty name]" NOTES="England" NOTES_MODIFIED="2009-02-03 09:18:34 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith CR, Lewith GT, Machin D, Smith CR, Lewith GT, Machin D</AU>
<TI>TNS and osteo-arthritic pain. Preliminary study to establish a controlled method of assessing transcutaneous nerve stimulation as a treatment for the pain caused by osteo-arthritis of the knee</TI>
<SO>Physiotherapy</SO>
<YR>1983</YR>
<VL>69</VL>
<NO>8</NO>
<PG>266-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yurtkuran-1999" MODIFIED="2009-02-03 09:13:09 -0500" MODIFIED_BY="[Empty name]" NAME="Yurtkuran 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-02-03 09:13:09 -0500" MODIFIED_BY="[Empty name]" NOTES="United states" NOTES_MODIFIED="2009-02-03 09:13:09 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yurtkuran M, Kocagil T, Yurtkuran M, Kocagil T</AU>
<TI>TENS, electroacupuncture and ice massage: comparison of treatment for osteoarthritis of the knee</TI>
<SO>American Journal of Acupuncture</SO>
<YR>1999</YR>
<VL>27</VL>
<NO>3-4</NO>
<PG>133-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zizic-1995" MODIFIED="2008-12-03 09:43:00 -0500" MODIFIED_BY="[Empty name]" NAME="Zizic 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-12-03 09:39:27 -0500" MODIFIED_BY="[Empty name]" NOTES="Canada" NOTES_MODIFIED="2008-12-03 09:39:27 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zizic TM, Hoffman KC, Holt PA, Hungerford DS, O'Dell JR, Jacobs MA, et al</AU>
<TI>The treatment of osteoarthritis of the knee with pulsed electrical stimulation</TI>
<SO>Journal of Rheumatology</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>9</NO>
<PG>1757-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-08-13 10:28:21 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Barr-2004" MODIFIED="2009-08-12 15:35:05 -0400" MODIFIED_BY="[Empty name]" NAME="Barr 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-08-12 15:35:05 -0400" MODIFIED_BY="[Empty name]" NOTES="3/10 [Eligibility criteria: Yes; Random allocation: Yes; Concealed allocation: No; Baseline comparability: No; Blind subjects: No; Blind therapists: No; Blind assessors: No; Adequate follow-up: No; Intention-to-treat analysis: No; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*EnglishDownloaded from PEDro http://www.pedro.fhs.usyd.edu.au" NOTES_MODIFIED="2009-08-12 15:35:05 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barr JO, Weissenbuehler SA, Cleary CK</AU>
<TI>Effectiveness and comfort of transcutaneous electrical nerve stimulation for older persons with chronic pain</TI>
<SO>Journal of Geriatric Physical Therapy</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>3</NO>
<PG>93-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bernau-1981" MODIFIED="2009-08-12 15:35:20 -0400" MODIFIED_BY="[Empty name]" NAME="Bernau 1981" YEAR="1981">
<REFERENCE MODIFIED="2009-08-12 15:35:20 -0400" MODIFIED_BY="[Empty name]" NOTES="GermanGermany, west" NOTES_MODIFIED="2009-08-12 15:35:20 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernau A, Kruppa G, Bernau A, Kruppa G</AU>
<TI>Low frequency electro-stimulation and ultrasonic therapy (author's transl)</TI>
<SO>Zeitschrift fur Orthopadie und Ihre Grenzgebiete</SO>
<YR>1981</YR>
<VL>119</VL>
<NO>1</NO>
<PG>126-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burch-2008" MODIFIED="2009-08-04 09:01:40 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Burch 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-08-04 09:01:40 -0400" MODIFIED_BY="Jenny Bellorini" NOTES="England" NOTES_MODIFIED="2009-08-04 09:01:40 -0400" NOTES_MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burch FX, Tarro JN, Greenberg JJ, Carroll WJ</AU>
<TI>Evaluating the benefits of patterned stimulation in the treatment of osteoarthritis of the knee. A multi-center, randomized, single-blind, controlled study with an independent masked evaluator</TI>
<SO>Osteoarthritis &amp; Cartilage</SO>
<YR>2008</YR>
<VL>16</VL>
<NO>8</NO>
<PG>865-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cauthen-1975" MODIFIED="2009-08-12 15:35:51 -0400" MODIFIED_BY="[Empty name]" NAME="Cauthen 1975" YEAR="1975">
<REFERENCE MODIFIED="2009-08-12 15:35:51 -0400" MODIFIED_BY="[Empty name]" NOTES="Journal: Article" NOTES_MODIFIED="2009-08-12 15:35:51 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cauthen J, Renner E</AU>
<TI>Transcutaneous and peripheral nerve stimulation for chronic pain states</TI>
<SO>Surgical Neurology</SO>
<YR>1975</YR>
<VL>4</VL>
<NO>1</NO>
<PG>102-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Commandre-1977" MODIFIED="2009-02-03 09:25:59 -0500" MODIFIED_BY="[Empty name]" NAME="Commandre 1977" YEAR="1977">
<REFERENCE MODIFIED="2009-02-03 09:25:59 -0500" MODIFIED_BY="[Empty name]" NOTES="FrenchElectrotherapie dans les reactions inflammatoires osteo articulairesJournal" NOTES_MODIFIED="2009-02-03 09:25:59 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Commandre F, Guillemin R, Revelli G</AU>
<TI>Electrotherapy in osteoarticular inflammatory reactions</TI>
<SO>Electro Diagnostic Therapie</SO>
<YR>1977</YR>
<VL>14</VL>
<NO>2</NO>
<PG>37-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cottingham-1985a" MODIFIED="2009-08-12 15:41:52 -0400" MODIFIED_BY="[Empty name]" NAME="Cottingham 1985a" YEAR="1985">
<REFERENCE MODIFIED="2009-02-03 09:36:00 -0500" MODIFIED_BY="[Empty name]" NOTES="Netherlands" NOTES_MODIFIED="2009-02-03 09:36:00 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cottingham B, Phillips PD, Davies GK, Getty CJ, Cottingham B, Phillips PD, et al</AU>
<TI>The effect of subcutaneous nerve stimulation (SCNS) on pain associated with osteoarthritis of the hip</TI>
<SO>Pain</SO>
<YR>1985</YR>
<VL>22</VL>
<NO>3</NO>
<PG>243-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cottingham-1985b" MODIFIED="2009-08-12 15:37:37 -0400" MODIFIED_BY="[Empty name]" NAME="Cottingham 1985b" YEAR="1985">
<REFERENCE MODIFIED="2009-08-12 15:36:18 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cottingham B, Phillips PD, Davies GK, Getty CJM</AU>
<TI>The effects of peripheral electrical nerve stimulation on pain associated with osteoarthritis of the hip</TI>
<SO>American Journal of Surgery</SO>
<YR>1985</YR>
<VL>67-B</VL>
<PG>152</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Durmus-2005" MODIFIED="2009-08-12 15:42:10 -0400" MODIFIED_BY="[Empty name]" NAME="Durmus 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-08-12 15:42:10 -0400" MODIFIED_BY="[Empty name]" NOTES="TurkishDiz osteoartritli hastalarda biofeedback yardimli i[dot zometrik egzersiz ve elektrik stimulasyon programinin agri, anksiyete ve depresyon uzerine etkisiJournal: Article" NOTES_MODIFIED="2009-08-12 15:42:10 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Durmus D, Alayli G, Canturk F</AU>
<TI>Effects of biofeedback assisted isometric exercise and electrical stimulation on pain, anxiety and depression scores in knee osteoarthritis</TI>
<SO>Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi</SO>
<YR>2005</YR>
<VL>51</VL>
<NO>4</NO>
<PG>142-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaines-2001" MODIFIED="2009-08-12 15:42:48 -0400" MODIFIED_BY="[Empty name]" NAME="Gaines 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-08-12 15:42:48 -0400" MODIFIED_BY="[Empty name]" NOTES="Accession Number: 2003065405. Language: English. Entry Date: 20030516. Revision Date: 20070126. Publication Type: doctoral dissertation; clinical trial; research. Special Interest: Pain and Pain Management. Instrumentation: Arthritis Impact Measurement Scale 2 - Pain Subscale (AIMS2-PS); McGill Pain Questionnaire.UMI Order AAI3028271." NOTES_MODIFIED="2009-08-12 15:42:48 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Gaines JM</AU>
<TI>The effects of neuromuscular electrical stimulation on chronic knee pain and functional performance in older adults with osteoarthritis of the knee</TI>
<SO>PhD Thesis</SO>
<YR>2001</YR>
<PG>269</PG>
<PB>Johns Hopkins University</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaines-2004" MODIFIED="2009-08-12 15:42:36 -0400" MODIFIED_BY="[Empty name]" NAME="Gaines 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-08-12 15:42:36 -0400" MODIFIED_BY="[Empty name]" NOTES="United States" NOTES_MODIFIED="2009-08-12 15:42:36 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaines JM, Metter EJ, Talbot LA</AU>
<TI>The effect of neuromuscular electrical stimulation on arthritis knee pain in older adults with osteoarthritis of the knee</TI>
<SO>Applied Nursing Research</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>3</NO>
<PG>201-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gibson-1989" MODIFIED="2009-02-03 10:10:05 -0500" MODIFIED_BY="[Empty name]" NAME="Gibson 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-02-03 10:10:05 -0500" MODIFIED_BY="[Empty name]" NOTES="England" NOTES_MODIFIED="2009-02-03 10:10:05 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gibson JN, Morrison WL, Scrimgeour CM, Smith K, Stoward PJ, Rennie MJ, et al</AU>
<TI>Effects of therapeutic percutaneous electrical stimulation of atrophic human quadriceps on muscle composition, protein synthesis and contractile properties</TI>
<SO>European Journal of Clinical Investigation</SO>
<YR>1989</YR>
<VL>19</VL>
<NO>2</NO>
<PG>206-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Godfrey-1979" MODIFIED="2009-08-12 15:43:08 -0400" MODIFIED_BY="[Empty name]" NAME="Godfrey 1979" YEAR="1979">
<REFERENCE MODIFIED="2009-08-12 15:43:08 -0400" MODIFIED_BY="[Empty name]" NOTES="4/10 [Eligibility criteria: No; Random allocation: No; Concealed allocation: No; Baseline comparability: No; Blind subjects: No; Blind therapists: No; Blind assessors: Yes; Adequate follow-up: Yes; Intention-to-treat analysis: No; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*EnglishDownloaded from PEDro http://www.pedro.fhs.usyd.edu.au" NOTES_MODIFIED="2009-08-12 15:43:08 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Godfrey CM, Jayawardena H, Quance TA, Welsh P</AU>
<TI>Comparison of electro-stimulation and isometric exercise in strengthening the quadriceps muscle</TI>
<SO>Physiotherapy Canada</SO>
<YR>1979</YR>
<VL>31</VL>
<NO>5</NO>
<PG>265-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grigor_x0027_eva-1992" MODIFIED="2009-08-12 15:43:25 -0400" MODIFIED_BY="[Empty name]" NAME="Grigor'eva 1992" YEAR="1992">
<REFERENCE MODIFIED="2009-08-12 15:43:25 -0400" MODIFIED_BY="[Empty name]" NOTES="RussianRussia" NOTES_MODIFIED="2009-08-12 15:43:25 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grigor'eva VD, Suzdal'nitskii DV, Strel'tsova EN, Nikolaeva TG, Grigor'eva VD, Suzdal'nitskii DV, et al</AU>
<TI>The effect of cryo- and cryoelectrotherapy on regional hemodynamics in coxarthrosis patients</TI>
<SO>Voprosy Kurortologii, Fizioterapii i Lechebnoi Fizicheskoi Kultury</SO>
<YR>1992</YR>
<VL>Sep-Dec</VL>
<NO>5-6</NO>
<PG>49-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guven-2003" MODIFIED="2009-08-12 15:44:15 -0400" MODIFIED_BY="[Empty name]" NAME="Guven 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-12 15:44:15 -0400" MODIFIED_BY="[Empty name]" NOTES="TurkishDi[dot z osteoartri[dot ti[dot nde yuksek voltaj galvani[dot k sti[dot mulasyonun kuadri[dot seps femori[dot s kas gucune etki[dot si[dotJournal: Article" NOTES_MODIFIED="2009-08-12 15:44:15 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guven Z, Coskun U, Gunduz O, Kaptan A</AU>
<TI>The effect of high voltage galvanic stimulation on quadriceps femoris muscle strength knee osteoarthritis</TI>
<SO>Journal of Rheumatology and Medical Rehabilitation</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>2</NO>
<PG>72-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamilton-1959" MODIFIED="2009-08-12 15:44:30 -0400" MODIFIED_BY="[Empty name]" NAME="Hamilton 1959" YEAR="1959">
<REFERENCE MODIFIED="2009-08-12 15:44:30 -0400" MODIFIED_BY="[Empty name]" NOTES="Journal: Article" NOTES_MODIFIED="2009-08-12 15:44:30 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton D, Bywaters E, Please N</AU>
<TI>A controlled trial of various forms of physiotherapy in arthritis</TI>
<SO>British Medical Journal</SO>
<YR>1959</YR>
<VL>1</VL>
<NO>5121</NO>
<PG>542-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2000" MODIFIED="2009-02-03 09:57:50 -0500" MODIFIED_BY="[Empty name]" NAME="Huang 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-02-03 09:57:50 -0500" MODIFIED_BY="[Empty name]" NOTES="United States" NOTES_MODIFIED="2009-02-03 09:57:50 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang MH, Chen CH, Chen TW, Weng MC, Wang WT, Wang YL, et al</AU>
<TI>The effects of weight reduction on the rehabilitation of patients with knee osteoarthritis and obesity</TI>
<SO>Arthritis Care &amp; Research</SO>
<YR>2000</YR>
<VL>13</VL>
<NO>6</NO>
<PG>398-405</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jensen-1991" MODIFIED="2009-02-03 10:06:08 -0500" MODIFIED_BY="[Empty name]" NAME="Jensen 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-02-03 10:06:08 -0500" MODIFIED_BY="[Empty name]" NOTES="England" NOTES_MODIFIED="2009-02-03 10:06:08 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jensen H, Zesler R, Christensen T, Jensen H, Zesler R, Christensen T</AU>
<TI>Transcutaneous electrical nerve stimulation (TNS) for painful osteoarthrosis of the knee</TI>
<SO>International Journal of Rehabilitation Research</SO>
<YR>1991</YR>
<VL>14</VL>
<NO>4</NO>
<PG>356-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kang-2007" MODIFIED="2009-02-03 10:03:50 -0500" MODIFIED_BY="[Empty name]" NAME="Kang 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-02-03 10:03:50 -0500" MODIFIED_BY="[Empty name]" NOTES="United States" NOTES_MODIFIED="2009-02-03 10:03:50 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kang RW, Lewis PB, Kramer A, Hayden JK, Cole BJ, Kang Richard W, et al</AU>
<TI>Prospective randomized single-blinded controlled clinical trial of percutaneous neuromodulation pain therapy device versus sham for the osteoarthritic knee: a pilot study</TI>
<SO>Orthopedics</SO>
<YR>2007</YR>
<VL>30</VL>
<NO>6</NO>
<PG>439-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katsnelson-2004" MODIFIED="2009-02-03 10:05:28 -0500" MODIFIED_BY="[Empty name]" NAME="Katsnelson 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-02-03 10:05:28 -0500" MODIFIED_BY="[Empty name]" NOTES="United States" NOTES_MODIFIED="2009-02-03 10:05:28 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katsnelson Y, Khokhlov A, Tsvetkov V, Bartoo G, Bartoo M, Katsnelson Y, et al</AU>
<TI>Temporary pain relief using transcranial electrotherapy stimulation: results of a randomized, double-blind pilot study</TI>
<SO>Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine &amp; Biology Society</SO>
<YR>2004</YR>
<VL>6</VL>
<PG>4087-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Komarova-1998" MODIFIED="2009-08-12 15:44:58 -0400" MODIFIED_BY="[Empty name]" NAME="Komarova 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-08-12 15:44:58 -0400" MODIFIED_BY="[Empty name]" NOTES="RussianRussia" NOTES_MODIFIED="2009-08-12 15:44:58 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Komarova LA, Kir'ianova VV, Zabolotnykh II, Zabolotnykh VA, Komarova LA, Kir'ianova VV, et al</AU>
<TI>The use of transcranial electrotherapy in the rehabilitation of osteoarthrosis patients</TI>
<SO>Voprosy Kurortologii, Fizioterapii i Lechebnoi Fizicheskoi Kultury</SO>
<YR>1998</YR>
<VL>Sep-Oct</VL>
<NO>5</NO>
<PG>27-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewis-1984" MODIFIED="2009-02-03 10:03:24 -0500" MODIFIED_BY="[Empty name]" NAME="Lewis 1984" YEAR="1984">
<REFERENCE MODIFIED="2009-02-03 10:03:24 -0500" MODIFIED_BY="[Empty name]" NOTES="England" NOTES_MODIFIED="2009-02-03 10:03:24 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis D, Lewis B, Sturrock RD, Lewis D, Lewis B, Sturrock RD</AU>
<TI>Transcutaneous electrical nerve stimulation in osteoarthrosis: a therapeutic alternative?</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1984</YR>
<VL>43</VL>
<NO>1</NO>
<PG>47-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewis-1985" MODIFIED="2009-08-12 15:45:21 -0400" MODIFIED_BY="[Empty name]" NAME="Lewis 1985" YEAR="1985">
<REFERENCE MODIFIED="2009-08-12 15:45:21 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis B</AU>
<TI>Analgesic efficacy of transcutaneous electrical nerve stimulation compared with a non-steroidal anti-inflammatory drug in osteoarthritis [abstract]</TI>
<SO>Australian and New Zealand Journal of Medicine Suppl</SO>
<YR>1985</YR>
<VL>15</VL>
<PG>189</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewis-1988" MODIFIED="2009-08-12 15:45:43 -0400" MODIFIED_BY="[Empty name]" NAME="Lewis 1988" YEAR="1988">
<REFERENCE MODIFIED="2009-08-12 15:45:43 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis B, Lewis D, Cumming G</AU>
<TI>The analgesic efficacy of transcutaneous electrical nerve stimulation (TENS) compared with a non-steroidal anti-inflammatory drug (naprosyn) in painful osteoarthritis (OA) of the knee [abstract]</TI>
<SO>Australian and New Zealand Journal of Medicine Suppl</SO>
<YR>1988</YR>
<VL>18</VL>
<PG>224</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewis-1994" MODIFIED="2009-02-03 09:30:37 -0500" MODIFIED_BY="[Empty name]" NAME="Lewis 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-02-03 09:30:37 -0500" MODIFIED_BY="[Empty name]" NOTES="5/10 [Eligibility criteria: Yes; Random allocation: Yes; Concealed allocation: No; Baseline comparability: Yes; Blind subjects: Yes; Blind therapists: No; Blind assessors: No; Adequate follow-up: No; Intention-to-treat analysis: No; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*EnglishDownloaded from PEDro http://www.pedro.fhs.usyd.edu.au" NOTES_MODIFIED="2009-02-03 09:30:37 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis B, Lewis D, Cumming G</AU>
<TI>The comparative analgesic efficacy of transcutaneous electrical nerve stimulation and a non-steroidal anti-inflammatory drug for painful osteoarthritis</TI>
<SO>British Journal of Rheumatology</SO>
<YR>1994</YR>
<VL>33</VL>
<NO>5</NO>
<PG>455-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lone-2003" MODIFIED="2009-02-03 09:31:45 -0500" MODIFIED_BY="[Empty name]" NAME="Lone 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-02-03 09:31:45 -0500" MODIFIED_BY="[Empty name]" NOTES="Accession Number: 2004010873. Language: English. Entry Date: 20040102. Publication Type: journal article; clinical trial; research; tables/charts. Journal Subset: Allied Health; Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; UK &amp;amp; Ireland. Special Interest: Pain and Pain Management; Physical Therapy. No. of Refs: 44 ref. NLM UID: 0401223.0031-9406" NOTES_MODIFIED="2009-02-03 09:31:45 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lone AR, Wafai ZA, Buth BA, Wani TA, Koul PA, Khan SH</AU>
<TI>Analgesic efficacy of transcutaneous electrical nerve stimulation compared with diclofenac sodium in osteo-arthritis of the knee</TI>
<SO>Physiotherapy</SO>
<YR>2003</YR>
<VL>89</VL>
<NO>8</NO>
<PG>478-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lund-2005" MODIFIED="2009-02-03 10:04:17 -0500" MODIFIED_BY="[Empty name]" NAME="Lund 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-02-03 10:04:17 -0500" MODIFIED_BY="[Empty name]" NOTES="Accession Number: 2009003430. Language: English. Entry Date: 20050930. Publication Type: journal article; pictorial; research; tables/charts. Journal Subset: Allied Health; Online/Print; Peer Reviewed; UK &amp;amp; Ireland. Special Interest: Pain and Pain Management; Physical Therapy. Grant Information: Karolinska Institutet's Foundation. No. of Refs: 32 ref. NLM UID: 9015520. Email: irene.lund@fyfa.ki.se.0959-3985" NOTES_MODIFIED="2009-02-03 10:04:17 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lund I, Lundeberg T, Kowalski J, Sandberg L, Norrbrink Budh C, Svensson E</AU>
<TI>Evaluation of variations in sensory and pain threshold assessments by electrocutaneous stimulation</TI>
<SO>Physiotherapy Theory &amp; Practice</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>2</NO>
<PG>81-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Macchione-1995" MODIFIED="2009-02-03 09:31:08 -0500" MODIFIED_BY="[Empty name]" NAME="Macchione 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-02-03 09:31:08 -0500" MODIFIED_BY="[Empty name]" NOTES="Accession Number: 1998015018. Language: English. Entry Date: 19980301. Revision Date: 20050414. Publication Type: journal article; pictorial. Journal Subset: Alternative/Complementary Therapies; Peer Reviewed; USA." NOTES_MODIFIED="2009-02-03 09:31:08 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macchione RA</AU>
<TI>Electrotherapeutic modalities: TENS</TI>
<SO>Chiropractic Journal</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>7</NO>
<PG>18-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matti-1987" MODIFIED="2009-08-12 15:46:12 -0400" MODIFIED_BY="[Empty name]" NAME="Matti 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-08-12 15:46:12 -0400" MODIFIED_BY="[Empty name]" NOTES="2/10 [Eligibility criteria: Yes; Random allocation: No; Concealed allocation: No; Baseline comparability: Yes; Blind subjects: No; Blind therapists: No; Blind assessors: No; Adequate follow-up: No; Intention-to-treat analysis: No; Between-group comparisons: Yes; Point estimates and variability: No. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*ItalianDownloaded from PEDro http://www.pedro.fhs.usyd.edu.au" NOTES_MODIFIED="2009-08-12 15:46:12 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matti A, Felicetti G, Maini M, Zelaschi F</AU>
<TI>Low-frequency muscular electrogymnastics; biologic action on parameters of muscle function [Italian]</TI>
<SO>Riabilitazione</SO>
<YR>1987</YR>
<VL>20</VL>
<NO>4</NO>
<PG>241-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miranda_x002d_Filloy-2005" MODIFIED="2009-02-03 10:01:37 -0500" MODIFIED_BY="[Empty name]" NAME="Miranda-Filloy 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-02-03 10:01:37 -0500" MODIFIED_BY="[Empty name]" NOTES="Accession Number: 2009051152. Language: Spanish. Entry Date: 20051209. Publication Type: journal article; clinical trial; research; tables/charts. Journal Subset: Allied Health; Blind Peer Reviewed; Editorial Board Reviewed; Europe; Peer Reviewed. Special Interest: Physical Therapy. Instrumentation: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC); Lequesne Method. No. of Refs: 17 ref. NLM UID: 7802471.0048-7120" NOTES_MODIFIED="2009-02-03 10:01:37 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miranda-Filloy JA, Barbazan Alvarez C, Monteagudo Sanchez B, Graña Gil J, Galdo Fernandez YF</AU>
<TI>Effect of transcutaneous electrical quadriceps muscle stimulation in knee osteoarthritis symptomatology [Spanish]</TI>
<SO>Rehabilitacion</SO>
<YR>2005</YR>
<VL>39</VL>
<NO>4</NO>
<PG>167-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mont-2006" MODIFIED="2009-02-03 09:54:40 -0500" MODIFIED_BY="[Empty name]" NAME="Mont 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-02-03 09:54:40 -0500" MODIFIED_BY="[Empty name]" NOTES="United States" NOTES_MODIFIED="2009-02-03 09:54:40 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mont MA, Hungerford DS, Caldwell JR, Ragland PS, Hoffman KC, He YD, et al</AU>
<TI>Pulsed electrical stimulation to defer TKA in patients with knee osteoarthritis</TI>
<SO>Orthopedics</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>10</NO>
<PG>887-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oldham-1995" MODIFIED="2009-02-03 09:55:22 -0500" MODIFIED_BY="[Empty name]" NAME="Oldham 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-02-03 09:55:22 -0500" MODIFIED_BY="[Empty name]" NOTES="3/10 [Eligibility criteria: Yes; Random allocation: Yes; Concealed allocation: No; Baseline comparability: No; Blind subjects: No; Blind therapists: No; Blind assessors: Yes; Adequate follow-up: No; Intention-to-treat analysis: No; Between-group comparisons: Yes; Point estimates and variability: No. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*EnglishDownloaded from PEDro http://www.pedro.fhs.usyd.edu.au" NOTES_MODIFIED="2009-02-03 09:55:22 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oldham JA, Howe TE, Petterson T, Smith GP, Tallis RC</AU>
<TI>Electrotherapeutic rehabilitation of the quadriceps in elderly osteoarthritic patients: a double blind assessment of patterned neuromuscular stimulation</TI>
<SO>Clinical Rehabilitation</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>1</NO>
<PG>10-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oldham-1997" MODIFIED="2009-02-03 09:39:13 -0500" MODIFIED_BY="[Empty name]" NAME="Oldham 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-02-03 09:39:13 -0500" MODIFIED_BY="[Empty name]" NOTES="Accession Number: 1997031309. Language: English. Entry Date: 19970901. Publication Type: journal article; commentary; research; tables/charts. Journal Subset: Nursing; Peer Reviewed; UK &amp;amp; Ireland. No. of Refs: 18 ref. NLM UID: 9708555.1361-9004" NOTES_MODIFIED="2009-02-03 09:39:13 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oldham J, Howe T</AU>
<TI>The effectiveness of placebo muscle stimulation in quadriceps muscle rehabilitation: a preliminary evaluation... including commentary by Draper P</TI>
<SO>Clinical Effectiveness in Nursing</SO>
<YR>1997</YR>
<VL>1</VL>
<NO>1</NO>
<PG>25-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oosterhof-2008" MODIFIED="2009-08-12 15:46:47 -0400" MODIFIED_BY="[Empty name]" NAME="Oosterhof 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-08-12 15:46:47 -0400" MODIFIED_BY="[Empty name]" NOTES="Netherlands" NOTES_MODIFIED="2009-08-12 15:46:47 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oosterhof J, Samwel HJ, de Boo TM, Wilder-Smith OH, Oostendorp RA, Crul BJ, et al</AU>
<TI>Predicting outcome of TENS in chronic pain: a prospective, randomized, placebo controlled trial</TI>
<SO>Pain</SO>
<YR>2008</YR>
<VL>136</VL>
<NO>1-2</NO>
<PG>11-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paillard-2005" MODIFIED="2009-08-12 15:46:59 -0400" MODIFIED_BY="[Empty name]" NAME="Paillard 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-08-12 15:46:59 -0400" MODIFIED_BY="[Empty name]" NOTES="3/10 [Eligibility criteria: No; Random allocation: Yes; Concealed allocation: No; Baseline comparability: Yes; Blind subjects: No; Blind therapists: No; Blind assessors: No; Adequate follow-up: No; Intention-to-treat analysis: No; Between-group comparisons: Yes; Point estimates and variability: No. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*EnglishDownloaded from PEDro http://www.pedro.fhs.usyd.edu.au" NOTES_MODIFIED="2009-08-12 15:46:59 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paillard T, Lafont C, Soulat JM, Montoya R, Costes-Salon MC, Dupui P</AU>
<TI>Short-term effects of electrical stimulation superimposed on muscular voluntary contraction in postural control in elderly women</TI>
<SO>Journal of Strength &amp; Conditioning Research</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>3</NO>
<PG>640-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Picaza-1975" MODIFIED="2009-08-12 15:47:12 -0400" MODIFIED_BY="[Empty name]" NAME="Picaza 1975" YEAR="1975">
<REFERENCE MODIFIED="2009-08-12 15:47:12 -0400" MODIFIED_BY="[Empty name]" NOTES="Journal: Article" NOTES_MODIFIED="2009-08-12 15:47:12 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Picaza J, Cannon B, Hunter S</AU>
<TI>Pain suppression by peripheral nerve stimulation. Part I. Observations with transcutaneous stimuli</TI>
<SO>Surgical Neurology</SO>
<YR>1975</YR>
<VL>4</VL>
<NO>1</NO>
<PG>105-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salaj-2001" MODIFIED="2009-08-12 15:47:31 -0400" MODIFIED_BY="[Empty name]" NAME="Salaj 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-08-12 15:47:31 -0400" MODIFIED_BY="[Empty name]" NOTES="CzechOsteoartroza a jeji terapie v ldn HostinneJournal: Article" NOTES_MODIFIED="2009-08-12 15:47:31 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salaj R</AU>
<TI>Osteoarthritis and its treatment in the sanatorium for chronic diseases in Hostinne</TI>
<SO>Rehabilitace a Fyzikalni Lekarstvi</SO>
<YR>2001</YR>
<VL>8</VL>
<NO>3</NO>
<PG>115-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salim-1996" MODIFIED="2009-08-12 15:47:43 -0400" MODIFIED_BY="[Empty name]" NAME="Salim 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-08-12 15:47:43 -0400" MODIFIED_BY="[Empty name]" NOTES="Accession Number: 1997004572. Language: English. Entry Date: 19970201. Publication Type: journal article; research; tables/charts. Journal Subset: Alternative/Complementary Therapies; Biomedical; Peer Reviewed; USA. No. of Refs: 6 ref. NLM UID: 9612767.1090-9222" NOTES_MODIFIED="2009-08-12 15:47:43 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salim M</AU>
<TI>Transcutaneous electrical nerve stimulation (TENS) in chronic pain</TI>
<SO>Alternative Therapies in Clinical Practice</SO>
<YR>1996</YR>
<VL>3</VL>
<NO>4</NO>
<PG>33-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sluka-1998" MODIFIED="2008-12-04 08:56:09 -0500" MODIFIED_BY="[Empty name]" NAME="Sluka 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-12-04 08:56:09 -0500" MODIFIED_BY="[Empty name]" NOTES="Journal: Article" NOTES_MODIFIED="2008-12-04 08:56:09 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sluka K, Bailey K, Bogush J, Olson R, Ricketts A</AU>
<TI>Treatment with either high or low frequency TENS reduces the secondary hyperalgesia observed after injection of kaolin and carrageenan into the knee joint</TI>
<SO>Pain</SO>
<YR>1998</YR>
<VL>77</VL>
<NO>1</NO>
<PG>97-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sok-2007" MODIFIED="2009-08-12 15:48:05 -0400" MODIFIED_BY="[Empty name]" NAME="Sok 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-12 15:48:05 -0400" MODIFIED_BY="[Empty name]" NOTES="KoreanKorea (South)" NOTES_MODIFIED="2009-08-12 15:48:05 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sok SR, Kim KB, Sok Sohyune R, Kim Kwuy Bun</AU>
<TI>Effects of muscle electric stimulation on chronic knee pain, activities of daily living, and living satisfaction for Korean elderly women</TI>
<SO>Daehan Ganho Haghoeji</SO>
<YR>2007</YR>
<VL>37</VL>
<NO>3</NO>
<PG>305-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svarcova-1988a" MODIFIED="2009-08-13 10:28:21 -0400" MODIFIED_BY="[Empty name]" NAME="Svarcova 1988a" YEAR="1988">
<REFERENCE MODIFIED="2009-08-13 10:27:21 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svarcova J, Zvarova J, Kouba A, Trnavsky K</AU>
<TI>Does physiotherapy affect the pain in activated arthrosis?</TI>
<TO>Beeinflusst Physiotherapie den Schmerz bei aktivierter Arthrose?</TO>
<SO>Zeitschrift für Physiotherapie</SO>
<YR>1988</YR>
<VL>40</VL>
<PG>333-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svarcova-1988b" MODIFIED="2009-08-13 10:28:13 -0400" MODIFIED_BY="[Empty name]" NAME="Svarcova 1988b" YEAR="1988">
<REFERENCE MODIFIED="2009-02-03 09:46:31 -0500" MODIFIED_BY="[Empty name]" NOTES="Sweden" NOTES_MODIFIED="2009-02-03 09:46:31 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svarcova J, Trnavsky K, Zvarova J, Svarcova J, Trnavsky K, Zvarova J</AU>
<TI>The influence of ultrasound, galvanic currents and shortwave diathermy on pain intensity in patients with osteoarthritis</TI>
<SO>Scandinavian Journal of Rheumatology - Supplement</SO>
<YR>1988</YR>
<VL>67</VL>
<PG>83-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svarcova-1990" MODIFIED="2009-08-12 15:50:54 -0400" MODIFIED_BY="[Empty name]" NAME="Svarcova 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-08-12 15:50:54 -0400" MODIFIED_BY="[Empty name]" NOTES="5/10 [Eligibility criteria: Yes; Random allocation: Yes; Concealed allocation: No; Baseline comparability: No; Blind subjects: No; Blind therapists: No; Blind assessors: No; Adequate follow-up: Yes; Intention-to-treat analysis: Yes; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*GermanDownloaded from PEDro http://www.pedro.fhs.usyd.edu.au" NOTES_MODIFIED="2009-08-12 15:50:54 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svarcova J, Zvarova J, Pichova A, Kouba A, Simacek K, Uhlemann C, et al</AU>
<TI>Comparison of the analgesic effects of electroacupuncture and of galvanic current in patients with activated osteoarthrosis (a controlled clinical study) [German]</TI>
<SO>Zeitschrift fur Physiotherapie</SO>
<YR>1990</YR>
<VL>42</VL>
<NO>6</NO>
<PG>375-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Talbot-2003" MODIFIED="2009-08-12 15:49:13 -0400" MODIFIED_BY="[Empty name]" NAME="Talbot 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-12 15:49:13 -0400" MODIFIED_BY="[Empty name]" NOTES="Canada" NOTES_MODIFIED="2009-08-12 15:49:13 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Talbot LA, Gaines JM, Ling SM, Metter EJ</AU>
<TI>A home-based protocol of electrical muscle stimulation for quadriceps muscle strength in older adults with osteoarthritis of the knee</TI>
<SO>Journal of Rheumatology</SO>
<YR>2003</YR>
<VL>30</VL>
<NO>7</NO>
<PG>1571-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tam-2004" MODIFIED="2009-08-12 15:49:27 -0400" MODIFIED_BY="[Empty name]" NAME="Tam 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-08-12 15:49:27 -0400" MODIFIED_BY="[Empty name]" NOTES="Accession Number: 2004113063. Language: English. Entry Date: 20040709. Publication Type: journal article; equations &amp;amp; formulas; pictorial; research; tables/charts. Journal Subset: Allied Health; Peer Reviewed; UK &amp;amp; Ireland. Special Interest: Physical Therapy. Grant Information: Funded by the Area of Strategic Development on East-meets-West in Rehabilitation Sciences, Hong Kong Polytechnic University. No. of Refs: 16 ref. NLM UID: 7805421. Email: rsalan@polyu.edu.hk.0342-5282PMID: 15097172" NOTES_MODIFIED="2009-08-12 15:49:27 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tam S, Cheing GLY, Hui-Chan CWY</AU>
<TI>Predicting osteoarthritic knee rehabilitation outcome by using a prediction model developed by data mining techniques</TI>
<SO>International Journal of Rehabilitation Research</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>1</NO>
<PG>65-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taylor-1981" MODIFIED="2009-02-03 09:45:35 -0500" MODIFIED_BY="[Empty name]" NAME="Taylor 1981" YEAR="1981">
<REFERENCE MODIFIED="2009-02-03 09:45:35 -0500" MODIFIED_BY="[Empty name]" NOTES="Netherlands" NOTES_MODIFIED="2009-02-03 09:45:35 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taylor P, Hallett M, Flaherty L, Taylor P, Hallett M, Flaherty L</AU>
<TI>Treatment of osteoarthritis of the knee with transcutaneous electrical nerve stimulation</TI>
<SO>Pain</SO>
<YR>1981</YR>
<VL>11</VL>
<NO>2</NO>
<PG>233-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tulgar-1991" MODIFIED="2009-08-12 15:49:45 -0400" MODIFIED_BY="[Empty name]" NAME="Tulgar 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-08-12 15:49:45 -0400" MODIFIED_BY="[Empty name]" NOTES="Journal: Article" NOTES_MODIFIED="2009-08-12 15:49:45 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tulgar M, McGlone F, Bowsher D, Miles J</AU>
<TI>Comparative effectiveness of different stimulation modes in relieving pain. Part II. A double-blind controlled long-term clinical trial</TI>
<SO>Pain</SO>
<YR>1991</YR>
<VL>47</VL>
<NO>2</NO>
<PG>157-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volklein-1990" MODIFIED="2009-08-12 15:50:01 -0400" MODIFIED_BY="[Empty name]" NAME="Volklein 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-08-12 15:50:01 -0400" MODIFIED_BY="[Empty name]" NOTES="GermanSchmerzanderung durch unterschiedliche stromformen diadynamischer strome bei gonarthrose und lumbalsyndromJournal: Article" NOTES_MODIFIED="2009-08-12 15:50:01 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volklein R, Callies R</AU>
<TI>Changes in pain by different types of diadynamic current in gonarthrosis and lumbar syndrome</TI>
<SO>Zeitschrift fur Physiotherapie</SO>
<YR>1990</YR>
<VL>42</VL>
<NO>2</NO>
<PG>113-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiner-2007" MODIFIED="2009-08-12 15:50:15 -0400" MODIFIED_BY="[Empty name]" NAME="Weiner 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-12 15:50:15 -0400" MODIFIED_BY="[Empty name]" NOTES="United States" NOTES_MODIFIED="2009-08-12 15:50:15 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiner DK, Rudy TE, Morone N, Glick R, Kwoh CK</AU>
<TI>Efficacy of periosteal stimulation therapy for the treatment of osteoarthritis-associated chronic knee pain: an initial controlled clinical trial</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2007</YR>
<VL>55</VL>
<NO>10</NO>
<PG>1541-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zivkovic-2005" MODIFIED="2009-02-03 09:58:54 -0500" MODIFIED_BY="[Empty name]" NAME="Zivkovic 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-02-03 09:58:54 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Zivkovic</AU>
<TI>Different physiotherapy programs for patients with knee osteoarthritis</TI>
<SO>EULAR</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-12-06 09:27:43 -0500" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2009-02-23 10:25:57 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Fary-2008" MODIFIED="2008-12-06 08:53:22 -0500" MODIFIED_BY="[Empty name]" NAME="Fary 2008" YEAR="2008">
<REFERENCE MODIFIED="2008-12-06 08:53:22 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fary RE, Carroll GJ, Briffa TG, Gupta R, Briffa NK, Fary Robyn E, et al</AU>
<TI>The effectiveness of pulsed electrical stimulation (E-PES) in the management of osteoarthritis of the knee: a protocol for a randomised controlled trial</TI>
<SO>BMC Musculoskeletal Disorders</SO>
<YR>2008</YR>
<VL>9</VL>
<PG>18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palmer-2007" MODIFIED="2009-02-23 10:23:33 -0500" MODIFIED_BY="[Empty name]" NAME="Palmer 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-02-23 10:22:05 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Palmer S</AU>
<TI>Effects of transcutaneous electrical nerve stimulation (TENS) and exercise on knee osteoarthritis (OA): a randomised controlled trial</TI>
<SO>ISTRCTN</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-08-12 15:58:10 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-08-12 15:58:10 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" MODIFIED="2009-02-03 10:38:16 -0500" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman R, Brandt K, Hochberg M, Moskowitz R, Bellamy N, Bloch DA, et al</AU>
<TI>Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop</TI>
<SO>Osteoarthritis Cartilage</SO>
<YR>1996</YR>
<VL>4</VL>
<NO>4</NO>
<PG>217-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andersson-1976" NAME="Andersson 1976" TYPE="JOURNAL_ARTICLE">
<AU>Andersson SA, Hansson G, Holmgren E, Renberg O</AU>
<TI>Evaluation of the pain suppression effect of different frequencies of peripheral electrical stimulation in chronic pain conditions</TI>
<SO>Acta Orthopaedica Scandinavia</SO>
<YR>1976</YR>
<VL>47</VL>
<PG>149-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bellamy-1995" MODIFIED="2009-08-04 09:11:05 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Bellamy 1995" TYPE="JOURNAL_ARTICLE">
<AU>Bellamy N</AU>
<TI>Outcome measurement in osteoarthritis clinical trials</TI>
<SO>Journal of Rheumatology</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>Suppl. 43</NO>
<PG>49-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bjordal-2007" MODIFIED="2009-08-12 15:52:38 -0400" MODIFIED_BY="[Empty name]" NAME="Bjordal 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bjordal JM, Johnson MI, Lopes-Martins RA, Bogen B, Chow R, Ljunggren AE</AU>
<TI>Short-term efficacy of physical interventions in osteoarthritic knee pain. A systematic review and meta-analysis of randomised placebo-controlled trials</TI>
<SO>BMC Musculoskeletal Disorders</SO>
<YR>2007</YR>
<VL>8</VL>
<PG>51</PG>
<IDENTIFIERS MODIFIED="2009-08-04 09:11:11 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<REFERENCE ID="REF-Brosseau-2004" MODIFIED="2009-08-12 15:52:49 -0400" MODIFIED_BY="[Empty name]" NAME="Brosseau 2004" TYPE="JOURNAL_ARTICLE">
<AU>Brosseau L, Yonge K, Marchand S, Robinson V, Osiri M, Wells G, et al</AU>
<TI>Efficacy of transcutaneous electrical nerve stimulation for osteoarthritis of the lower extremities: a meta-analysis</TI>
<SO>Physical Therapy Reviews</SO>
<YR>2004</YR>
<VL>9</VL>
<PG>213-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carroll-2001" MODIFIED="2009-02-03 10:47:42 -0500" MODIFIED_BY="[Empty name]" NAME="Carroll 2001" TYPE="COCHRANE_REVIEW">
<AU>Carroll D, Moore RA, McQuay HJ, Fairman F, Tramer M, Leijon G</AU>
<TI>Transcutaneous electrical nerve stimulation (TENS) for chronic pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2009-02-03 10:47:34 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-03 10:47:34 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003222 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chinn-2000" MODIFIED="2009-07-17 08:20:45 -0400" MODIFIED_BY="[Empty name]" NAME="Chinn 2000" TYPE="JOURNAL_ARTICLE">
<AU>Chinn S</AU>
<TI>A simple method for converting an odds ratio to effect size for use in meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>22</NO>
<PG>3127-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clegg-2006" MODIFIED="2009-07-17 07:54:01 -0400" MODIFIED_BY="[Empty name]" NAME="Clegg 2006" TYPE="JOURNAL_ARTICLE">
<AU>Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al</AU>
<TI>Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>354</VL>
<NO>8</NO>
<PG>795-808</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1988" MODIFIED="2009-08-12 15:53:05 -0400" MODIFIED_BY="[Empty name]" NAME="Cohen 1988" TYPE="BOOK">
<AU>Cohen J</AU>
<SO>Statistical power analysis for the behavioral sciences</SO>
<YR>1988</YR>
<EN>2nd</EN>
<PB>Lawrence Earlbaum Associates</PB>
<CY>Hillsdale, NJ</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2009-08-12 15:53:20 -0400" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS MODIFIED="2009-08-04 09:11:43 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<REFERENCE ID="REF-Deyo-1990" MODIFIED="2008-12-12 05:35:25 -0500" MODIFIED_BY="[Empty name]" NAME="Deyo 1990" TYPE="JOURNAL_ARTICLE">
<AU>Deyo RA, Wash NE, Schoenfeld LS, Ramamurthy S</AU>
<TI>Can trials of physical treatments be blinded: the example of transcutaneous electrical nerve stimulation for chronic pain</TI>
<SO>American Journal of Physical Medicine and Rehabilitation</SO>
<YR>1990</YR>
<VL>69</VL>
<PG>6-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" MODIFIED="2009-08-12 15:53:34 -0400" MODIFIED_BY="[Empty name]" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6964</NO>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gezondheidsraad-1999" MODIFIED="2009-02-03 10:23:30 -0500" MODIFIED_BY="[Empty name]" NAME="Gezondheidsraad 1999" TYPE="OTHER">
<AU>Gezondheidsraad</AU>
<TI>Efficacy of physical therapy: electrostimulation, laser therapy, ultrasound therapy (own translation)</TI>
<TO>De effectiviteit van fysische therapie: electrotherapie, lasertherapie, ultrageluidbehandeling</TO>
<SO>Den Haag: Gezondheidsraad</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2009-08-12 15:54:11 -0400" MODIFIED_BY="[Empty name]" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al; GRADE Working Group</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haddad-2007" MODIFIED="2009-08-12 15:54:29 -0400" MODIFIED_BY="[Empty name]" NAME="Haddad 2007" TYPE="JOURNAL_ARTICLE">
<AU>Haddad JB, Obolensky AG, Shinnick P</AU>
<TI>The biologic effects and the therapeutic mechanism of action of electric and electromagnetic field stimulation on bone and cartilage: new findings and a review of earlier work</TI>
<SO>Journal of Alternative and Complementary Medicine (New York, N.Y.)</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>5</NO>
<PG>485-90</PG>
<IDENTIFIERS MODIFIED="2009-08-04 09:12:17 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2009-02-03 10:21:07 -0500" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-08-12 15:54:48 -0400" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hulme-2002" MODIFIED="2009-02-03 10:50:14 -0500" MODIFIED_BY="[Empty name]" NAME="Hulme 2002" TYPE="COCHRANE_REVIEW">
<AU>Hulme J, Robinson V, DeBie R, Wells G, Judd M, Tugwell P</AU>
<TI>Electromagnetic fields for the treatment of osteoarthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-02-03 10:50:14 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-03 10:50:14 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003523 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jamtvedt-2008" MODIFIED="2009-08-12 15:55:02 -0400" MODIFIED_BY="[Empty name]" NAME="Jamtvedt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Jamtvedt G, Dahm KT, Christie A, Moe RH, Haavardsholm E, Holm I, et al</AU>
<TI>Physical therapy interventions for patients with osteoarthritis of the knee: an overview of systematic reviews</TI>
<SO>Physical Therapy</SO>
<YR>2008</YR>
<VL>88</VL>
<NO>1</NO>
<PG>123-36</PG>
<IDENTIFIERS MODIFIED="2009-08-04 09:13:49 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2001" MODIFIED="2009-08-12 15:55:17 -0400" MODIFIED_BY="[Empty name]" NAME="Jüni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: assessing the quality of controlled clinical trials</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7303</NO>
<PG>42-6</PG>
<IDENTIFIERS MODIFIED="2009-08-04 09:14:00 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2006" MODIFIED="2009-08-12 15:55:31 -0400" MODIFIED_BY="[Empty name]" NAME="Jüni 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Reichenbach S, Dieppe P</AU>
<TI>Osteoarthritis: rational approach to treating the individual</TI>
<SO>Best Practice &amp; Research. Clinical Rheumatology</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>4</NO>
<PG>721-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mayer-1989" MODIFIED="2009-07-10 08:57:51 -0400" MODIFIED_BY="[Empty name]" NAME="Mayer 1989" TYPE="BOOK_SECTION">
<AU>Mayer DJ, Prince DD</AU>
<TI>The neurobiology of pain</TI>
<SO>Clinical Electrophysiology, Electrotherapy and Electrophysiologic Testing</SO>
<YR>1989</YR>
<PG>141-201</PG>
<EN>1st</EN>
<ED>Snyder-Mackper L, Robinson A</ED>
<PB>Williams &amp; WIlkins</PB>
<CY>Baltimore, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Melzack-1965" MODIFIED="2009-08-12 15:55:54 -0400" MODIFIED_BY="[Empty name]" NAME="Melzack 1965" TYPE="JOURNAL_ARTICLE">
<AU>Melzack R, Wall P</AU>
<TI>Pain mechanisms: a new theory</TI>
<SO>Science</SO>
<YR>1965</YR>
<VL>150</VL>
<PG>971-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nuesch-2009" MODIFIED="2009-07-17 17:24:57 -0400" MODIFIED_BY="[Empty name]" NAME="Nuesch 2009" TYPE="UNPUBLISHED">
<AU>Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Bürgi E, Scherer M, et al</AU>
<TI>The effects of the exclusion of patients from the analysis in randomised controlled trials: meta-epidemiological study</TI>
<SO>BMJ (in press)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nuesch-2009a" MODIFIED="2009-08-12 15:56:11 -0400" MODIFIED_BY="[Empty name]" NAME="Nuesch 2009a" TYPE="JOURNAL_ARTICLE">
<AU>Nüesch E, Juni P</AU>
<TI>Commentary: Which meta-analyses are conclusive?</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>298-303</PG>
<IDENTIFIERS MODIFIED="2009-08-04 09:14:42 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<REFERENCE ID="REF-Pham-2004" MODIFIED="2009-02-03 10:37:26 -0500" MODIFIED_BY="[Empty name]" NAME="Pham 2004" TYPE="JOURNAL_ARTICLE">
<AU>Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, et al</AU>
<TI>OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited</TI>
<SO>Osteoarthritis Cartilage</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>5</NO>
<PG>389-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Regence-Medical-Policy-2009" MODIFIED="2009-08-12 15:56:27 -0400" MODIFIED_BY="[Empty name]" NAME="Regence Medical Policy 2009" TYPE="OTHER">
<AU>Regence Medical Policy</AU>
<TI>Durable medical equipment section. Electrical stimulation for the treatment of arthritis</TI>
<SO>Available from: http://blue.regence.com/trgmedpol/dme/dme70.html</SO>
<NO>Accessed 14 July 2009</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reichenbach-2007" MODIFIED="2009-08-04 09:15:48 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Reichenbach 2007" TYPE="JOURNAL_ARTICLE">
<AU>Reichenbach S, Sterchi R, Scherer M, Trelle S, Burgi E, Burgi U, et al</AU>
<TI>Meta-analysis: chondroitin for osteoarthritis of the knee or hip</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2007</YR>
<VL>146</VL>
<NO>8</NO>
<PG>580-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2009-08-12 15:56:42 -0400" MODIFIED_BY="[Empty name]" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre. The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rucker-2008" MODIFIED="2009-08-12 15:57:11 -0400" MODIFIED_BY="[Empty name]" NAME="Rucker 2008" TYPE="JOURNAL_ARTICLE">
<AU>Rucker G, Schwarzer G, Carpenter JR, Schumacher M</AU>
<TI>Undue reliance on I<SUP>2</SUP> in assessing heterogeneity may mislead</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2008</YR>
<VL>8</VL>
<NO>1</NO>
<PG>79</PG>
<IDENTIFIERS MODIFIED="2009-08-04 09:15:11 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<REFERENCE ID="REF-Shang-2005" MODIFIED="2009-08-04 09:15:58 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Shang 2005" TYPE="JOURNAL_ARTICLE">
<AU>Shang A, Huwiler-Muntener K, Nartey L, Juni P, Dorig S, Sterne JA, et al</AU>
<TI>Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>366</VL>
<NO>9487</NO>
<PG>726-32</PG>
<IDENTIFIERS MODIFIED="2009-08-04 09:15:58 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<REFERENCE ID="REF-Sluka-2003" MODIFIED="2009-08-12 15:57:27 -0400" MODIFIED_BY="[Empty name]" NAME="Sluka 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sluka KA, Walsh D</AU>
<TI>Transcutaneous electrical nerve stimulation: basic science mechanisms and clinical effectiveness</TI>
<SO>The Journal of Pain</SO>
<YR>2003</YR>
<VL>4</VL>
<NO>3</NO>
<PG>109-21</PG>
<IDENTIFIERS MODIFIED="2009-08-04 09:16:17 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<REFERENCE ID="REF-Solomon-1997" NAME="Solomon 1997" TYPE="BOOK_SECTION">
<AU>Solomon L</AU>
<TI>Clinical features of osteoarthritis</TI>
<SO>Textbook of Rheumatology</SO>
<YR>1997</YR>
<VL>2</VL>
<PG>1383-93</PG>
<EN>5th</EN>
<ED>Kelly WN, Harris ED Jr, Ruddy S, Sledge CB</ED>
<PB>WB Saunders</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2000" MODIFIED="2009-08-12 15:57:42 -0400" MODIFIED_BY="[Empty name]" NAME="Sterne 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Gavaghan D, Egger M</AU>
<TI>Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2000</YR>
<VL>53</VL>
<NO>11</NO>
<PG>1119-29</PG>
<IDENTIFIERS MODIFIED="2009-08-04 09:16:32 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2001" MODIFIED="2009-08-04 09:16:52 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Sterne 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Egger M</AU>
<TI>Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2001</YR>
<VL>54</VL>
<NO>10</NO>
<PG>1046-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-1999" MODIFIED="2009-08-12 15:57:55 -0400" MODIFIED_BY="[Empty name]" NAME="Thompson 1999" TYPE="JOURNAL_ARTICLE">
<AU>Thompson SG, Sharp SJ</AU>
<TI>Explaining heterogeneity in meta-analysis: a comparison of methods</TI>
<SO>Statistics in Medicine</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>20</NO>
<PG>2693-708</PG>
<IDENTIFIERS MODIFIED="2009-08-04 09:17:04 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<REFERENCE ID="REF-Wadsworth-1980" MODIFIED="2009-08-04 09:17:15 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Wadsworth 1980" TYPE="BOOK">
<AU>Wadsworth H, Chanmugan A</AU>
<SO>Electrophysical agents in physiotherapy</SO>
<YR>1980</YR>
<PG>347-72</PG>
<PB>Science Press</PB>
<CY>Marrickville, Australia</CY>
<IDENTIFIERS MODIFIED="2009-08-04 09:17:15 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2009-08-12 15:58:10 -0400" MODIFIED_BY="[Empty name]" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7644</NO>
<PG>601-5</PG>
<IDENTIFIERS MODIFIED="2009-08-04 09:17:21 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-02-23 10:27:16 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Osiri-2000" MODIFIED="2009-02-03 10:45:37 -0500" MODIFIED_BY="[Empty name]" NAME="Osiri 2000" TYPE="COCHRANE_REVIEW">
<AU>Osiri M, Welch V, Brosseau L, Shea B, McGowan J, Tugwell P, et al</AU>
<TI>Transcutaneous electrical nerve stimulation for knee osteoarthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2009-02-03 10:45:27 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-03 10:45:27 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002823 "/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2008-12-05 10:41:31 -0500" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-08-13 10:28:21 -0400" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-08-12 15:27:37 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-08-12 15:17:36 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adedoyin-2002">
<CHAR_METHODS MODIFIED="2009-02-06 11:11:19 -0500" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised trial using alternation for the allocation of patients<BR/>2-arm parallel group design<BR/>Trial duration: 4 weeks<BR/>No power calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-29 03:16:56 -0500" MODIFIED_BY="[Empty name]">
<P>30 patients randomised<BR/>30 patients with knee OA reported at baseline<BR/>Study joints: 30 knees<BR/>Number of females: 20 of 30 (67%)<BR/>Average age: 59 years<BR/>Average BMI: 28 kg/m<SUP>2</SUP>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:17:33 -0400" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: interferential current stimulation, dietary advice and exercise, twice per week<BR/>Control intervention: Sham interferential current stimulation, dietary advice and exercise, twice per week<BR/>Duration of treatment period: 4 weeks<BR/>Analgesics not allowed</P>
<P>Device: Enraf-Nonius Endomed 5921 (4 pole)<BR/>Self-administered: no<BR/>Waveform: interferential<BR/>Pulse width: not applicable<BR/>Pulse frequency: amplitude-modulated frequency of 100 Hz for 15 min (beat frequency), 80 Hz for last 5 min (beat frequency)<BR/>Amplitude: above sensory threshold, up to appreciable sensation<BR/>Duration of stimulation per session: 20 minutes<BR/>Electrodes: 4 electrodes covered with padding<BR/>Placement: 2 latero-medial, 2 antero-posterior<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 15:17:36 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: global pain after 4 weeks, described as "Pain perception (VAS)"<BR/>No function outcome reported</P>
<P>Primary outcome: global pain (VAS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-06 11:11:20 -0500" MODIFIED_BY="[Empty name]">
<P>All subjects from black Nigerian population</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-12 15:27:34 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adedoyin-2005">
<CHAR_METHODS MODIFIED="2009-02-06 11:11:20 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>3-arm parallel group design<BR/>Trial duration: 4 weeks<BR/>Power calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-07 10:43:19 -0500" MODIFIED_BY="[Empty name]">
<P>51 patients randomised<BR/>46 patients with knee OA reported at baseline<BR/>Study joints: 46 knees<BR/>Number of females: 28 of 46 (61%)<BR/>Average age: 55 years<BR/>Average BMI: 28 kg/m2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:27:34 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Comparison 1</I>
<BR/>Experimental intervention: TENS and exercise twice per week<BR/>Control intervention: exercise, twice per week</P>
<P>
<I>Comparison 2</I>
<BR/>Experimental intervention: interferential current stimulation and exercise, twice per week<BR/>Control intervention: exercise, twice per week</P>
<P>Duration of treatment period: 4 weeks<BR/>Analgesics not allowed, patients confirmed not to take analgesics</P>
<P>TENS Device: Endomed 5921D<BR/>Self-administered: no<BR/>Waveform: not reported<BR/>Pulse width: 200 ms<BR/>Pulse frequency: 80 Hz<BR/>Amplitude: above sensory threshold, strong but comfortable<BR/>Duration of stimulation per session: 20 minutes<BR/>Electrodes: 2 electrodes 8 x 6 cm<BR/>Placement: Each side of affected knee joint, aligned longitudinally along length of limb</P>
<P>Interferential Current Stimulation Device: Endomed 5921D (2 pole)<BR/>Waveform: interferential<BR/>Pulse width: not applicable<BR/>Pulse frequency: 80 Hz (beat)<BR/>Amplitude: above sensory threshold: strong but comfortable, strong tingling sensation without muscle contraction<BR/>Duration of stimulation per session: 20 minutes<BR/>Electrodes: 2 electrodes 8 x 6 cm<BR/>Placement: each side of affected knee joint, aligned longitudinally along length of limb</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 15:17:50 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: pain on activities other than walking after 4 weeks, described as "Pain recorded while standing (10-point pain rating scale with 0 &#8220;no pain&#8221;, 5 &#8220;moderate pain&#8221; and 10 &#8220;worst pain imaginable&#8221;)"<BR/>Extracted function outcome: WOMAC global scale after 4 weeks (Likert)</P>
<P>No primary outcome reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-12 15:17:51 -0400" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-12 15:27:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bal-2007">
<CHAR_METHODS MODIFIED="2009-02-06 11:11:21 -0500" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised single centre controlled trial with allocation according to hospital registration number<BR/>2-arm parallel group design<BR/>Trial duration: 13 weeks<BR/>No power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-07 10:43:21 -0500" MODIFIED_BY="[Empty name]">
<P>56 patients randomised<BR/>56 patients with knee OA reported at baseline<BR/>Study joints: 56 knees<BR/>Number of females: 50 of 56 (89%)<BR/>Average age: 57 years<BR/>Average BMI: 31 kg/m2<BR/>Average disease duration: 2 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:27:29 -0400" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: TENS and infra-red therapy, 5 times per week<BR/>Control intervention: sham TENS and infra-red therapy, 5 times per week<BR/>Duration of treatment period: 2 weeks<BR/>Unclear whether analgesics were allowed and the intake was assessed</P>
<P>Device: PlusMED 1-904<BR/>Self-administered: no<BR/>Waveform: not reported<BR/>Pulse width: 140 µsec</P>
<P>Pulse frequency: 80 Hz<BR/>Amplitude: above sensory threshold, not up to maximum tolerance, no muscle contractions observed*<BR/>Duration of stimulation per session: 40 minutes<BR/>Electrodes: 4, type unclear<BR/>Placement: acupuncture points: ST36, GB34, SP10, SP9, ST34</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-03-05 05:47:11 -0500" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: WOMAC pain subscore after 13 weeks (Likert)<BR/>Extracted function outcome: WOMAC disability subscore after 13 weeks (Likert)</P>
<P>No primary outcome reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-01-07 10:49:40 -0500" MODIFIED_BY="[Empty name]">
<P>Article in Turkish, outcome assessment done by AR and RS assisted by a native Turkish researcher. Serpil Bal verified all extracted data. *as indicated by Serpil Bal in personal communication.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-12 15:18:09 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cetin-2008">
<CHAR_METHODS MODIFIED="2009-02-06 11:11:22 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>5-arm parallel group design<BR/>Trial duration: 8 weeks <BR/>No power calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-07 10:43:23 -0500" MODIFIED_BY="[Empty name]">
<P>100 patients randomised<BR/>100 patients with knee OA reported at baseline<BR/>Study joints: 100 knees<BR/>Number of females: 100 of 100 (100%)<BR/>Average age: 60 years<BR/>Average BMI: 28 kg/m2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:18:08 -0400" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: TENS + hot packs + isokinetic exercise, 3 times per week<BR/>Control intervention: hot packs + isokinetic exercise, 3 times per week<BR/>Duration of treatment period: 8 weeks<BR/>Analgesics allowed, unclear whether intake was similar between groups</P>
<P>Device: MED911<BR/>Self-administered: no<BR/>Waveform: not reported<BR/>Puls width: 60 msecs<BR/>Pulse frequency: 60-100 Hz<BR/>Amplitude: above sensory threshold, increased to point of seeing no contraction, while patient felt comfortable<BR/>Duration of stimulation per session: 20 minutes<BR/>Electrodes: not reported<BR/>Electrode placement: around painful areas<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 15:18:09 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: pain on walking after 8 weeks, described as "Knee pain severity after a 50-m walk (VAS)"<BR/>Extracted function outcome: Lequesne OA index global score after 8 weeks (Likert)</P>
<P>No primary outcome reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-10 11:01:55 -0400" MODIFIED_BY="[Empty name]">
<P>Only 2 arms qualified for inclusion in this review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-12 15:27:18 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cheing-2002">
<CHAR_METHODS MODIFIED="2009-02-06 11:11:23 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>4-arm parallel group design<BR/>Trial duration: 8 weeks<BR/>Randomisation stratified according to age, gender, BMI<BR/>No power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-07 10:43:25 -0500" MODIFIED_BY="[Empty name]">
<P>66 patients randomised<BR/>62 patients with knee OA reported at baseline<BR/>Study joints: 62 knees<BR/>Number of females: 53 of 62 (85%)<BR/>Average age: 64 years<BR/>Average BMI: 28 kg/m<SUP>2</SUP>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:27:18 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Comparison 1 </I>
<BR/>Experimental intervention: 60 min TENS, 5 times per week<BR/>Control intervention: sham TENS, 5 times per week</P>
<P>
<I>Comparison 2</I>
<BR/>Experimental intervention: TENS plus exercise, 5 times per week<BR/>Control intervention: exercise alone, 5 times per week</P>
<P>Duration of treatment period: 4 weeks<BR/>Analgesics allowed, unclear whether intake was similar between groups</P>
<P>Device: MAXIMA III (dual channel)<BR/>Self-administered: unclear, most likely not<BR/>Waveform: square<BR/>Pulse width: 140 µsec<BR/>Pulse frequency: 80 Hz<BR/>Amplitude: above sensory threshold, tingling sensation, 3 to 4 times above sensory threshold<BR/>Duration of stimulation per session: 60 minutes<BR/>Electrodes: 4 electrodes of 4 x 4 cm<BR/>Placement: at acupuncture points: ST35, SP9, GB34, extra 31,32 (one electrode covering both extra 32 and ST35)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 15:18:22 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: global pain after 8 weeks, described as "Intensity of subjective pain sensation (Baseline score on 0-10 cm VAS was standardised to be 100% in each of the groups. Follow up values were expressed as mean decrease in % from baseline)".<BR/>No function outcome reported</P>
<P>No primary outcome reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-12 15:18:23 -0400" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-12 15:27:10 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cheing-2003">
<CHAR_METHODS MODIFIED="2009-02-06 11:11:24 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>4-arm parallel group design<BR/>Trial duration: 4 weeks<BR/>Randomisation stratified according to gender<BR/>No power calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-12 15:18:29 -0400" MODIFIED_BY="[Empty name]">
<P>40 patients randomised<BR/>38 patients with knee OA reported at baseline<BR/>Study joints: 38 knees<BR/>Number of females: 34 of 38 (89%)<BR/>Average age: 66 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:27:10 -0400" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: 20 min TENS in group 1, 40 min TENS in group 2, 60 min TENS in group 4, 5 times per week<BR/>Control intervention: sham TENS, 5 times per week<BR/>Duration of treatment period: 2 weeks<BR/>Unclear whether analgesics were allowed and whether intake was similar between groups</P>
<P>Device: ITO 120Z TENS (dual channel)<BR/>Self-administered: no<BR/>Waveform: not reported<BR/>Pulse width: 200 µsec<BR/>Pulse frequency: 100 Hz<BR/>Amplitude: above sensory threshold, strong but comfortable<BR/>Duration of stimulation per session: 20 minutes<BR/>Electrodes: 4 of 2 x 3 cm rubber electrodes<BR/>Placement: 4 acupuncture points extra 31,32, ST35, GB34, SP9</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 15:18:35 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: pain on walking after 4 weeks, described as "pain during walking (VAS)"<BR/>No function outcome reported</P>
<P>No primary outcome reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-12 15:18:35 -0400" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-12 15:18:48 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Defrin-2005">
<CHAR_METHODS MODIFIED="2009-02-06 11:11:26 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>6-arm parallel group design<BR/>Trial duration: 4 weeks<BR/>No power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-06 11:11:26 -0500" MODIFIED_BY="[Empty name]">
<P>62 patients randomised<BR/>62 patients with knee OA reported at baseline<BR/>Study joints: 62 knees<BR/>Average age: 67 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:18:46 -0400" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: noxious adjusted interferential current stimulation in group 1, noxious unadjusted interferential current stimulation in group 2, innocuous adjusted interferential current stimulation in group 3, innocuous unadjusted interferential current stimulation in group 4, 3 times per week<BR/>Control intervention: sham interferential current stimulation, 3 times per week<BR/>Duration of treatment period: 4 weeks<BR/>Analgesics allowed, unclear whether intake was similar between groups.</P>
<P>Device: Uniphy: Phyaction electrical stimulator<BR/>Self-administered: no<BR/>Waveform: interferential<BR/>Pulse width: not applicable<BR/>Pulse frequency: 30 to 60 Hz (beat)<BR/>Amplitude: above sensory threshold, 2 groups 30% above pain threshold; 2 groups 30% below pain threshold<BR/>Duration of stimulation per session: 20 minutes<BR/>Electrodes: 2 of 8 x 6 cm wet sponge electrodes<BR/>Placement: medial and lateral aspects of the knee, 2 cm from outer margins of patella</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 15:18:47 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: global pain after 4 weeks, described as "chronic pain intensity (VAS)"<BR/>No function outcome reported</P>
<P>No primary outcome reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-12 15:18:48 -0400" MODIFIED_BY="[Empty name]">
<P>1 out of 6 trial arms, the no-intervention control group was excluded in the review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-12 15:19:00 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fargas_x002d_Babjak-1989">
<CHAR_METHODS MODIFIED="2009-02-06 11:11:27 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>2-arm parallel group design<BR/>Trial duration: 13 weeks<BR/>No power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-12 15:18:53 -0400" MODIFIED_BY="[Empty name]">
<P>56 patients randomised<BR/>56 patients with knee OA reported at baseline<BR/>Study joints: 56 joints, most likely &gt; 75% knees<BR/>Average age; gender, BMI: not reported<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:18:58 -0400" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: burst TENS, twice per day<BR/>Control intervention: sham TENS, twice per day<BR/>Duration of treatment period: 6 weeks<BR/>Analgesics allowed, but change of dosage prohibited. Unclear whether analgesics were assessed and whether intake was similar between groups.</P>
<P>Device: Codetron<BR/>Self-administered: yes<BR/>Waveform: square<BR/>Pulse width: 1000 µsec<BR/>Pulse frequency: 200 Hz, train length of 125 ms, repetition frequency of 4 Hz (25 pulses per train)<BR/>Amplitude: above sensory threshold, highest intensity that could be tolerated without inducing frank pain<BR/>Duration of stimulation per session: 30 minutes<BR/>Electrodes: 7 carbon rubber (self-adhesive) Karaya Pads electrodes of 2 x 3 cm<BR/>Placement: 10 acupuncture points: GV14, GV4, GB30, GB34, SP13, B1 60, ST36, B1 40, SP9, LI4 and 3 extra tender points</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 15:18:59 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: global pain after 13 weeks described as "Pain improvement (percentage pain improvement based on VAS)"<BR/>No function outcome reported</P>
<P>No primary outcome reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-12 15:19:00 -0400" MODIFIED_BY="[Empty name]">
<P>*Investigators named their intervention AL-TENS, but we coded it burst TENS in the analyses</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-12 15:26:49 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garland-2007">
<CHAR_METHODS MODIFIED="2009-08-12 15:26:49 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised multicentre controlled trial<BR/>2-arm parallel group design<BR/>Number of participating centres: 3<BR/>Trial duration: 12 weeks<BR/>Randomisation stratified according to study site<BR/>No power calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-07 10:58:59 -0500" MODIFIED_BY="[Empty name]">
<P>100 patients randomised<BR/>58 patients with knee OA reported at baseline; 41 out of 58 candidates for total knee arthroplasty<BR/>Study joints: 58 knees<BR/>Number of females: 38 of 58 (66%)<BR/>Average age: 66<BR/>Disease duration: 8.4 years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:19:17 -0400" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: pulsed electrical stimulation<BR/>Control intervention: sham intervention<BR/>Duration of treatment period: 12 weeks<BR/>Analgesics allowed and intake assessed, but unclear whether intake was similar.</P>
<P>Device: BIO-1000<BR/>Self-administered: yes<BR/>Waveform: unclear<BR/>Pulse width: unclear<BR/>Pulse frequency: 100 Hz<BR/>Amplitude: below sensory threshold, initial increase of amplitude up to 12 Volt until a tingling sensation was felt then reduction of the amplitude until this sensation disappeared <BR/>Duration of stimulation per session: 8.2 hours in active group, 7.8 hours in sham group (mean daily application time)<BR/>Electrodes: flexible electrodes embedded in garment, type not reported<BR/>Electrode placement: negative electrode at patella, positive over anterior distal thigh</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 15:19:18 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: global pain after 12 weeks, described as "Considering your pain and symptoms in your study joint how are you doing today? (VAS)"<BR/>Extracted function outcome: WOMAC disability subscore after 12 weeks (VAS)</P>
<P>No primary outcome reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-01-07 10:45:31 -0500" MODIFIED_BY="[Empty name]">
<P>*Due to major protocol violations, all 42 randomised patient of one site were excluded by Garland et al</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-12 15:26:34 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grimmer-1992">
<CHAR_METHODS MODIFIED="2009-02-06 11:11:29 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>3-arm parallel group design<BR/>Trial duration: 1 day<BR/>No power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-07 10:43:28 -0500" MODIFIED_BY="[Empty name]">
<P>60 patients randomised<BR/>60 patients with knee OA reported at baseline<BR/>Study joints: 60 knees<BR/>Number of females: 37 of 60 (62%)<BR/>Average age: 66 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:26:34 -0400" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: high frequency TENS, once only in group 1, burst TENS, once only in group 2<BR/>Control intervention: sham TENS, once only<BR/>Duration of treatment period: 1 day<BR/>Analgesics not allowed</P>
<P>Device: Medtronic Neuromed Selectra (dual channel)<BR/>Self-administered: no<BR/>Waveform: unclear<BR/>Pulse width: unclear<BR/>Pulse frequency: 80 Hz in group 1, 3 Hz trains of 7 80 Hz pulses in group 2<BR/>Amplitude: above sensory threshold, strong tolerable tingling paraesthesia<BR/>Duration of stimulation per session: 30 minutes<BR/>Electrodes: 4 carbon rubber silicone electrodes, 2 x 3 cm<BR/>Placement: 4 acupuncture points around the knee: medial (SP9), lateral (GB33), posterior (UB40), anterior (SP10)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 15:19:30 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: global pain immediately after first and only application, described as "Immediate pain relief (VAS)"<BR/>No function outcome reported</P>
<P>No primary outcome reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-12 15:19:31 -0400" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-12 15:26:24 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Itoh-2008">
<CHAR_METHODS MODIFIED="2009-08-12 15:26:24 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>2 x 2 factorial design<BR/>Trial duration: 10 weeks<BR/>No power calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-07 10:43:29 -0500" MODIFIED_BY="[Empty name]">
<P>32 patients randomised<BR/>32 patients with knee OA reported at baseline<BR/>Study joints: 32 knees<BR/>Number of females: 21 of 32 (66%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:26:23 -0400" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: interferential current stimulation*, once per week<BR/>Control intervention: no intervention, optional use of poultice</P>
<P>16 out of 32 patients (50%) allocated to acupuncture using a factorial design; no evidence for an interaction between treatments</P>
<P>Duration of treatment period: 5 weeks<BR/>Analgesics allowed and intake assessed, but unclear whether intake was similar.<BR/>
</P>
<P>Device: HV-F3000 (single channel, 2 pole)<BR/>Self-administered: no<BR/>Waveform: sinusoidal<BR/>Pulse width: not applicable<BR/>Pulse frequency: amplitude-modulated frequency of 122 Hz (beat frequency)<BR/>Amplitude: above sensory threshold, up to a tingling sensation, 2 to 3 times above sensory threshold<BR/>Duration of stimulation per session: 15 minutes<BR/>Placement: site of tenderness and opposite site<BR/>Electrodes: 2 disposable electrodes different in size, 809 mm<SUP>2</SUP> and 5688 mm<SUP>2</SUP>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 15:19:53 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: global pain after 10 weeks, described as "Pain intensity (VAS)"<BR/>Extracted function outcome: WOMAC global scale after 10 weeks (VAS)</P>
<P>Primary outcomes: pain intensity, WOMAC global scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-12 15:19:54 -0400" MODIFIED_BY="[Empty name]">
<P>*The investigators used the label TENS in their report, but from their description of the intervention it was clear that interferential current stimulation was applied</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-12 15:26:17 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Law-2004">
<CHAR_METHODS MODIFIED="2009-02-06 11:11:31 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>4-arm parallel group design<BR/>Trial duration: 4 weeks<BR/>No power calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-12 15:20:00 -0400" MODIFIED_BY="[Empty name]">
<P>36 patients randomised<BR/>36 patients with knee OA reported at baseline<BR/>Study joints: 48 knees*<BR/>Number of females: 35 of 36 (97%)<BR/>Average age: 82 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:26:17 -0400" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: 2 Hz TENS in group 1, 100 Hz TENS in group 2, modulation TENS with alternations between 2 to 100 Hz in group 3, 5 times per week in all groups<BR/>Control intervention: sham TENS, 5 times per week<BR/>Duration of treatment period: 2 weeks<BR/>Unclear whether analgesics were allowed and whether intake was similar between groups</P>
<P>Device: Han Acupoint Nerve Stimulation LH204H<BR/>Self-administered: no<BR/>Waveform: unclear<BR/>Pulse width and frequency: 576 µsec and 2 Hz in group 1, 200 µsec and 100 Hz in group 2, 576/200 µsec and 2/100 Hz alternation in group 3<BR/>Amplitude: above sensory threshold, up to comfortable level, range 25 to 35 mA<BR/>Duration of stimulation per session: 40 minutes<BR/>Electrodes: 4 rubber electrodes of 4.5 x 3.8 cm<BR/>Placement: 4 acupuncture points: ST35, LE4, SP9, GB34</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 15:20:06 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: pain on walking after 4 weeks, described as "intensity of pain felt while walking (VAS)"<BR/>No function outcome reported</P>
<P>No primary outcome reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-12 14:43:05 -0400" MODIFIED_BY="[Empty name]">
<P>Outcome data were reported on knee level.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-12 15:26:11 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Law-2004a">
<CHAR_METHODS MODIFIED="2009-02-06 11:11:32 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>2-arm parallel group design<BR/>Trial duration: 2 weeks<BR/>Unstratified randomisation<BR/>Multicentre trial with 2 centres<BR/>No power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-12 14:43:58 -0400" MODIFIED_BY="[Empty name]">
<P>39 patients randomised<BR/>39 patients with knee OA reported at baseline<BR/>Study joints: 39 knees<BR/>Number of females: 37 of 39 (95%)<BR/>Average age: 75 years<BR/>Average BMI: 27 kg/m2<BR/>Average disease duration: 7.6 years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:26:11 -0400" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: TENS, 5 times per week<BR/>Control intervention: sham TENS, 5 times per week<BR/>Duration of treatment period: 2 weeks<BR/>Unclear whether analgesics were allowed and whether intake was similar between groups</P>
<P>Device: ITO model 120Z (dual channel)<BR/>Self-administered: no<BR/>Waveform: unclear<BR/>Pulse width: 200 µsec<BR/>Pulse frequency: 100 Hz<BR/>Amplitude: above sensory threshold, up to a comfortable level, range 25-35 mA<BR/>Duration of stimulation per session: 40 minutes<BR/>Electrodes: 4 rubber electrodes, 4.5 x 3.8 cm<SUP>2</SUP>
<BR/>Placement: acupuncture points: ST35, LE4, SP9, GB34</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 15:20:39 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: pain on walking after 2 weeks, described as "intensity of pain felt while walking (VAS)"**<BR/>Extracted function outcome: walking disability after 2 weeks, described as "Timed-Up-and-Go test over 3 meters (seconds)"</P>
<P>No primary outcome reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-12 15:20:40 -0400" MODIFIED_BY="[Empty name]">
<P>**Only baseline values reported in the report. Contact established with investigators Law and Cheing, who provided end of treatment and follow-up data.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-12 15:26:02 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ng-2003">
<CHAR_METHODS MODIFIED="2009-02-06 11:11:33 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>3-arm parallel group design<BR/>Trial duration: 4 weeks<BR/>Unstratified randomisation<BR/>No power calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-12 15:26:02 -0400" MODIFIED_BY="[Empty name]">
<P>24 patients randomised<BR/>24 patients with knee OA reported at baseline<BR/>Study joints: 24 knees<BR/>Number of females: 23 of 24 (96%)<BR/>Average age: 85 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:26:00 -0400" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: TENS, 4 times per week, with a total of 8 applications and educational pamphlet<BR/>Control intervention: educational pamphlet<BR/>Duration of treatment period: 2 weeks<BR/>Unclear whether analgesics were allowed and whether intake was similar between groups</P>
<P>Device: ITO model F-2 (dual channel)<BR/>Self-administered: no<BR/>Waveform: unclear<BR/>Pulse width: 200 µsec<BR/>Pulse frequency: 2 Hz<BR/>Amplitude: above sensory threshold, until strong, tolerable, stroking sensation, preferably evoking phasic muscle contraction<BR/>Duration of stimulation per session: 20 minutes<BR/>Electrode placement: acupuncture points ST35, EX-LE-4<BR/>Electrodes: 50 x 35 mm<SUP>2</SUP>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 15:20:52 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: global pain after 4 weeks, described as "pain (Numeric rating scale (NRS))"<BR/>No function outcome reported</P>
<P>No primary outcome reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-01-07 07:49:58 -0500" MODIFIED_BY="[Empty name]">
<P>2 out of 3 trial arms qualified for inclusion in this review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-12 15:25:52 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Quirk-1985">
<CHAR_METHODS MODIFIED="2009-02-06 11:11:34 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>3-arm parallel group design*<BR/>Trial duration: 26 weeks<BR/>No power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-07 10:43:31 -0500" MODIFIED_BY="[Empty name]">
<P>38 patients randomised<BR/>38 patients with knee OA reported at baseline<BR/>Study joints: 38 knees<BR/>Number of females: 29 of 38 (76%)<BR/>Average age: 63 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:25:52 -0400" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: interferential current + exercise, interferential current stimulation: 3 times per week, exercise twice daily<BR/>Control intervention: exercise twice daily<BR/>Duration of treatment period: 4 weeks<BR/>Analgesics allowed, unclear whether intake was similar between groups</P>
<P>Device: Endomed 433 and Vacutron 423 (unclear whether 2 or 4 pole)<BR/>Self-administered: no<BR/>Waveform: interferential<BR/>Pulse width: not applicable<BR/>Pulse frequency: 0 to 100 Hz 10 minutes, 130 Hz last 5 minutes<BR/>Amplitude: not reported<BR/>Duration of stimulation per session: 15 minutes<BR/>Electrodes: suction electrodes<BR/>Placement: not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 15:21:05 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: other after 26 weeks, described as "Pain composite score with items rest, post-exercise and night pain (approach unclear; either VAS or verbal scoring technique modified after Newland)"**<BR/>Extracted function outcome: other algofunctional scale after 26 weeks, described as "Overall clinical condition scale developed by authors, which was based on 3 items for pain; rest-, post-exercise-, night pain and 3 for function; gait, method of climbing stairs and using walking aids (most likely Likert)".</P>
<P>No primary outcome reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-12 15:21:06 -0400" MODIFIED_BY="[Empty name]">
<P>*1 trial arm, in which shortwave diathermy was given, was excluded, **only baseline values with standard error and P values for change from baseline per group reported. No contact could be established with the investigators.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-12 15:25:45 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-1983">
<CHAR_METHODS MODIFIED="2009-02-06 11:11:35 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised sham controlled trial<BR/>2-arm parallel group design<BR/>Trial duration: 8 weeks<BR/>Randomisation stratified according to gender<BR/>Multicentre trial with 2 centres<BR/>No power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-07 10:46:19 -0500" MODIFIED_BY="[Empty name]">
<P>32 patients randomised<BR/>30 patients with knee OA reported at baseline<BR/>Study joints: 30 knees<BR/>Number of females: 20 of 30 (67%)<BR/>Average age: 68 years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:25:45 -0400" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: TENS, twice per week*<BR/>Control intervention: sham TENS, twice per week*<BR/>Duration of treatment period: 4 weeks<BR/>Analgesics intake assessed and found to be similar between groups</P>
<P>Device: RDG Tiger Pulse<BR/>Self-administered: no<BR/>Waveform: square<BR/>Pulse width: 80 µsec<BR/>Pulse frequency: 32 to 50 Hz<BR/>Amplitude: above sensory threshold, adjusted up to a comfortable tingling sensation<BR/>Duration of stimulation per session: 20 minutes<BR/>Electrodes: 4 Lec Tec pads applied with electrode jelly<BR/>Placement: tender knee points or acupuncture points (SP9, xiyan and UB40)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 15:21:18 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: global pain after 8 weeks, described as "Weekly pain score derived from daily pain recording (linear 7-point scale)"**<BR/>No function outcome reported</P>
<P>No primary outcome reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-12 15:21:21 -0400" MODIFIED_BY="[Empty name]">
<P>*Preceded by 1 'standard' week without any treatment, **No pain outcome data presented, investigators were contacted, but we did not receive any reply. This study only contributed in safety analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-12 15:25:38 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yurtkuran-1999">
<CHAR_METHODS MODIFIED="2009-02-06 11:11:36 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>4-arm parallel group design<BR/>Trial duration: 2 weeks<BR/>No power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-07 10:43:33 -0500" MODIFIED_BY="[Empty name]">
<P>100 patients randomised, 25 per group<BR/>100 patients with knee OA reported at baseline<BR/>Study joints: 100 knees<BR/>Number of females: 91 of 100 (91%)<BR/>Average age: 58 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:25:38 -0400" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: TENS, 5 times per week<BR/>Control intervention: sham TENS, 5 times per week<BR/>Duration of treatment period: 2 weeks<BR/>Unclear whether analgesics were allowed and whether intake was similar between groups</P>
<P>Device: MEA-TENS (dual channel)<BR/>Self-administered: no<BR/>Waveform: rectangular<BR/>Pulse width: 1000 µsec<BR/>Pulse frequency: 4 Hz*<BR/>Amplitude: above sensory threshold, up to muscle contraction, just below pain tolerance threshold<BR/>Duration of stimulation per session: 20 minutes<BR/>Electrodes: 4 small MEA rubber electrodes<BR/>Placement: 4 acupuncture points SP-9, GB-34, ST-34, ST-35</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 15:21:30 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: global pain after 2 weeks described as "Overall present pain intensity at rest (Likert)"<BR/>Extracted function outcome: walking disability after 2 weeks, described as "50 foot walking time (in minutes)"</P>
<P>No primary outcome reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-12 15:21:31 -0400" MODIFIED_BY="[Empty name]">
<P>Two out of 4 groups, the electroacupuncture and ice massage groups, were excluded in this review. *Investigators named their intervention AL-TENS, but we coded it low frequency TENS in our analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-12 15:25:33 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zizic-1995">
<CHAR_METHODS MODIFIED="2009-02-06 11:11:37 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>2-arm parallel group design<BR/>Trial duration: 34 weeks<BR/>Multicentre trial with 5 centres<BR/>No power calculation reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-07 10:43:34 -0500" MODIFIED_BY="[Empty name]">
<P>78 patients randomised<BR/>71 patients with knee OA reported at baseline<BR/>Study joints: 71 knees<BR/>Number of females: 33 of 71 (46%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:25:33 -0400" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: pulsed electrostimulation stimulation, daily application<BR/>Control intervention: sham pulsed electrostimulation, daily application<BR/>Duration of treatment period: 4 weeks<BR/>Analgesics allowed, intake assessed and found to be similar between groups.</P>
<P>Device: Bionicare Stimulator BIO-1000<BR/>Self-administered: yes<BR/>Waveform: monophasic, spiked<BR/>Pulse width: unclear<BR/>Pulse frequency: 100 Hz<BR/>Amplitude: below sensory threshold, initial increase of amplitude until a tingling sensation was felt then reduction of the amplitude until this sensation disappeared<BR/>Duration of stimulation: 6 to 10 hours per day<BR/>Electrodes: 2, unclear whether positioned in knee garment<BR/>Placement: one on knee, other on thigh directly above that knee</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 15:21:46 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: global pain after 34 weeks described as "Patient evaluation of pain of treated knee (Baseline based on 0-10 VAS, follow-up based on % change from baseline)"<BR/>Extracted function outcome: patient's global assessment after 34 weeks, described as "Patient evaluation of function of treated knee (Baseline based on 0-10 VAS, follow-up based on % change from baseline)"</P>
<P>More than 2 primary outcomes reported (1 physician global evaluation; 2) VAS pain; 3) VAS function)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-12 15:21:47 -0400" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BMI = body mass index<BR/>min = minutes<BR/>OA = osteoarthritis<BR/>VAS = visual analogue scale</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-08-13 10:28:21 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:21:56 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barr-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:21:56 -0400" MODIFIED_BY="[Empty name]">
<P>Less than 50% of patients diagnosed with osteoarthritis of the knee</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:21:57 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bernau-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:21:57 -0400" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial, use of active control groups. Additional description: comparing diadynamic electrostimulation df, diadynamic electrostimulation cf and galvanic current</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-04 09:42:37 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burch-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-04 09:42:37 -0500" MODIFIED_BY="[Empty name]">
<P>Use of active control group. Additional description: randomised controlled trial comparing interferential current stimulation followed by patterned muscle stimulation and low-current transcutaneous electrical nerve stimulation (TENS).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:21:58 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cauthen-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:21:58 -0400" MODIFIED_BY="[Empty name]">
<P>Not concerning osteoarthritis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:21:58 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Commandre-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:21:58 -0400" MODIFIED_BY="[Empty name]">
<P>No randomised controlled trial (review)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:21:59 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cottingham-1985a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:21:59 -0400" MODIFIED_BY="[Empty name]">
<P>Not transcutaneous but subcutaneous application</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:41:52 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cottingham-1985b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:41:52 -0400" MODIFIED_BY="[Empty name]">
<P>Not transcutaneous but subcutaneous application. Abstract referring to same RCT as described in <LINK REF="STD-Cottingham-1985a" TYPE="STUDY">Cottingham 1985a</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-04 08:44:05 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Durmus-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-04 08:44:05 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Use of active control group (exercise)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-04 08:44:08 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Gaines-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-04 08:44:08 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Neuromuscular electrostimulation primarily aiming at muscle strengthening</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:00 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gaines-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:00 -0400" MODIFIED_BY="[Empty name]">
<P>Neuromuscular electrostimulation primarily aiming at muscle strengthening</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:02 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gibson-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:02 -0400" MODIFIED_BY="[Empty name]">
<P>Most likely not a randomised controlled trial; percutaneous electrostimulation primarily aiming at muscle strengthening</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:03 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Godfrey-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:03 -0400" MODIFIED_BY="[Empty name]">
<P>Faradic electrostimulation with parameters set to increase muscle strength and use of active control (exercise plus low intensity (sham) faradic electrostimulation)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:03 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grigor_x0027_eva-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:03 -0400" MODIFIED_BY="[Empty name]">
<P>No relevant pain or function outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:04 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guven-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:04 -0400" MODIFIED_BY="[Empty name]">
<P>High voltage galvanic electrostimulation for muscle strengthening</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:06 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hamilton-1959">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:06 -0400" MODIFIED_BY="[Empty name]">
<P>Only 34% of patients suffered OA; use of active controls. Additional description: cross-over design evaluating faradic electrostimulation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:17 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:17 -0400" MODIFIED_BY="[Empty name]">
<P>TENS as part of a combined experimental intervention. Additional description design: 3 groups, Group A receiving auricular acupuncture, diet control and aerobic exercise, Group B like A with addition of TENS and ultrasound, Group C receiving TENS and ultrasound; unclear whether allocation was at random.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:18 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jensen-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:18 -0400" MODIFIED_BY="[Empty name]">
<P>Use of active control: high frequency TENS versus low frequency TENS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kang-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:19 -0400" MODIFIED_BY="[Empty name]">
<P>Percutaneous electrostimulation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Katsnelson-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:19 -0400" MODIFIED_BY="[Empty name]">
<P>Electrode placement not involving knee innervation: transcranial electrostimulation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:20 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Komarova-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:20 -0400" MODIFIED_BY="[Empty name]">
<P>Electrode placement not involving knee innervation: transcranial electrostimulation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:22 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lewis-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:22 -0400" MODIFIED_BY="[Empty name]">
<P>Cross-over RCT reporting pooled results after completion of all phases. Contact established with Daniel and Beverly Lewis, who were unable to provide results for the first phase (before cross-over)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:23 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lewis-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:23 -0400" MODIFIED_BY="[Empty name]">
<P>RCT reporting P values of effect only. Contact established with Daniel and Beverly Lewis, who could not provide any additional outcome data, nor could they indicate whether the design concerned a cross-over or a parallel RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:24 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lewis-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:24 -0400" MODIFIED_BY="[Empty name]">
<P>Published abstract addressing the same cross-over RCT reported by <LINK REF="STD-Lewis-1994" TYPE="STUDY">Lewis 1994</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-20 07:25:57 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lewis-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-20 07:25:57 -0400" MODIFIED_BY="[Empty name]">
<P>Cross-over RCT reporting pooled results after completion of all phases. Contact established with Daniel and Beverly Lewis, who were unable to provide results for the first phase (before cross-over)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:24 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lone-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:24 -0400" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled study. Additional description: before-after study design that was incorrectly labelled as randomised study by original authors.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:25 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lund-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:25 -0400" MODIFIED_BY="[Empty name]">
<P>Not concerning osteoarthritis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:27 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Macchione-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:27 -0400" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial (review)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:30 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matti-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:30 -0400" MODIFIED_BY="[Empty name]">
<P>Not concerning osteoarthritis, not a randomised clinical trial. Tetanus-like faradisation electrostimulation with exercise after surgical removal of meniscus, primarily aiming at muscle enhancement. Active control with 10 Hz sinusoidal current application and exercise.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miranda_x002d_Filloy-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:31 -0400" MODIFIED_BY="[Empty name]">
<P>Electrical muscle stimulation using sport400 (Complex), primarily aiming at muscle strengthening</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:34 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mont-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:34 -0400" MODIFIED_BY="[Empty name]">
<P>Not a randomised clinical trial. Description: comparative study with historical control evaluating pulsed electrostimulation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:35 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oldham-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:35 -0400" MODIFIED_BY="[Empty name]">
<P>Neuromuscular electrostimulation primarily aiming at muscle strengthening</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:36 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oldham-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:36 -0400" MODIFIED_BY="[Empty name]">
<P>Electrostimulation primarily aiming at muscle strengthening</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:37 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oosterhof-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:37 -0400" MODIFIED_BY="[Empty name]">
<P>Mixed population, only 4 out of 163 patients reported to have knee, hip or ankle OA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:38 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Paillard-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:38 -0400" MODIFIED_BY="[Empty name]">
<P>Not concerning osteoarthritis (healthy volunteers)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:38 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Picaza-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:38 -0400" MODIFIED_BY="[Empty name]">
<P>Not concerning osteoarthritis and not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:39 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salaj-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:39 -0400" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial, combined multiple interventions in both interventions and control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:39 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salim-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:39 -0400" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial (review)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:40 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sluka-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:40 -0400" MODIFIED_BY="[Empty name]">
<P>Animal study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-06 11:11:39 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sok-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-06 11:11:39 -0500" MODIFIED_BY="[Empty name]">
<P>Concerns chronic knee pain. First author was contacted by email to verify how many patients had osteoarthritis. No response received. Additional description: article in Korean, using a TENS device, abstract however suggests that parameters were set to strengthen muscles.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svarcova-1988a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:41 -0400" MODIFIED_BY="[Empty name]">
<P>Use of active control groups. Additional description: controlled trial with groups receiving either galvanic electrostimulation or YES ultrasound or pulsed shortwaves. Within these groups, half of the patients received ibuprofen, half received placebo ibuprofen. It was unclear whether allocation was at random.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-13 10:28:21 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svarcova-1988b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-13 10:28:21 -0400" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="STD-Svarcova-1988a" TYPE="STUDY">Svarcova 1988a</LINK>. Double publication of the same study, including the same number of patient and outcome data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-22 11:11:05 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svarcova-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-22 11:11:05 -0500" MODIFIED_BY="[Empty name]">
<P>Use of active control group. Additional description: galvanic electrostimulation versus electroacupuncture.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:42 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Talbot-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:42 -0400" MODIFIED_BY="[Empty name]">
<P>Neuromuscular electrostimulation primarily aiming at muscle strengthening</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:42 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tam-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:42 -0400" MODIFIED_BY="[Empty name]">
<P>No relevant pain or function outcomes used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-04 09:09:08 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taylor-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-04 09:09:08 -0500" MODIFIED_BY="[Empty name]">
<P>Incomplete presentation of data. Additional description: cross-over randomised clinical trial presenting pooled results only. Contact established with Mark Hallett, who was unable to provide data concerning the first phase, before cross-over. We were unable to contact the other authors.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:43 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tulgar-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:43 -0400" MODIFIED_BY="[Empty name]">
<P>Not concerning osteoarthritis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:44 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Volklein-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:44 -0400" MODIFIED_BY="[Empty name]">
<P>Use of active control group. Additional description: random allocation of patients to 4 different types of diadynamic current.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-12 15:22:44 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weiner-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-12 15:22:44 -0400" MODIFIED_BY="[Empty name]">
<P>Not transcutaneous but periosteal (needle) application</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-20 11:29:27 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zivkovic-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-20 11:29:27 -0500" MODIFIED_BY="[Empty name]">
<P>Use of active control group. Additional description: the combination of low-energy laser, pulsed electromagnetic field and kinesitherapy was compared to the combination of electrotherapy, pulsed electromagnetic field and kinesitherapy. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>OA = osteoarthritis<BR/>RCT = randomised controlled trial<BR/>TENS = transcutaneous electrical nerve stimulation<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-12-06 09:27:43 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-08-12 15:23:15 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2009-08-12 15:23:03 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fary-2008">
<CHAR_STUDY_NAME MODIFIED="2008-12-08 08:02:23 -0500" MODIFIED_BY="[Empty name]">
<P>ACTRNI2607000492459</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-08-12 15:22:54 -0400" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomised placebo-controlled trial</P>
<P>Randomisation method: computer-generated block randomisation with stratification for gender, age and intensity of pain<BR/>Concealment of allocation: by independent administrator</P>
<P>Blinding: patients, those administering treatment/s, those assessing outcomes, those analysing results/data</P>
<P>Sample size calculation: reported</P>
<P>Analyses based on intention-to-treat principle</P>
<P>Trial duration: 26 weeks</P>
<P>Sponsored by: non-profit organisation Arthritis Australia and Physiotherapy Research Foundation </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-07 10:42:24 -0500" MODIFIED_BY="[Empty name]">
<P>70 patients with primary knee OA to be randomised<BR/>Study joints: 70 knees<BR/>Selection criteria: persistent, stable pain for minimum of 3 months, at least 25 mm on a 100 mm VAS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:22:58 -0400" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: pulsed electrostimulation, daily<BR/>Control intervention: sham pulsed electrostimulation, daily<BR/>Duration of treatment period: 26 weeks<BR/>Analgesics allowed and measured with diary</P>
<P>Device: Metron Digi-10s, adapted by engineer<BR/>Self-administered: yes<BR/>Waveform: pulsed, exponentially declining<BR/>Pulse width: not reported<BR/>Pulse frequency: 100 Hz<BR/>Amplitude: below sensory threshold<BR/>Duration of stimulation: minimally 7 hours per day<BR/>Electrodes: not reported<BR/>Electrode placement: not reported</P>
<P>Sham device: identical in appearance</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 15:23:03 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: conflicting information reported in Australian/New Zealand clinical trial register (ANZCTR) and subsequent publication in BMC. In ANZCR reported as pain on VAS, in BMC more than 2 primary outcomes are reported; pain (VAS and WOMAC), function (WOMAC), and patient global assessment (VAS). Main time points of interest are reported consistently as baseline, 4, 16 and 26 weeks.</P>
<P>Secondary outcomes: in ANZCTR reported as function (WOMAC) and patient global assessment (VAS); in BMC reported as stiffness (WOMAC 3.1), quality of life (SF-36), global perceived effect scale (GPES), physical activity (Human Activity Profile (HAP) questionnaire plus accelerometers</P>
<P>Safety outcomes: in BMC, the recording of adverse events was reported</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-02-06 11:11:39 -0500" MODIFIED_BY="[Empty name]">
<P>26th of September 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-02-06 11:11:39 -0500" MODIFIED_BY="[Empty name]">
<P>Robyn E Fary<BR/>Curtin University of Technology, School of Physiotherapy,<BR/>Kent Street, Bentley, WA, 6102, Australia<BR/>Tel: 08 9266 3667<BR/>Email: R.Fary@curtin.edu.au</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-07-17 07:47:31 -0400" MODIFIED_BY="[Empty name]">
<P>Status at 17 July 2009: open to recruitment</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-08-12 15:23:13 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Palmer-2007">
<CHAR_STUDY_NAME MODIFIED="2009-02-23 10:24:59 -0500" MODIFIED_BY="[Empty name]">
<P>ISRCTN12912789</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-08-12 15:23:04 -0400" MODIFIED_BY="[Empty name]">
<P>A randomised, sham-controlled trial with 3 parallel arms</P>
<P>Randomisation method: not reported<BR/>Concealment of allocation: not reported</P>
<P>Blinding: not reported</P>
<P>Sample size calculation: not reported</P>
<P>Analyses: not reported whether is based on intention-to-treat principle</P>
<P>Trial duration: 6 weeks</P>
<P>Sponsored by: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-12 15:23:07 -0400" MODIFIED_BY="[Empty name]">
<P>261 (87 in each arm) patients with primary knee OA to be randomised<BR/>Study joints: knees<BR/>Selection criteria: knee pain, radiographic (X-ray) evidence of osteophytes, and at least 1 of the following 3 criteria: 50 years or older, morning stiffness that lasts for less than 30 minutes, crepitus on active movement</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:23:09 -0400" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: TENS, as much as needed and group education including self-efficacy and exercise training, once per week<BR/>Control intervention 1: Sham TENS, as much as needed and group education once per week, as described above<BR/>Control intervention 2: group education once per week, as described above<BR/>Duration of treatment period: 6 weeks<BR/>Analgesics: unclear wether analgesic intake is allowed and is measured</P>
<P>Device: not reported<BR/>Self-administered: yes<BR/>Waveform: not reported<BR/>Pulse width: not reported<BR/>Pulse frequency: not reported<BR/>Amplitude: "strong but comfortable" tingling sensation<BR/>Duration of stimulation: defined as "as much as needed"<BR/>Electrodes: not reported<BR/>Electrode placement: within or close to the site of pain</P>
<P>Sham device: identical in appearance, displays are active but there is no current output</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 15:23:11 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcome: WOMAC function subscale (at baseline, 3, 6, 12 and 24 weeks)</P>
<P>Secondary outcomes:<BR/>1. Total WOMAC score and WOMAC pain and stiffness subscale scores (at baseline, 3, 6, 12 and 24 weeks)<BR/>2. Knee extensor torque (quadriceps strength) (at baseline, 3, 6, 12 and 24 weeks)<BR/>3. Patient global assessment of change (at 3, 6, 12 and 24 weeks)<BR/>4. Self-efficacy for exercise (at baseline and 24 weeks)<BR/>5. Self-reported exercise adherence (at baseline, 3, 6, 12 and 24 weeks)<BR/>6. Logged TENS usage time (at 6 weeks)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-08-12 15:23:12 -0400" MODIFIED_BY="[Empty name]">
<P>1 October 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-08-12 15:23:13 -0400" MODIFIED_BY="[Empty name]">
<P>Dr Shea Palmer<BR/>Faculty of Health and Social Care<BR/>University of the West of England<BR/>Blackberry Hill<BR/>Bristol<BR/>BS16 1DD<BR/>United Kingdom<BR/>Tel  +44 (0)117 328 8919<BR/>Email  Shea.Palmer@uwe.ac.uk </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-08-12 15:23:13 -0400" MODIFIED_BY="[Empty name]">
<P>Status at 17 July 2009: completed at 30 June 2009</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>OA = osteoarthritis<BR/>TENS = transcutaneous electrical nerve stimulation<BR/>VAS = visual analogue scale</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-08-12 15:27:37 -0400" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-08-12 15:21:48 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:17:37 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Adedoyin-2002">
<DESCRIPTION>
<P>Alternation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:17:51 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Adedoyin-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-04 10:36:56 -0400" MODIFIED_BY="Jenny Bellorini" RESULT="NO" STUDY_ID="STD-Bal-2007">
<DESCRIPTION>
<P>The published report only stated that there was a random allocation of patients to comparison groups. In personal communication, investigator Serpil Bal stated that the patients were allocated according to last digit of their hospital registration number. Patients with even numbers were assigned to TENS group, patients with odd numbers to a sham intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:18:10 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cetin-2008">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:18:23 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheing-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:18:36 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheing-2003">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:18:48 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Defrin-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:19:00 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fargas_x002d_Babjak-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:19:18 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garland-2007">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:19:32 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grimmer-1992">
<DESCRIPTION>
<P>Quote: "randomly allocated (by dice) into three groups of 20"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:19:54 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Itoh-2008">
<DESCRIPTION>
<P>Computer generated block randomisation. Quote "According to a block randomised allocation table (generated by Sample Size, version 2.0, Int), the enrolled patients were allocated to (1) the control (CT) group, (2) the acupuncture (ACP) group, (3) the transcutaneous electrical nerve stimulation (TENS) group or (4) the acupuncture and TENS (A&amp;T) group."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-17 07:47:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Law-2004">
<DESCRIPTION>
<P>Quote: "Randomization was carried out by drawing lots from the randomization envelope."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:20:41 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Law-2004a">
<DESCRIPTION>
<P>Quote: "'by drawing lots from the randomization envelope without replacement"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:20:53 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ng-2003">
<DESCRIPTION>
<P>Drawing lots. Quote: "Subjects were randomly assigned by drawing a piece of paper that designated each person to the EA, TENS, and control groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:21:06 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quirk-1985">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-17 07:47:29 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-1983">
<DESCRIPTION>
<P>Computer generated. Quote: "(...) assigned by random computer programme and effected by using sealed envelopes containing cards which defined the treatment (...)".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:21:32 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yurtkuran-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:21:48 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zizic-1995">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-08-12 15:26:08 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:17:37 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Adedoyin-2002">
<DESCRIPTION>
<P>Alternation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:17:52 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Adedoyin-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:18:00 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bal-2007">
<DESCRIPTION>
<P>No, the same investigator responsible of randomisation was giving interventions, as indicated by Serpil Bal in personal communication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:18:10 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cetin-2008">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:18:24 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheing-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:18:37 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheing-2003">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:18:49 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Defrin-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:19:01 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fargas_x002d_Babjak-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:19:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garland-2007">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:19:32 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grimmer-1992">
<DESCRIPTION>
<P>By a person independent of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:19:55 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-2008">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:20:07 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Law-2004">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:26:08 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Law-2004a">
<DESCRIPTION>
<P>Quote : "(...) carried out by physiotherapists who performed the treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:20:54 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ng-2003">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:21:07 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quirk-1985">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:21:22 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1983">
<DESCRIPTION>
<P>Sealed assignment envelopes, but unclear whether these were opaque and sequential</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:21:32 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yurtkuran-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:21:48 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zizic-1995">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-12-05 10:33:54 -0500" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-07-08 09:08:00 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-08-12 15:26:30 -0400" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:17:38 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Adedoyin-2002">
<DESCRIPTION>
<P>Trial protocol not accessible, methods section not explicit about pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:17:53 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Adedoyin-2005">
<DESCRIPTION>
<P>Trial protocol not accessible, methods section not explicit about pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:18:01 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bal-2007">
<DESCRIPTION>
<P>Trial protocol not accessible, methods section not explicit about pre-specified outcomes, we have been unable to sort out this item with investigator Serpil Bal</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:18:11 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cetin-2008">
<DESCRIPTION>
<P>Trial protocol not accessible, methods section not explicit about pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:18:25 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheing-2002">
<DESCRIPTION>
<P>Trial protocol not accessible, methods section not explicit about pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:18:37 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheing-2003">
<DESCRIPTION>
<P>Trial protocol not accessible, methods section not explicit about pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:18:49 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Defrin-2005">
<DESCRIPTION>
<P>Trial protocol not accessible, methods section not explicit about pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-17 07:47:21 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fargas_x002d_Babjak-1989">
<DESCRIPTION>
<P>Quote: "Full details of this (Percent Improvement Pain Scale) are reported elsewhere". Investigators however failed to provide reference.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:19:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garland-2007">
<DESCRIPTION>
<P>Quote: "Total WOMAC scores were not a defined outcome in the protocol, but are shown in Tables II(a)-(d)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:26:30 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grimmer-1992">
<DESCRIPTION>
<P>Insufficient information provided; no access to study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:19:55 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-2008">
<DESCRIPTION>
<P>Insufficient information provided, no access to study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:26:16 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Law-2004">
<DESCRIPTION>
<P>Insufficient information provided; no access to study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:20:43 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Law-2004a">
<DESCRIPTION>
<P>No results reported for some outcomes mentioned in the methods section, including pain intensity on VAS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-17 07:47:27 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ng-2003">
<DESCRIPTION>
<P>Quote: "In each evaluation session, three outcome measures were collected." The authors present results of all these 3 outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:21:07 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Quirk-1985">
<DESCRIPTION>
<P>No results reported for some outcomes mentioned in the methods section, including maximum knee girth</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:21:22 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Smith-1983">
<DESCRIPTION>
<P>No results reported for some outcomes mentioned in the methods section, including sleep disturbance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:21:33 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yurtkuran-1999">
<DESCRIPTION>
<P>Trial protocol not accessible, methods section not explicit about pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:21:49 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zizic-1995">
<DESCRIPTION>
<P>No results reported for some outcomes mentioned in the methods, including walking time, tenderness and swelling</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2008-12-05 10:33:54 -0500" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2009-08-12 15:27:33 -0400" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Adequate blinding of patients?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:17:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Adedoyin-2002">
<DESCRIPTION>
<P>Sham device: identical in appearance, not increasing intensity, flash light on, patient in position unable to read level of intensity</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:27:33 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Adedoyin-2005">
<DESCRIPTION>
<P>No sham intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 11:11:21 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bal-2007">
<DESCRIPTION>
<P>Trial is described as single blind study using sham device PlusMED 1-904, indistinguishable from real TENS unit. Sham device had broken leads, no current passed but flashing light was on. None of the patients had prior experience with TENS.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:27:21 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cetin-2008">
<DESCRIPTION>
<P>No sham intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:27:16 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cheing-2002">
<DESCRIPTION>
<P>Comparison 1: Yes, sham device identical in appearance to real TENS unit, no current passed but indicator light was lit up Comparison 2: No, no sham intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:18:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cheing-2003">
<DESCRIPTION>
<P>Sham device: electronic circuit disconnected, no current passed, but indicator light on</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:18:50 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Defrin-2005">
<DESCRIPTION>
<P>Use of sham device: Uniphy-Phyaction electrical stimulator, however the device described as shut-off</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:26:57 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fargas_x002d_Babjak-1989">
<DESCRIPTION>
<P>Use of sham device: Codetron, identical in appearance, set at frequency of 0.2 Hz with a threshold electrical stimulus of 0.5 mA, which caused a sensation on the skin but failed causing the deep muscle afferent stimulation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:26:36 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garland-2007">
<DESCRIPTION>
<P>Use of sham device: BIO-1000, indistinguishable from active device, with automatic shut-off as soon as amplitude is reduced (all patients were instructed to reduce intensity just below perception level). Further adjustments required all devices to be restarted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:26:27 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grimmer-1992">
<DESCRIPTION>
<P>Sham device: Medtronic Neuromed Selectra, with non-functioning leads. Patient were told that a very high frequency current was being tested and that no skin sensation would be felt.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:19:56 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Itoh-2008">
<DESCRIPTION>
<P>No sham intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-17 07:47:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Law-2004">
<DESCRIPTION>
<P>Use of sham device: identical in appearance, internal circuit disconnected, no current passed, indicator light on, digital display of intensity control functioned normally. Quote: "Only therapists who administered treatment to the subjects knew the group allocation, while the subjects and the assessor were not given this information."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-17 07:47:26 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Law-2004a">
<DESCRIPTION>
<P>Use of sham device: ITO model 120Z, no current delivered but flashing light on. Quote: "The assessors and subjects were blind to the group allocation. All subjects were told that when the indicator light of the TENS was blinking, it meant the machine was working properly. They might or might not feel any tingling sensation during treatment because the intensity of the current was small."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:20:54 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ng-2003">
<DESCRIPTION>
<P>No sham intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:21:08 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Quirk-1985">
<DESCRIPTION>
<P>No sham intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-17 07:47:29 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-1983">
<DESCRIPTION>
<P>Use of sham device: RDG Tiger Pulse with broken electrode connection at jack point, no current passed but flashing light on. Quote: "Exactly the same procedure were followed for both the treatment and control groups".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-17 07:47:30 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yurtkuran-1999">
<DESCRIPTION>
<P>Sham device: MEA-TENS with broken lead at jack plug, no current passed but red indicator light on. Quote: "(...) treatment appeared to be done in the same way as the other groups without the subjects suspecting the nature of the stimulation".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:25:27 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zizic-1995">
<DESCRIPTION>
<P>Sham device: BIO-1000, identical in appearance to active device, with automatic shut-off as soon as amplitude is reduced (all patients were instructed to reduce intensity just below perception level)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2009-07-17 07:52:55 -0400" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Adequate blinding of outcome assessors?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="STUDY" MODIFIED="2009-07-17 07:52:55 -0400" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Intention-to-treat analysis reported?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-14" LEVEL="GROUP" MODIFIED="2009-08-12 15:27:37 -0400" MODIFIED_BY="[Empty name]" NO="14">
<NAME>Incomplete outcome reporting: intention-to-treat analysis performed?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-14.01" NO="1">
<NAME>Pain</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-14.02" NO="2">
<NAME>Function</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2009-08-04 08:28:11 -0400" MODIFIED_BY="Jenny Bellorini" RESULT="YES" STUDY_ID="STD-Adedoyin-2002">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2009-08-12 15:27:37 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Adedoyin-2002">
<DESCRIPTION>
<P>Not applicable, no function outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2009-08-12 15:27:31 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Adedoyin-2005">
<DESCRIPTION>
<P>15 out of 15 (100%) in TENS group, 16 out of 19 (84%) in interferential current stimulation group, 15 out of 17 (88%) in control group analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2009-08-12 15:27:30 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Adedoyin-2005">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2009-08-12 15:18:02 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bal-2007">
<DESCRIPTION>
<P>All subjects were available for end of treatment measurements, as indicated by Serpil Bal in personal communication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2009-08-12 15:27:26 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bal-2007">
<DESCRIPTION>
<P>All subjects were available for end of treatment measurements, as indicated by Serpil Bal in personal communication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2009-08-12 15:18:12 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cetin-2008">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2009-08-12 15:27:20 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cetin-2008">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2009-08-12 15:27:12 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cheing-2002">
<DESCRIPTION>
<P>Comparison 1: 16 out of 16 (100%) randomised to experimental and 16 out of 18 (89%) randomised to control group were analysed<BR/>Comparison 2: 15 out of 17 (88%) randomised to experimental and 15 out of 15 (100%) randomised to control group were analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2009-08-12 15:27:11 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheing-2002">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2009-08-12 15:27:07 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cheing-2003">
<DESCRIPTION>
<P>30 out of 30 (100%) randomised to experimental and 8 out of 10 (80%) randomised to control group were analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2009-08-12 15:27:06 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheing-2003">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2009-08-12 15:27:02 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Defrin-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2009-08-12 15:27:01 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Defrin-2005">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2009-08-12 15:26:53 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fargas_x002d_Babjak-1989">
<DESCRIPTION>
<P>56 patients randomised but only 19 analysed in the experimental, and 18 analysed in the control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2009-08-12 15:26:52 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fargas_x002d_Babjak-1989">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2009-08-12 15:19:24 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garland-2007">
<DESCRIPTION>
<P>Due to major protocol violations, all 42 randomised patient of 1 site were excluded by original authors. From the other site, all patients randomised were included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2009-08-12 15:19:24 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garland-2007">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2009-08-12 15:26:26 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grimmer-1992">
<DESCRIPTION>
<P>Degrees of freedom reported indicate that all randomised patients were included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2009-08-12 15:19:36 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grimmer-1992">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2009-08-12 15:26:21 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Itoh-2008">
<DESCRIPTION>
<P>12 out of 16 (75%) randomised to experimental and 12 out of 16 (75%) randomised to control group were analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2009-08-12 15:26:20 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Itoh-2008">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2009-08-12 15:26:13 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Law-2004">
<DESCRIPTION>
<P>In total, 3 patients dropped out and were excluded from analysis, as indicated by Gladys Cheing and Pearl Law in personal communication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2009-08-12 15:20:31 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Law-2004">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2009-08-12 15:26:04 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Law-2004a">
<DESCRIPTION>
<P>In total, 3 patients dropped out and were excluded from analysis, as indicated by Gladys Cheing and Pearl Law in personal communication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2009-08-12 15:20:45 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Law-2004a">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2009-08-12 15:25:58 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ng-2003">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2009-08-12 15:25:55 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ng-2003">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2009-08-12 15:25:51 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Quirk-1985">
<DESCRIPTION>
<P>Quote: "All patients completed their therapy and the first two assessments (baseline and end of treatment), while 92% completed the final assessment (3-6 months after treatment)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2009-08-12 15:25:48 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Quirk-1985">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2009-08-12 15:21:23 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Smith-1983">
<DESCRIPTION>
<P>15 out of 16 (0.94) randomised to experimental and 15 out of 16 (0.94) randomised to control group were analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2009-08-12 15:21:24 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1983">
<DESCRIPTION>
<P>Not applicable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2009-07-17 07:47:30 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yurtkuran-1999">
<DESCRIPTION>
<P>Investigators reported that "no subject was withdrawn either active or placebo groups". However, the reported degrees of freedom indicate that 5 out of 100 patients were not included. It remained unclear to which of the 4 groups the excluded patients belonged.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2009-08-12 15:25:34 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yurtkuran-1999">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2009-08-12 15:25:22 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zizic-1995">
<DESCRIPTION>
<P>38 out of 41 (0.93) randomised to experimental and 33 out of 37 (0.89) randomised to control group were analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.02" MODIFIED="2009-08-12 15:25:21 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zizic-1995">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-17" LEVEL="STUDY" MODIFIED="2009-08-12 15:27:36 -0400" MODIFIED_BY="[Empty name]" NO="17">
<NAME>Funding by commercial organisation avoided?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:27:36 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Adedoyin-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:17:56 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Adedoyin-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:27:25 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bal-2007">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:27:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cetin-2008">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:18:28 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheing-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:27:05 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheing-2003">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:27:00 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Defrin-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:26:52 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fargas_x002d_Babjak-1989">
<DESCRIPTION>
<P>Sponsor: Electronic Health Machines</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:19:25 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garland-2007">
<DESCRIPTION>
<P>Sponsor: BioniCare Medical Technologies</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:26:25 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grimmer-1992">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:26:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-2008">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:26:12 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Law-2004">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:26:03 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Law-2004a">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:20:56 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ng-2003">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:25:47 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quirk-1985">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:25:41 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1983">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:21:39 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yurtkuran-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:21:52 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zizic-1995">
<DESCRIPTION>
<P>Sponsor: Murray Electronics</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-18" LEVEL="STUDY" MODIFIED="2009-08-12 15:27:35 -0400" MODIFIED_BY="[Empty name]" NO="18">
<NAME>Funding by non-profit organisation?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:27:35 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Adedoyin-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:17:56 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Adedoyin-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:27:24 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bal-2007">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:18:14 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cetin-2008">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:18:29 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheing-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:27:03 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheing-2003">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:26:58 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Defrin-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:19:06 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fargas_x002d_Babjak-1989">
<DESCRIPTION>
<P>NRC grant no: 689</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:26:35 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garland-2007">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:19:37 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grimmer-1992">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:19:59 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-2008">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:20:32 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Law-2004">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:20:46 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Law-2004a">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:25:54 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ng-2003">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:21:10 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quirk-1985">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:25:39 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1983">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:21:40 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yurtkuran-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-12 15:21:53 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zizic-1995">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2009-10-08 09:42:38 -0400" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2009-10-08 09:42:38 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-04-17 06:31:43 -0400" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Any type of transcutaneous electrostimulation compared with sham or no intervention for osteoarthritis of the knee</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>patients<B> </B>with osteoarthritis</P>
<P>
<B>Settings:</B> physical therapy practice of outpatient clinic</P>
<P>
<B>Intervention: </B>any type of transcutaneous applied electrostimulation</P>
<P>
<B>Comparison: </B>sham or no specific intervention</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed risk*</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Sham or no specific intervention</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Any type of transcutaneous electrostimulation</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Pain</B>
</P>
<P>Various pain scales</P>
<P>Median follow-up: 4 weeks</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>-1.8 cm change</B> on 10 cm VAS<SUP>1</SUP>
</P>
<P>29% improvement</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>-2.0 cm change</B>
<BR/>(&#916; -0.2 cm, -1.2 to 0.8 cm)<SUP>2</SUP>
</P>
<P>33% improvement<BR/>(&#916; +4%, -13% to +20%)<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>SMD -0.07 (-0.46 to 0.32)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<BR/>726<BR/>(16 studies)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+OOO<BR/>very low<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="MIDDLE">
<P>Little evidence of beneficial effect (NNT: not statistically significant)</P>
<P>The estimated pain in the intervention group of large trials was derived from meta-regression using the standard error as independent variable</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>Function</B>
</P>
<P>Various validated function scales</P>
<P>Median follow-up: 4 weeks</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>-1.2 units on WOMAC</B>
<BR/>(range 0 to 10)<SUP>1</SUP>
</P>
<P>21% improvement</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>-2.3 units on WOMAC</B>
<BR/>(&#916; -1.1, -1.6 to -0.6)<SUP>5</SUP>
<BR/>
</P>
<P>41% improvement<BR/>(&#916; +20%, +11% to +29%)<SUP>6</SUP>
</P>
</TD>
<TD>
<P>SMD -0.34<BR/>(-0.54 to -0.14)</P>
</TD>
<TD ALIGN="CENTER">
<P>
<BR/>407<BR/>(9 studies)</P>
</TD>
<TD ALIGN="CENTER">
<P>+OOO<BR/>very low<SUP>7</SUP>
</P>
</TD>
<TD>
<P>NNT: 10 (95% CI 7 to 22)<SUP>8</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>Number of patients experiencing any adverse event</B>
</P>
<P>Median follow-up: 4 weeks</P>
</TD>
<TD ALIGN="CENTER">
<P/>
<P>150 per 1000 patient-years<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>153 per 1000 patient-years<BR/>(80 to 296)</P>
</TD>
<TD>
<P>RR 1.02 (0.53 to 1.97)</P>
</TD>
<TD ALIGN="CENTER">
<P>175<BR/>(3 studies)</P>
</TD>
<TD ALIGN="CENTER">
<P>++OO<BR/>low<SUP>9</SUP>
</P>
</TD>
<TD>
<P>No evidence of harmful effect</P>
<P>(NNH: not statistically significant)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>Number of patients withdrawn or dropped out because of adverse events</B>
</P>
<P>Median follow-up: 4 weeks</P>
</TD>
<TD ALIGN="CENTER">
<P/>
<P>17 per 1000 patient-years<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>16 per 1000 patient-years<BR/>(3 to 102)</P>
</TD>
<TD>
<P>RR 0.97 (0.16 to 6.00)</P>
</TD>
<TD ALIGN="CENTER">
<P>363<BR/>(8 studies)</P>
</TD>
<TD ALIGN="CENTER">
<P>+++O<BR/>moderate<SUP>10</SUP>
</P>
</TD>
<TD>
<P>No evidence of harmful effect</P>
<P>(NNH: not statistically significant)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>Number of patients experiencing any serious adverse event</B>
</P>
<P>Median follow -up: 4 weeks</P>
</TD>
<TD ALIGN="CENTER">
<P/>
<P>4 per 1000 patient-years<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1 per 1000 patient-years<BR/>(0 to 29)</P>
</TD>
<TD>
<P>RR 0.33 (0.02 to 7.32)</P>
</TD>
<TD ALIGN="CENTER">
<P>195<BR/>(4 studies)</P>
</TD>
<TD ALIGN="CENTER">
<P>++OO<BR/>low<SUP>11</SUP>
</P>
</TD>
<TD>
<P>No evidence of harmful effect</P>
<P>(NNH: not statistically significant)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> in the safety outcomes (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: confidence interval; GRADE: GRADE Working Group grades of evidence (see explanations); NNT: number needed to treat; NNH: number needed to harm; RR: risk ratio; SMD: standardised mean difference</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality (++++):</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality (+++O):</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality (++OO):</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality (+OOO):</B> We are very uncertain about the estimate.</P>
<P>
<SUP>1 </SUP>Median reduction as observed across control groups in large osteoarthritis trials (<LINK REF="REF-Nuesch-2009" TYPE="REFERENCE">Nuesch 2009</LINK>).<BR/>
<SUP>2</SUP> Standardised mean differences (SMDs) were back-transformed onto a 10 cm visual analogue scale (VAS) on the basis of a typical pooled SD of 2.5 cm in trials that assessed<BR/>pain using a VAS, and expressed as change based on an assumed standardised reduction of 0.72 standard deviation units in the control group.<BR/>
<SUP>3</SUP> The median observed pain score at baseline across control groups in large osteoarthritis trials was 6.1 cm on a 10 cm VAS (<LINK REF="REF-Nuesch-2009" TYPE="REFERENCE">Nuesch 2009</LINK>).<BR/>
<SUP>4 </SUP>Downgraded (3 levels) because the effect was estimated from a meta-regression model using the standard error as independent variable and because included trials were generally of low quality and small sample size: only 2 out of 16 trials used adequate concealment of allocation, only 3 performed analyses according to the intention-to-treat principle, and the presence of large between trial heterogeneity.<BR/>
<SUP>5</SUP> Standardised mean differences (SMDs) were back-transformed onto a 0 to 10 standardised WOMAC function score on the basis of a typical pooled SD of 2.1 in trials that<BR/>assessed function on WOMAC function scale and expressed as change based on an assumed standardised reduction of 0.58 standard deviation units in the control group.<BR/>
<SUP>6 </SUP>The median observed standardised WOMAC function score at baseline across control groups in large osteoarthritis trials was 5.6 units (<LINK REF="REF-Nuesch-2009" TYPE="REFERENCE">Nuesch 2009</LINK>).<BR/>
<SUP>7</SUP> Downgraded (3 levels) because included trials were generally of low quality and small sample size: 1 out of 9 studies used adequate concealment of allocation methods, only 2 performed analyses according to the intention-to-treat principle, presence of moderate between trial heterogeneity, 9 out of 18 studies reported this outcome, likely leading to selective outcome reporting bias.<BR/>
<SUP>8 </SUP>Absolute response risks for function in the control groups were assumed 26% (see Methods section).<BR/>
<SUP>9</SUP> Downgraded (2 levels) because the confidence interval crosses no difference in the pooled estimate, 1 out of 3 studies included all patients in this analysis, 3 out of 18 studies reported this outcome, likely leading to selective outcome reporting bias.<BR/>
<SUP>10</SUP> Downgraded (1 level) because the confidence interval of the pooled estimate is wide and crossed no difference, 8 out of 18 studies reported this outcome, possibly leading to selective outcome reporting bias.<BR/>
<SUP>11</SUP> Downgraded (2 levels) because 4 out of 18 studies reported this outcome, possibly leading to selective outcome reporting bias, the confidence interval of the pooled estimate is wide and crossed no difference.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2009-08-12 15:24:55 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-08-12 15:24:41 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-01-08 16:31:04 -0500" MODIFIED_BY="[Empty name]">Results of stratified analyses of pain outcomes</TITLE>
<TABLE COLS="7" ROWS="40">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Variable</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>N of trials</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>N of patients </B>
<BR/>
<B>(experimental)</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>N of patients </B>
<BR/>(<B>control)</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>
<B>Pain intensity</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Heterogeneity</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>P for interaction</B>
</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P/>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>n</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>n</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>n</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>SMD (95% CI)</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>I<SUP>2</SUP> (%)</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P> </P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>All trials</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>16</P>
</TD>
<TD ALIGN="CENTER">
<P>440</P>
</TD>
<TD ALIGN="CENTER">
<P>286</P>
</TD>
<TD ALIGN="CENTER">
<P> -0.86 (-1.23 to -0.49)</P>
</TD>
<TD ALIGN="CENTER">
<P>80%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Allocation concealment</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.47</P>
</TD>
</TR>
<TR>
<TD>
<P>Adequate</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>79</P>
</TD>
<TD ALIGN="CENTER">
<P>39</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.52 (-0.91 to -0.13)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Inadequate or unclear</P>
</TD>
<TD ALIGN="CENTER">
<P>14</P>
</TD>
<TD ALIGN="CENTER">
<P>361</P>
</TD>
<TD ALIGN="CENTER">
<P>247</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.03 (-1.49 to -0.57)</P>
</TD>
<TD ALIGN="CENTER">
<P>84%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Type of control intervention*</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.12</P>
</TD>
</TR>
<TR>
<TD>
<P>Sham intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>12</P>
</TD>
<TD ALIGN="CENTER">
<P>354</P>
</TD>
<TD ALIGN="CENTER">
<P>216</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.13 (-1.59 to -0.67)</P>
</TD>
<TD ALIGN="CENTER">
<P>82%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>No control intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>86</P>
</TD>
<TD ALIGN="CENTER">
<P>70</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.31 (-0.80 to 0.19)</P>
</TD>
<TD ALIGN="CENTER">
<P>58%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Blinding of patients</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.37</P>
</TD>
</TR>
<TR>
<TD>
<P>Adequate</P>
</TD>
<TD ALIGN="CENTER">
<P>11</P>
</TD>
<TD ALIGN="CENTER">
<P>309</P>
</TD>
<TD ALIGN="CENTER">
<P>205</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.05 (-1.52 to -0.59)</P>
</TD>
<TD ALIGN="CENTER">
<P>82%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Inadequate or unclear</P>
</TD>
<TD ALIGN="CENTER">
<P>6</P>
</TD>
<TD ALIGN="CENTER">
<P>131</P>
</TD>
<TD ALIGN="CENTER">
<P>79</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.63 (-1.31 to 0.05)</P>
</TD>
<TD ALIGN="CENTER">
<P>81%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Use of analgesic cointerventions</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.36</P>
</TD>
</TR>
<TR>
<TD>
<P>Similar between groups</P>
</TD>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
<TD ALIGN="CENTER">
<P>124</P>
</TD>
<TD ALIGN="CENTER">
<P>83</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.57 (-1.16 to 0.02)</P>
</TD>
<TD ALIGN="CENTER">
<P>74%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Not similar or unclear<BR/>
</P>
</TD>
<TD ALIGN="CENTER">
<P>12</P>
</TD>
<TD ALIGN="CENTER">
<P>316</P>
</TD>
<TD ALIGN="CENTER">
<P>23</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.10 (-1.60 to -0.59)</P>
</TD>
<TD ALIGN="CENTER">
<P>84%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Intention-to-treat analysis</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.73</P>
</TD>
</TR>
<TR>
<TD>
<P>Yes</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>83</P>
</TD>
<TD ALIGN="CENTER">
<P>63</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.76 (-1.43 to -0.09)</P>
</TD>
<TD ALIGN="CENTER">
<P>72%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>No or unclear</P>
</TD>
<TD ALIGN="CENTER">
<P>13</P>
</TD>
<TD ALIGN="CENTER">
<P>357</P>
</TD>
<TD ALIGN="CENTER">
<P>223</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.00 (-1.48 to -0.53)</P>
</TD>
<TD ALIGN="CENTER">
<P>84%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Type of ES**</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.94</P>
</TD>
</TR>
<TR>
<TD>
<P>High frequency TENS</P>
</TD>
<TD ALIGN="CENTER">
<P>8</P>
</TD>
<TD ALIGN="CENTER">
<P>177</P>
</TD>
<TD ALIGN="CENTER">
<P>139</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.82 (-1.51 to -0.12)</P>
</TD>
<TD ALIGN="CENTER">
<P>86%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Burst TENS</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>39</P>
</TD>
<TD ALIGN="CENTER">
<P>38</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.85 (-1.32 to -0.38)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Modulation TENS</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>13</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.41 (-2.92 to 0.10)</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Low frequency TENS</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>46</P>
</TD>
<TD ALIGN="CENTER">
<P>40</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.82 (-1.29 to -0.34)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Interferential current stimulation</P>
</TD>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
<TD ALIGN="CENTER">
<P>88</P>
</TD>
<TD ALIGN="CENTER">
<P>44</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.20 (-1.99 to -0.42)</P>
</TD>
<TD ALIGN="CENTER">
<P>71%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pulsed ES</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>77</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.41 (-0.77 to -0.05)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Duration of ES per session&#8224;</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.69&#8225;</P>
</TD>
</TR>
<TR>
<TD>
<P>&#8804; 20 minutes</P>
</TD>
<TD ALIGN="CENTER">
<P>8</P>
</TD>
<TD ALIGN="CENTER">
<P>166</P>
</TD>
<TD ALIGN="CENTER">
<P>112</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.95 (-1.55 to -0.35)</P>
</TD>
<TD ALIGN="CENTER">
<P>78%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>30 to 40 minutes</P>
</TD>
<TD ALIGN="CENTER">
<P>6</P>
</TD>
<TD ALIGN="CENTER">
<P>156</P>
</TD>
<TD ALIGN="CENTER">
<P>99</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.45 (-2.28 to -0.62)</P>
</TD>
<TD ALIGN="CENTER">
<P>85%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>&#8805; 60 minutes</P>
</TD>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
<TD ALIGN="CENTER">
<P>118</P>
</TD>
<TD ALIGN="CENTER">
<P>91</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.47 (-0.96 to 0.02)</P>
</TD>
<TD ALIGN="CENTER">
<P>58%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Number of sessions per week</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.90&#8225;</P>
</TD>
</TR>
<TR>
<TD>
<P>&#8804; 3</P>
</TD>
<TD ALIGN="CENTER">
<P>6</P>
</TD>
<TD ALIGN="CENTER">
<P>163</P>
</TD>
<TD ALIGN="CENTER">
<P>91</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.81 (-1.48 to -0.14)</P>
</TD>
<TD ALIGN="CENTER">
<P>82%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>4 to 6</P>
</TD>
<TD ALIGN="CENTER">
<P>7</P>
</TD>
<TD ALIGN="CENTER">
<P>182</P>
</TD>
<TD ALIGN="CENTER">
<P>125</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.33 (-2.11 to -0.54)</P>
</TD>
<TD ALIGN="CENTER">
<P>88%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>&#8805; 7</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>96</P>
</TD>
<TD ALIGN="CENTER">
<P>70</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.51 (-0.83 to -0.19)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Duration of ES per week***</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.74&#8225;</P>
</TD>
</TR>
<TR>
<TD>
<P>&#8804;1 hour</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>123</P>
</TD>
<TD ALIGN="CENTER">
<P>71</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.85 (-1.72 to 0.01)</P>
</TD>
<TD ALIGN="CENTER">
<P>86%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>&gt; 1 to 5 hours</P>
</TD>
<TD ALIGN="CENTER">
<P>8</P>
</TD>
<TD ALIGN="CENTER">
<P>180</P>
</TD>
<TD ALIGN="CENTER">
<P>122</P>
</TD>
<TD ALIGN="CENTER">
<P> -1.42 (-2.11 to -0.74)</P>
</TD>
<TD ALIGN="CENTER">
<P>81%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>&gt; 5 hours</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>137</P>
</TD>
<TD ALIGN="CENTER">
<P>109</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.53 (-0.96 to -0.11)</P>
</TD>
<TD ALIGN="CENTER">
<P>55%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Duration of treatment period</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.14</P>
</TD>
</TR>
<TR>
<TD>
<P>&lt; 4 weeks</P>
</TD>
<TD ALIGN="CENTER">
<P>7</P>
</TD>
<TD ALIGN="CENTER">
<P>190</P>
</TD>
<TD ALIGN="CENTER">
<P>114</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.39 (-2.13 to -0.66)</P>
</TD>
<TD ALIGN="CENTER">
<P>86%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>&#8805; 4 weeks</P>
</TD>
<TD ALIGN="CENTER">
<P>9</P>
</TD>
<TD ALIGN="CENTER">
<P>250</P>
</TD>
<TD ALIGN="CENTER">
<P>172</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.64 (-1.06 to -0.22)</P>
</TD>
<TD ALIGN="CENTER">
<P>75%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>ES: electrostimulation; *In <LINK REF="STD-Cheing-2002" TYPE="STUDY">Cheing 2002</LINK>, two independent comparisons contributed in the two different strata. **<LINK REF="STD-Adedoyin-2005" TYPE="STUDY">Adedoyin 2005</LINK>, <LINK REF="STD-Grimmer-1992" TYPE="STUDY">Grimmer 1992</LINK> and <LINK REF="STD-Law-2004" TYPE="STUDY">Law 2004</LINK> contributed to two, two and three different strata: high-frequency TENS and interferential current stimulation, high-frequency TENS and burst, and high-, low-frequency and modulation TENS, respectively. &#8224; = <LINK REF="STD-Cheing-2003" TYPE="STUDY">Cheing 2003</LINK> contributed to all three different strata, with the same 8 control patients displayed in each stratum. &#8225; = P values from test for trend.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2009-08-12 15:24:55 -0400" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-07-17 07:53:24 -0400" MODIFIED_BY="[Empty name]">Results of stratified analyses of function</TITLE>
<TABLE COLS="7" ROWS="40">
<TR>
<TH>
<P>
<B>Variable</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>N of trials</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>N of patients </B>
<BR/>
<B>(experimental)</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>N of patients </B>
<BR/>
<B>(control)</B>
<BR/>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Function</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Heterogeneity</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>P for interaction</B>
</P>
</TH>
</TR>
<TR>
<TH>
<P> </P>
</TH>
<TH ALIGN="CENTER">
<P/>
</TH>
<TH ALIGN="CENTER">
<P/>
</TH>
<TH ALIGN="CENTER">
<P/>
</TH>
<TH ALIGN="CENTER">
<P>SMD (95% CI)</P>
</TH>
<TH ALIGN="CENTER">
<P>I<SUP>2</SUP> (%)</P>
</TH>
<TH ALIGN="CENTER">
<P> </P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>All trials</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>9</P>
</TD>
<TD ALIGN="CENTER">
<P>226</P>
</TD>
<TD ALIGN="CENTER">
<P>181</P>
</TD>
<TD ALIGN="CENTER">
<P> -0.34 (-0.54 to -0.14)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Allocation concealment</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.88</P>
</TD>
</TR>
<TR>
<TD>
<P>Adequate</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>39</P>
</TD>
<TD ALIGN="CENTER">
<P>19</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.29 (-0.85 to 0.26)</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Inadequate or unclear</P>
</TD>
<TD ALIGN="CENTER">
<P>8</P>
</TD>
<TD ALIGN="CENTER">
<P>187</P>
</TD>
<TD ALIGN="CENTER">
<P>162</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.34 (-0.56 to -0.12)</P>
</TD>
<TD ALIGN="CENTER">
<P>5%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Type of control intervention</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.14</P>
</TD>
</TR>
<TR>
<TD>
<P>Sham intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>151</P>
</TD>
<TD ALIGN="CENTER">
<P>120</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.46 (-0.70 to -0.21)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>No control intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
<TD ALIGN="CENTER">
<P>75</P>
</TD>
<TD ALIGN="CENTER">
<P>61</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.10 (-0.45 to 0.24)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Blinding of patients</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.14</P>
</TD>
</TR>
<TR>
<TD>
<P>Adequate</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>151</P>
</TD>
<TD ALIGN="CENTER">
<P>120</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.46 (-0.70 to -0.21)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Inadequate or unclear</P>
</TD>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
<TD ALIGN="CENTER">
<P>75</P>
</TD>
<TD ALIGN="CENTER">
<P>61</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.10 (-0.45 to 0.24)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Use of analgesic cointerventions</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.95</P>
</TD>
</TR>
<TR>
<TD>
<P>Similar between groups</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>69</P>
</TD>
<TD ALIGN="CENTER">
<P>48</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.33 (-0.70 to 0.05)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Not similar or unclear</P>
</TD>
<TD ALIGN="CENTER">
<P>7</P>
</TD>
<TD ALIGN="CENTER">
<P>157</P>
</TD>
<TD ALIGN="CENTER">
<P>133</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.34 (-0.60 to -0.08)</P>
</TD>
<TD ALIGN="CENTER">
<P>15%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Intention-to-treat analysis</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.76</P>
</TD>
</TR>
<TR>
<TD>
<P>Yes</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>40</P>
</TD>
<TD ALIGN="CENTER">
<P>42</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.28 (-0.71 to 0.16)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>No or unclear</P>
</TD>
<TD ALIGN="CENTER">
<P>7</P>
</TD>
<TD ALIGN="CENTER">
<P>186</P>
</TD>
<TD ALIGN="CENTER">
<P>139</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.35 (-0.58 to -0.12)</P>
</TD>
<TD ALIGN="CENTER">
<P>5%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Type of ES**</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.32</P>
</TD>
</TR>
<TR>
<TD>
<P>High frequency TENS</P>
</TD>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
<TD ALIGN="CENTER">
<P>84</P>
</TD>
<TD ALIGN="CENTER">
<P>70</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.18 (-0.50 to 0.14)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Burst TENS</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Modulation TENS</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Low frequency TENS</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>25</P>
</TD>
<TD ALIGN="CENTER">
<P>25</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.88 (-1.46 to -0.30)</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Interferential current stimulation</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>40</P>
</TD>
<TD ALIGN="CENTER">
<P>34</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.27 (-0.75 to 0.20)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pulsed ES</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>77</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.36 (-0.72 to -0.00)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Duration of ES per session</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.80&#8225;</P>
</TD>
</TR>
<TR>
<TD>
<P>&#8804; 20 minutes</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>100</P>
</TD>
<TD ALIGN="CENTER">
<P>86</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.29 (-0.69 to 0.11)</P>
</TD>
<TD ALIGN="CENTER">
<P>44%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>30 to 40 minutes</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>49</P>
</TD>
<TD ALIGN="CENTER">
<P>43</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.37 (-0.79 to 0.04)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>&#8805; 60 minutes</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>77</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.36 (-0.72 to -0.00)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Number of sessions per week</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.32&#8225;</P>
</TD>
</TR>
<TR>
<TD>
<P>&#8804; 3</P>
</TD>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
<TD ALIGN="CENTER">
<P>75</P>
</TD>
<TD ALIGN="CENTER">
<P>61</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.10 (-0.45 to 0.24)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>4 to 6</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>74</P>
</TD>
<TD ALIGN="CENTER">
<P>68</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.54 (-0.88 to -0.20)</P>
</TD>
<TD ALIGN="CENTER">
<P>2%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>&#8805; 7</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>77</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.36 (-0.72 to -0.00)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Duration of ES per week</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.32&#8225;</P>
</TD>
</TR>
<TR>
<TD>
<P>&#8804; 1 hour</P>
</TD>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
<TD ALIGN="CENTER">
<P>75</P>
</TD>
<TD ALIGN="CENTER">
<P>61</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.10 (-0.45 to 0.24)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>&gt; 1 to 5 hours</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>74</P>
</TD>
<TD ALIGN="CENTER">
<P>68</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.54 (-0.88 to -0.20)</P>
</TD>
<TD ALIGN="CENTER">
<P>2%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>&gt; 5 hours</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>77</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.36 (-0.72 to -0.00)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Duration of treatment period</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0.18</P>
</TD>
</TR>
<TR>
<TD>
<P>&lt; 4 weeks</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>74</P>
</TD>
<TD ALIGN="CENTER">
<P>68</P>
</TD>
<TD>
<P>-0.54 (-0.88 to -0.20)</P>
</TD>
<TD>
<P>2%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>&#8805; 4 weeks</P>
</TD>
<TD ALIGN="CENTER">
<P>6</P>
</TD>
<TD ALIGN="CENTER">
<P>152</P>
</TD>
<TD ALIGN="CENTER">
<P>113</P>
</TD>
<TD>
<P>-0.23 (-0.47 to 0.02)</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>ES: electrostimulation; **<LINK REF="STD-Adedoyin-2005" TYPE="STUDY">Adedoyin 2005</LINK> contributed to two different strata: high-frequency TENS and interferential current stimulation; &#8225; = P values from test for trend.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-07-17 07:49:47 -0400" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-07-17 07:49:47 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Any type of transcutaneous electrostimulation versus control</NAME>
<IV_OUTCOME CHI2="84.34295067021954" CI_END="-0.48867824784029706" CI_START="-1.231670927446399" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_SIZE="-0.8601745876433481" ESTIMABLE="YES" I2="79.84419579240249" I2_Q="77.31993875544717" ID="CMP-001.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-07-17 07:48:29 -0400" MODIFIED_BY="[Empty name]" NO="1" NOTES="&lt;p&gt;For Adedoyin 2005, the standard error was inflated and the number of patients in the control group was halfed to avoid duplicate counting of patients when including 2 different comparisons in the overall meta-analysis.&lt;/p&gt;" NOTES_MODIFIED="2009-07-17 07:48:29 -0400" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="6.428702015170984E-11" P_Q="0.012165451730047794" P_Z="5.674619718498742E-6" Q="8.818318338890506" RANDOM="YES" SCALE="4.6" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.49813198887248955" TOTALS="YES" TOTAL_1="440" TOTAL_2="286" WEIGHT="100.0" Z="4.538163722128033">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="64.89538407815179" CI_END="-0.3448429117227759" CI_START="-1.355558058773259" DF="11" EFFECT_SIZE="-0.8502004852480174" ESTIMABLE="YES" I2="83.04964188708246" ID="CMP-001.01.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-05-06 09:51:55 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.1275753664108379E-9" P_Z="9.758698331744311E-4" STUDIES="11" TAU2="0.6431560084858894" TOTAL_1="275" TOTAL_2="190" WEIGHT="66.19792268839696" Z="3.2973926146995023">
<NAME>TENS</NAME>
<IV_DATA CI_END="1.501583432888425" CI_START="-0.30158343288842504" EFFECT_SIZE="0.6" ESTIMABLE="YES" ESTIMATE="0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:48:57 -0400" MODIFIED_BY="[Empty name]" ORDER="76" SE="0.46" STUDY_ID="STD-Adedoyin-2005" TOTAL_1="15" TOTAL_2="7" WEIGHT="5.06195775348324"/>
<IV_DATA CI_END="0.2791902758258147" CI_START="-0.7791902758258147" EFFECT_SIZE="-0.25" ESTIMABLE="YES" ESTIMATE="-0.25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:51:30 -0400" MODIFIED_BY="[Empty name]" ORDER="77" SE="0.27" STUDY_ID="STD-Bal-2007" TOTAL_1="28" TOTAL_2="28" WEIGHT="6.291474757941114"/>
<IV_DATA CI_END="0.6471884750528174" CI_START="-0.6071884750528174" EFFECT_SIZE="0.02" ESTIMABLE="YES" ESTIMATE="0.02" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:51:55 -0400" MODIFIED_BY="[Empty name]" ORDER="78" SE="0.32" STUDY_ID="STD-Cetin-2008" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.982417940322242"/>
<IV_DATA CI_END="0.45598739458901894" CI_START="-0.9159873945890189" EFFECT_SIZE="-0.23" ESTIMABLE="YES" ESTIMATE="-0.23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:50:12 -0400" MODIFIED_BY="[Empty name]" ORDER="79" SE="0.35" STUDY_ID="STD-Cheing-2002" TOTAL_1="16" TOTAL_2="16" WEIGHT="5.788669305452599"/>
<IV_DATA CI_END="0.5951866742798201" CI_START="-0.8551866742798201" EFFECT_SIZE="-0.13" ESTIMABLE="YES" ESTIMATE="-0.13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:50:05 -0400" MODIFIED_BY="[Empty name]" ORDER="127" SE="0.37" STUDY_ID="STD-Cheing-2002" TOTAL_1="15" TOTAL_2="15" WEIGHT="5.65740530700975"/>
<IV_DATA CI_END="-2.20201980850297" CI_START="-4.357980191497029" EFFECT_SIZE="-3.28" ESTIMABLE="YES" ESTIMATE="-3.28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:50:19 -0400" MODIFIED_BY="[Empty name]" ORDER="81" SE="0.55" STUDY_ID="STD-Cheing-2003" TOTAL_1="30" TOTAL_2="8" WEIGHT="4.487246817389344"/>
<IV_DATA CI_END="-0.20361224525638144" CI_START="-1.5363877547436187" EFFECT_SIZE="-0.87" ESTIMABLE="YES" ESTIMATE="-0.87" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:49:15 -0400" MODIFIED_BY="[Empty name]" ORDER="114" SE="0.34" STUDY_ID="STD-Fargas_x002d_Babjak-1989" TOTAL_1="19" TOTAL_2="18" WEIGHT="5.853749534171003"/>
<IV_DATA CI_END="-0.10121008432878476" CI_START="-1.1987899156712154" EFFECT_SIZE="-0.65" ESTIMABLE="YES" ESTIMATE="-0.65" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:49:24 -0400" MODIFIED_BY="[Empty name]" ORDER="82" SE="0.28" STUDY_ID="STD-Grimmer-1992" TOTAL_1="40" TOTAL_2="20" WEIGHT="6.2314553455987935"/>
<IV_DATA CI_END="-0.888416567111575" CI_START="-2.691583432888425" EFFECT_SIZE="-1.79" ESTIMABLE="YES" ESTIMATE="-1.79" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:51:09 -0400" MODIFIED_BY="[Empty name]" ORDER="83" SE="0.46" STUDY_ID="STD-Law-2004" TOTAL_1="38" TOTAL_2="10" WEIGHT="5.06195775348324"/>
<IV_DATA CI_END="-1.6684165671115747" CI_START="-3.471583432888425" EFFECT_SIZE="-2.57" ESTIMABLE="YES" ESTIMATE="-2.57" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:50:59 -0400" MODIFIED_BY="[Empty name]" ORDER="210" SE="0.46" STUDY_ID="STD-Law-2004a" TOTAL_1="21" TOTAL_2="15" WEIGHT="5.06195775348324"/>
<IV_DATA CI_END="-0.041619448348370724" CI_START="-2.1583805516516295" EFFECT_SIZE="-1.1" ESTIMABLE="YES" ESTIMATE="-1.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:50:33 -0400" MODIFIED_BY="[Empty name]" ORDER="84" SE="0.54" STUDY_ID="STD-Ng-2003" TOTAL_1="8" TOTAL_2="8" WEIGHT="4.549180474628396"/>
<IV_DATA CI_END="-0.09161044448338429" CI_START="-1.2283895555166158" EFFECT_SIZE="-0.66" ESTIMABLE="YES" ESTIMATE="-0.66" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:49:49 -0400" MODIFIED_BY="[Empty name]" ORDER="115" SE="0.29" STUDY_ID="STD-Yurtkuran-1999" TOTAL_1="25" TOTAL_2="25" WEIGHT="6.170449945433994"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="10.61086590023606" CI_END="-0.41553852593881024" CI_START="-1.990434526131341" DF="3" EFFECT_SIZE="-1.2029865260350756" ESTIMABLE="YES" I2="71.72709533598706" ID="CMP-001.01.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-07-17 07:48:15 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.014027408794764495" P_Z="0.0027512718322760003" STUDIES="4" TAU2="0.46293094567139537" TOTAL_1="88" TOTAL_2="44" WEIGHT="21.105935001956738" Z="2.9942424955393405">
<NAME>Interferential current stimulation</NAME>
<IV_DATA CI_END="-0.7568151264931773" CI_START="-2.403184873506823" EFFECT_SIZE="-1.58" ESTIMABLE="YES" ESTIMATE="-1.58" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:49:56 -0400" MODIFIED_BY="[Empty name]" ORDER="71" SE="0.42" STUDY_ID="STD-Adedoyin-2002" TOTAL_1="15" TOTAL_2="15" WEIGHT="5.326112628065908"/>
<IV_DATA CI_END="0.7423841531976239" CI_START="-0.9823841531976238" EFFECT_SIZE="-0.12" ESTIMABLE="YES" ESTIMATE="-0.12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:49:04 -0400" MODIFIED_BY="[Empty name]" ORDER="128" SE="0.44" STUDY_ID="STD-Adedoyin-2005" TOTAL_1="16" TOTAL_2="8" WEIGHT="5.193678190051765"/>
<IV_DATA CI_END="-1.1864147663385778" CI_START="-2.793585233661422" EFFECT_SIZE="-1.99" ESTIMABLE="YES" ESTIMATE="-1.99" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:51:19 -0400" MODIFIED_BY="[Empty name]" ORDER="73" SE="0.41" STUDY_ID="STD-Defrin-2005" TOTAL_1="45" TOTAL_2="9" WEIGHT="5.392465993787301"/>
<IV_DATA CI_END="-0.21761584680237622" CI_START="-1.942384153197624" EFFECT_SIZE="-1.08" ESTIMABLE="YES" ESTIMATE="-1.08" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:52:02 -0400" MODIFIED_BY="[Empty name]" ORDER="74" SE="0.44" STUDY_ID="STD-Itoh-2008" TOTAL_1="12" TOTAL_2="12" WEIGHT="5.193678190051765"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.01838235294117646" CI_END="-0.0516757864533095" CI_START="-0.76597127237022" DF="1" EFFECT_SIZE="-0.40882352941176475" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-07-17 07:48:29 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8921521090360803" P_Z="0.02486126569755527" STUDIES="2" TAU2="0.0" TOTAL_1="77" TOTAL_2="52" WEIGHT="12.696142309646303" Z="2.2435516098804476">
<NAME>Pulsed electrostimulation</NAME>
<IV_DATA CI_END="0.16878991567121526" CI_START="-0.9287899156712153" EFFECT_SIZE="-0.38" ESTIMABLE="YES" ESTIMATE="-0.38" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:51:48 -0400" MODIFIED_BY="[Empty name]" ORDER="98" SE="0.28" STUDY_ID="STD-Garland-2007" TOTAL_1="39" TOTAL_2="19" WEIGHT="6.2314553455987935"/>
<IV_DATA CI_END="0.04039135628961299" CI_START="-0.900391356289613" EFFECT_SIZE="-0.43" ESTIMABLE="YES" ESTIMATE="-0.43" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:49:42 -0400" MODIFIED_BY="[Empty name]" ORDER="99" SE="0.24" STUDY_ID="STD-Zizic-1995" TOTAL_1="38" TOTAL_2="33" WEIGHT="6.46468696404751"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="2.505811862480976" CI_END="5.996337955918009" CI_START="0.15571144216304814" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9662807205015618" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="20.185548247033093" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.777886101870399" LOG_CI_START="-0.80767947294447" LOG_EFFECT_SIZE="-0.014896685537035518" METHOD="IV" MODIFIED="2009-07-17 07:49:11 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.28567353747390534" P_Q="0.5009464300767614" P_Z="0.9706217836803738" Q="0.4529308809757193" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.5358987969645258" TOTALS="YES" TOTAL_1="205" TOTAL_2="158" WEIGHT="100.0" Z="0.03682845743547046">
<NAME>Number of patients withdrawn or dropped out because of adverse events</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0528809815052567" CI_END="14.149678726229162" CI_START="0.025034732810053757" DF="1" EFFECT_SIZE="0.595175122345725" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="51.287969979303966" ID="CMP-001.02.01" LOG_CI_END="1.1507465791528988" LOG_CI_START="-1.6014570393654715" LOG_EFFECT_SIZE="-0.22535523010628644" MODIFIED="2008-12-12 03:47:05 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.15191892728722434" P_Z="0.7482327201833008" STUDIES="6" TAU2="2.6809082642180306" TOTAL_1="149" TOTAL_2="106" WEIGHT="56.28841447074625" Z="0.3209705355840188">
<NAME>TENS</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-08 10:16:41 -0500" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.0" STUDY_ID="STD-Cheing-2002" TOTAL_1="16" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.694238093904506" CI_START="0.005192583641957926" EFFECT_SIZE="0.11827956989247312" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.4304359723445885" LOG_CI_START="-2.2846164991360087" LOG_EFFECT_SIZE="-0.9270902633957101" MODIFIED="2008-12-08 10:16:30 -0500" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="1.5948352614741896" STUDY_ID="STD-Cheing-2003" TOTAL_1="30" TOTAL_2="10" VAR="2.5434995112414467" WEIGHT="28.169410149167167"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-10 03:41:26 -0500" MODIFIED_BY="[Empty name]" ORDER="120" O_E="0.0" SE="0.0" STUDY_ID="STD-Grimmer-1992" TOTAL_1="40" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-12 03:47:05 -0500" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.0" STUDY_ID="STD-Law-2004a" TOTAL_1="22" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="68.56773372198825" CI_START="0.13125707255384883" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8361197955452926" LOG_CI_START="-0.8818772861059678" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-12-08 10:16:07 -0500" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="1.5965649400644928" STUDY_ID="STD-Smith-1983" TOTAL_1="16" TOTAL_2="16" VAR="2.5490196078431375" WEIGHT="28.11900432157908"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-11 09:54:09 -0500" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="0.0" STUDY_ID="STD-Yurtkuran-1999" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-07-17 07:48:43 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Interferential current stimulation</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-02-03 08:54:53 -0500" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.0" STUDY_ID="STD-Adedoyin-2002" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.095419603191672" CI_START="0.17059508712891433" DF="0" EFFECT_SIZE="1.8048780487804879" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="1.2809292060111717" LOG_CI_START="-0.7680334799886901" LOG_EFFECT_SIZE="0.25644786301124073" MODIFIED="2009-07-17 07:49:11 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6236969393193128" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="37" WEIGHT="43.71158552925376" Z="0.4906175977226433">
<NAME>Pulsed electrostimulation</NAME>
<DICH_DATA CI_END="19.095419603191672" CI_START="0.17059508712891433" EFFECT_SIZE="1.8048780487804879" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2809292060111717" LOG_CI_START="-0.7680334799886901" LOG_EFFECT_SIZE="0.25644786301124073" MODIFIED="2008-12-08 10:17:47 -0500" MODIFIED_BY="[Empty name]" ORDER="122" O_E="0.0" SE="1.203570824285191" STUDY_ID="STD-Zizic-1995" TOTAL_1="41" TOTAL_2="37" VAR="1.448582729070534" WEIGHT="43.71158552925376"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="7.63943178865648" CI_END="-0.1360306008884564" CI_START="-0.5371924575637603" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_SIZE="-0.3366115292261084" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-07-17 07:49:47 -0400" MODIFIED_BY="[Empty name]" NO="3" NOTES="&lt;p&gt;For Adedoyin 2005, the standard error was inflated and the number of patients in the control group was halfed to avoid duplicate counting of patients when including 2 different comparisons in the overall meta-analysis.&lt;/p&gt;" NOTES_MODIFIED="2009-07-17 07:49:47 -0400" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.5708507199111257" P_Q="0.956673707658906" P_Z="0.0010048028243975465" Q="0.0885858008653484" RANDOM="YES" SCALE="4.13" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="226" TOTAL_2="181" WEIGHT="100.00000000000001" Z="3.289178485371883">
<NAME>Function</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="6.296532363814584" CI_END="0.03259898358726554" CI_START="-0.686964093506018" DF="4" EFFECT_SIZE="-0.3271825549593762" ESTIMABLE="YES" I2="36.47297005908331" ID="CMP-001.03.01" LOG_CI_END="-1.4867959407088542" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-05-06 12:11:32 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.17807073695790443" P_Z="0.07468791640625165" STUDIES="5" TAU2="0.060953242378203404" TOTAL_1="109" TOTAL_2="95" WEIGHT="50.463394297865676" Z="1.7823761238016973">
<NAME>TENS</NAME>
<IV_DATA CI_END="0.8819837930430244" CI_START="-0.8819837930430244" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:53:03 -0400" MODIFIED_BY="[Empty name]" ORDER="90" SE="0.45" STUDY_ID="STD-Adedoyin-2005" TOTAL_1="15" TOTAL_2="7" WEIGHT="5.171994619587554"/>
<IV_DATA CI_END="0.09919027582581469" CI_START="-0.9591902758258146" EFFECT_SIZE="-0.43" ESTIMABLE="YES" ESTIMATE="-0.43" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:53:22 -0400" MODIFIED_BY="[Empty name]" ORDER="91" SE="0.27" STUDY_ID="STD-Bal-2007" TOTAL_1="28" TOTAL_2="28" WEIGHT="14.36665172107654"/>
<IV_DATA CI_END="0.7771884750528174" CI_START="-0.47718847505281736" EFFECT_SIZE="0.15" ESTIMABLE="YES" ESTIMATE="0.15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:58:08 -0400" MODIFIED_BY="[Empty name]" ORDER="92" SE="0.32" STUDY_ID="STD-Cetin-2008" TOTAL_1="20" TOTAL_2="20" WEIGHT="10.227821391274217"/>
<IV_DATA CI_END="0.38638775474361853" CI_START="-0.9463877547436186" EFFECT_SIZE="-0.28" ESTIMABLE="YES" ESTIMATE="-0.28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:52:57 -0400" MODIFIED_BY="[Empty name]" ORDER="93" SE="0.34" STUDY_ID="STD-Law-2004a" TOTAL_1="21" TOTAL_2="15" WEIGHT="9.05993867185536"/>
<IV_DATA CI_END="-0.2920108046379838" CI_START="-1.467989195362016" EFFECT_SIZE="-0.88" ESTIMABLE="YES" ESTIMATE="-0.88" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 12:11:32 -0400" MODIFIED_BY="[Empty name]" ORDER="116" SE="0.3" STUDY_ID="STD-Yurtkuran-1999" TOTAL_1="25" TOTAL_2="25" WEIGHT="11.636987894071998"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.148431271035372" CI_END="0.19991146936746557" CI_START="-0.7457667913225368" DF="2" EFFECT_SIZE="-0.2729276609775356" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-0.6991622887227507" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-07-17 07:48:52 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.563146583914077" P_Z="0.2579239887362167" STUDIES="3" TAU2="0.0" TOTAL_1="40" TOTAL_2="34" WEIGHT="17.9950249943499" Z="1.1313115847887292">
<NAME>Interferential current stimulation</NAME>
<IV_DATA CI_END="0.5219837930430244" CI_START="-1.2419837930430244" EFFECT_SIZE="-0.36" ESTIMABLE="YES" ESTIMATE="-0.36" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:53:13 -0400" MODIFIED_BY="[Empty name]" ORDER="129" SE="0.45" STUDY_ID="STD-Adedoyin-2005" TOTAL_1="16" TOTAL_2="8" WEIGHT="5.171994619587554"/>
<IV_DATA CI_END="0.26318487350682274" CI_START="-1.3831848735068228" EFFECT_SIZE="-0.56" ESTIMABLE="YES" ESTIMATE="-0.56" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:53:51 -0400" MODIFIED_BY="[Empty name]" ORDER="95" SE="0.42" STUDY_ID="STD-Itoh-2008" TOTAL_1="12" TOTAL_2="12" WEIGHT="5.937238721465306"/>
<IV_DATA CI_END="0.8043859539706212" CI_START="-0.7243859539706211" EFFECT_SIZE="0.04" ESTIMABLE="YES" ESTIMATE="0.04" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:52:39 -0400" MODIFIED_BY="[Empty name]" ORDER="97" SE="0.39" STUDY_ID="STD-Quirk-1985" TOTAL_1="12" TOTAL_2="14" WEIGHT="6.88579165329704"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.10588235294117646" CI_END="-0.002028727629780014" CI_START="-0.7163242135466905" DF="1" EFFECT_SIZE="-0.35917647058823526" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-07-17 07:49:19 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7448816526146212" P_Z="0.04871274924864928" STUDIES="2" TAU2="0.0" TOTAL_1="77" TOTAL_2="52" WEIGHT="31.54158070778443" Z="1.9710972848820156">
<NAME>Pulsed electrostimulation</NAME>
<IV_DATA CI_END="0.2587899156712153" CI_START="-0.8387899156712153" EFFECT_SIZE="-0.29" ESTIMABLE="YES" ESTIMATE="-0.29" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:53:30 -0400" MODIFIED_BY="[Empty name]" ORDER="110" SE="0.28" STUDY_ID="STD-Garland-2007" TOTAL_1="39" TOTAL_2="19" WEIGHT="13.358787123296935"/>
<IV_DATA CI_END="0.06039135628961301" CI_START="-0.880391356289613" EFFECT_SIZE="-0.41" ESTIMABLE="YES" ESTIMATE="-0.41" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-06 09:52:45 -0400" MODIFIED_BY="[Empty name]" ORDER="111" SE="0.24" STUDY_ID="STD-Zizic-1995" TOTAL_1="38" TOTAL_2="33" WEIGHT="18.182793584487495"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.16059641843468353" CI_END="1.966878633791739" CI_START="0.530152044571899" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.021148730170818" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.29377756261344057" LOG_CI_START="-0.27559955936363184" LOG_EFFECT_SIZE="0.009089001624904404" METHOD="IV" MODIFIED="2009-07-17 07:49:26 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6886082123318193" P_Q="1.0" P_Z="0.9501056951551042" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="73" WEIGHT="99.99999999999999" Z="0.06257404856163487">
<NAME>Number of patients experiencing any adverse event</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-12-12 03:45:46 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>TENS</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-12 03:45:46 -0500" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="0.0" STUDY_ID="STD-Law-2004a" TOTAL_1="22" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.16059641843468353" CI_END="1.966878633791739" CI_START="0.530152044571899" DF="1" EFFECT_SIZE="1.021148730170818" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.29377756261344057" LOG_CI_START="-0.27559955936363184" LOG_EFFECT_SIZE="0.009089001624904404" MODIFIED="2009-07-17 07:49:26 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6886082123318193" P_Z="0.9501056951551042" STUDIES="2" TAU2="0.0" TOTAL_1="80" TOTAL_2="56" WEIGHT="99.99999999999999" Z="0.06257404856163487">
<NAME>Pulsed electrostimulation</NAME>
<DICH_DATA CI_END="2.559455428158507" CI_START="0.28399226686432405" EFFECT_SIZE="0.8525641025641025" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.4081475708960875" LOG_CI_START="-0.5466934856708392" LOG_EFFECT_SIZE="-0.06927295738737582" MODIFIED="2008-12-08 10:03:10 -0500" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.0" SE="0.5608783631668713" STUDY_ID="STD-Garland-2007" TOTAL_1="39" TOTAL_2="19" VAR="0.31458453826874877" WEIGHT="35.5580434584713"/>
<DICH_DATA CI_END="2.552502629998363" CI_START="0.49852800784806234" EFFECT_SIZE="1.1280487804878048" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.40696619823913904" LOG_CI_START="-0.3023104375285073" LOG_EFFECT_SIZE="0.052327880355315874" MODIFIED="2008-12-08 10:03:38 -0500" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.41663260682588676" STUDY_ID="STD-Zizic-1995" TOTAL_1="41" TOTAL_2="37" VAR="0.17358272907053396" WEIGHT="64.44195654152868"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.3225436971144395" CI_START="0.015173840636129785" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="IV" MODIFIED="2009-07-17 07:49:33 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.48584124712227683" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="112" TOTAL_2="83" WEIGHT="100.0" Z="0.6969385642065118">
<NAME>Number of patients experiencing any serious adverse event</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.3225436971144395" CI_START="0.015173840636129785" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2008-12-12 03:47:50 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.48584124712227683" STUDIES="2" TAU2="0.0" TOTAL_1="32" TOTAL_2="27" WEIGHT="100.0" Z="0.6969385642065118">
<NAME>TENS</NAME>
<DICH_DATA CI_END="7.3225436971144395" CI_START="0.015173840636129785" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2008-12-10 03:53:16 -0500" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Cheing-2003" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-12 03:47:50 -0500" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.0" STUDY_ID="STD-Law-2004a" TOTAL_1="22" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-07-17 07:49:33 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="80" TOTAL_2="56" WEIGHT="0.0" Z="0.0">
<NAME>Pulsed electrostimulation</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-08 10:05:26 -0500" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.0" STUDY_ID="STD-Garland-2007" TOTAL_1="41" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-08 10:05:40 -0500" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.0" STUDY_ID="STD-Zizic-1995" TOTAL_1="39" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-08-12 15:27:38 -0400" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flow-chart-TENS_7AUG2009.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-08-12 14:49:54 -0400" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow chart</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAooAAAGuCAYAAAAXoScxAACAAElEQVR42uydB5gURfr/i2VhWTJL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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-08-12 15:27:38 -0400" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological characteristics and source of funding of included trials. (+) indicates low risk of bias, (?) unclear and (-) a high risk of bias on a specific item. </P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAXkAAAPmCAIAAACOznjVAABABklEQVR42u2dvU4kybZGU7rONTAw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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2009-08-04 09:18:50 -0400" MODIFIED_BY="Jenny Bellorini" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of 16 trials comparing the effects of any type of transcutaneous electrostimulation and control (sham or no intervention) on knee pain. Values on x-axis denote standardised mean differences. The plot is stratified according to type of electrostimulation. <LINK REF="STD-Law-2004" TYPE="STUDY">Law 2004</LINK> reported on knee level, we inflated the standard error with sqrt(number knees)/sqrt(number patients) to correct for clustering of knees within patients. <LINK REF="STD-Adedoyin-2005" TYPE="STUDY">Adedoyin 2005</LINK> and <LINK REF="STD-Cheing-2002" TYPE="STUDY">Cheing 2002</LINK> contributed with two comparisons each. In <LINK REF="STD-Adedoyin-2005" TYPE="STUDY">Adedoyin 2005</LINK>, the standard error was inflated and the number of patients in the control group was halved to avoid duplicate counting of patients when including 2 both comparisons in the overall meta-analysis. Data relating to the 3, 2, 3 and 4 active intervention arms in <LINK REF="STD-Cheing-2003" TYPE="STUDY">Cheing 2003</LINK>, <LINK REF="STD-Grimmer-1992" TYPE="STUDY">Grimmer 1992</LINK>, <LINK REF="STD-Law-2004" TYPE="STUDY">Law 2004</LINK> and <LINK REF="STD-Defrin-2005" TYPE="STUDY">Defrin 2005</LINK>, respectively, were pooled.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA1IAAAJwCAMAAAC066C8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="TENS_funnel_plot_pain.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2009-05-06 10:46:23 -0400" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot for effects on knee pain. <BR/>Numbers on x-axis refer to standardised mean differences (SMDs), on y-axis to standard errors of SMDs.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlIAAAGwCAYAAABiu4tnAABP3UlEQVR42u2dCbxM5f/Hj33fl6QQ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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2009-08-04 09:19:47 -0400" MODIFIED_BY="Jenny Bellorini" NO="5" REF_ID="CMP-001.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of 8 trials comparing patients withdrawn or dropped out because of adverse events between any transcutaneous electrostimulation and control (sham or no intervention). Values on x-axis denote risk ratios. Risk ratios could not be estimated in 5 trials, because no drop-out occurred in either group. The plot is stratified according to type of electrostimulation. Data relating to the 3 and 2 active intervention arms in <LINK REF="STD-Cheing-2003" TYPE="STUDY">Cheing 2003</LINK> and <LINK REF="STD-Grimmer-1992" TYPE="STUDY">Grimmer 1992</LINK>, respectively, were pooled.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAssAAAIQCAMAAABAL9MFAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2009-07-17 07:49:48 -0400" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.03" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of 9 trials comparing the effects of any type of transcutaneous electrostimulation and control (sham or no intervention) on function. Values on x-axis denote standardised mean differences. The plot is stratified according to type of electrostimulation. In <LINK REF="STD-Adedoyin-2005" TYPE="STUDY">Adedoyin 2005</LINK>, the standard error was inflated and the number of patients in the control group was halved to avoid duplicate counting of patients when including both comparisons in the overall meta-analysis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0sAAAHwCAMAAABACATbAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="TENS_funnel_plot_function.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2009-07-17 07:47:32 -0400" MODIFIED_BY="[Empty name]" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot for effects on functioning of the knee.<BR/>Numbers on x-axis refer to standardised mean differences (SMDs), on y-axis to standard errors of SMDs.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlIAAAGwCAYAAABiu4tnAABDCklEQVR42u2dCbhN5f6Al3nKkJkk
yixkSAjV1SBRIWUeqlup3IpSKtxEaaY0USn1D43UzVAqlCbJUMgQMiUphEy3+/2/39rfOr6zztr7
7H0czh7e93nep87ea217OGfvd6/1rW85DgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAHB25eAoAAAAAYuSqq646uWfPnndu3bq1
1//+97/uiInonj17uvft27d7+/bteT4w4T18+PAVfDoBJAhDhgxpNXToULVz506l/4ARE1IdUqpf
v36qQ4cOPB+Y8P7999+/8+kEkCDoiGo1fPhwQgoJKURCCgAIKSSkeD6QkAIAQgqRkEJCCgAIKURC
CpGQAshuemi3WXaKYp1bfOu0IqQQCSkkpABSjY7aPdr3tYO0s7U7tZdEWKeX9m/tZLPOAu0W7TmE
FBJShBQSUgCpwgnaKdp3tMXNZSdqZ2gnaosErCPXf6idYNYXSmu/0T6mzU9IISFFSCEhBZAK/EOr
tBV9l1czlzcLWKeruS6v7/IW5vKqUQZca+2V2lu1A8WaNWs+deutt6o//viDNzAkpBAJKQBCKgxn
aKdrP9PO1X4qlitX7rv+/fuzRQoJKURCCoCQYtceElI8H0hIARBShBQiIYWEFAAQUoiEFCIhBZBd
yIDvA9rqvssbaPdrmwSsI3NMHXSOHOXncYH2L+0phBQSUoQUElIAqcI47U/aeubnhtpN2ocirPOG
drEVYLI1arcTmlPKIaSQkCKkkJACSBXGaA9pV2j/o12t/Vlby1rmASc0k7nH69rD2iVmnQ3aZdpT
CSkkpAgpJKQAUg3ZsjTZsrK/cbTX+y5r7Fun+NHeCUIKCSlEQgoACCkkpAgpJKQAgJBCJKSQkAIA
QgqRkEIkpAAIKURCCpGQAgBCCgkpREIKAAgpREIKCSkAIKQQCSlEQgqAkEIkpBAJKQBCCpGQQiSk
AICQQkIKkZACAEIKkZBCQgoACClEQgqRkAIgpBAJKURCCoCQIqSQkEIkpACAkEJCiucDCSkAIKQQ
CSkkpACAkEIkpBAJKQBCCpGQQiSkAICQQkIKkZACAEIKkZBCQgoACClEQgqRkAIgpBAJKURCCoCQ
QiSkEAkpACCkkJBCJKQAgJBCJKSQkAIAQgqRkEIkpAAIKURCCpGQAiCkCCkkpBAJKQAgpJCQQiSk
AICQQiSkkJACAEIKkZBCJKQACClEQgqRkAIAQgoJKURCCgAIKURCCgkpACCkEAkpREIKgJBCJKQQ
CSkAQgqRkEIkpACAkEJCCpGQAgBCCpGQQkIKAAgpREIKkZACIKQQCSlEQgqAkOINDAkpREIKAAgp
JKQQCSkAIKQQCSkkpACAkEIkpBAJKQBCCpGQQiSkAICQQkIKkZACAEIKCSlCCgkpACCkEAkpJKQI
KQBCCpGQQiSkAAgpREIKkZACAEIKCSlEQgoACClEQgoJKQAgpBAJKURCCoCQQiSkEAkpAEIKkZBC
JKQAgJBCQgqRkAIAQgqRkEJCCgAIKURCCpGQAiCkEAkpREIKAAgpJKQQCSkAIKSQkCKkkJACAEIK
kZBCQgoACClEQgqRkAIgpBAJKURCCgAIKSSkEAkpACCkEAkpJKQAgJBCJKQQCSkAQgqRkEIkpAAI
KURCCpGQAgBCCgkpREIKAI4dQ4YMIaQw4f3zzz9Vnz59CCkkpADg+HLDDTe0GjFihNq9ezdvYJiw
yheBLl26EFJISAHA8aVv376t7r//fvcbPW9gmKj+8ccfqmPHjoQUElIAQEghElJISAEAIYVISCES
UgCEFCIhhUhIAQAhhYQUIiEFAIQUIiGFhBQAEFKIhBQiIQVASCESUoiEFAAhhUhIIRJSAEBIISGF
SEgBACGFSEghIQUAhBQiIYVISAEQUoiEFCIhBUBIEVJISCESUgBASCEhxfOBhBQAEFKIhBQSUgBA
SCESUoiEFAAhhUhIIRJSAEBIISGFSEgBACGFSEghIQUAhBQiIYVISAEQUoiEFCIhBUBIIRJSiIQU
ABBSSEghElIAQEghElJISAEAIYVISCESUgCEFCIhhUhIARBShBQSUoiEFEAicaP2oGXfTJZvpL3P
t04P7amEFBJShBQSUgCphATQPu0b2qu107W7tVdEWEeWXWyW95R1BhFSSEgRUkhIAaQKJ2rf1b6k
LWguk/9O0U7WFgtYp5P2kLa47/ILtH9pTyGkkJAipJCQAkgF/qFV2oq+y6uZy5sFrFNde7M2t+/y
FmadqlEG3HVm92CaZcqUeeO2224jpJCQQiSkAJI2pMLRR/tzwG0FUVM7XjvNtlKlSpPuvvtuQgoJ
KURCCiClQupy7XJtU8ZIISFFSCEhBUBIRR9SXbUrtKcf7Z0hpJCQQiSkAFIppC4zEXVmdtwZQgoJ
KURCCiCRaO6Epi1o6Lv8bO3OgMttrtT+qK2XXXeGkEJCCpGQAkg0xmk3WFuV5Oi7rdqHIqzTQbta
2yQ77wghhYQUIiEFkGg8oP3dxNQC7Ubt9076+aCe0g4x/3++dodZZ0GAFQgpJKQIKSSkAFIJmfvp
GcuTfNffqu1p/r+Jb1m/pQgpJKQIKSSkABKR/NoiiXrnCSkkpBAJKYCcZKj2J0IKkZBCJKQACClE
QgqRkAI4blzhhKYkqE9IIRJSiIQUQGx01P6hXal9PYzNCSlEQgqRkALISDftB5l4DiGFSEghElIA
SQYhhYQUIiEFkNMU1D7mhCbMtB1ESCESUoiEFEBkRjqhEw4/of2X8f+0f0urEFKIhBQiIQUQzC3a
Pdp7tQWsy2WSTpl1fJ/2UkIKkZBCJKQAMhJpHqm8ZktVV0IKkZBCJKQAgkNqk7ZcwHVVCSlMdf/7
3/+qtWvXqttuu001b95ctW7dWo0YMUJt3LiRkEIkpACcc7XbtJ9rK1mXN3BCc0st19YjpDBVXbp0
qWrSpInKlSuXMl8sXC+88EK1Zs0aQgqRkAJwY0om5VylXWTcoN1qtko5hBSmqn369FG5c+dOF1Fi
3rx51Z133qn2799PSCESUgBuTD3us26832lCCjNzz549avny5Vlev0yZMhkiylN2823bti2m29u6
davr4cOHCSkkpACSgD7aqYl65wkpzOQNXT366KPq4osvzvKYpkghdfbZZ8cUUnJ/hg0bprp166Z2
795NSCEhBZAERDpqj5DChPeLL75QZcuWVS+++KI7cDzW9bt27RoYUXny5FEDBgxQ+/bti/q29u7d
q6688krVpk2bdPeFkEJCCiBxuUu7VpufkMJk9NChQ+4uuMsvv9zdzRfr+nPnzlXVq1dPN9hcxkyd
ccYZ6ocffojptnbs2KEuu+wy1bt3b8ZIISEFkCTIEXkbtDO0PcNYhZDCRD/ybsmSJe6utaysv3Ll
SnfL1KmnnqpatGihbrnlFnecU1aibsWKFe79IaSQkAJInl17KhOZRwpTXhnTtHDhQrVhwwZ18OBB
JuREJKQAXGppL2KMFCa7MpZJxktt2bKFmc0RCSmAbN0ixWBzTHoloGrXrq3Gjh2bpUHnXozFOi7K
VmZIf/7559MdsUdIISEFQEgRUpgQUyHIIG8ZJL558+YsjW+SgedZGRvl+cgjj6iSJUu64URIISEF
kBw0ckKngbmCkMJkd8aMGap06dLq008/zZF/X6Y+kCMI/UcPElJISAEkLoO0h7V/aX8LY0dCCpNl
nJQMFs/qaV1kl6BskfLvmotW/fuqRo8enWGwOiGFhBRA4nKW9tZMrElIIf5P7dy5Uw0fPlx98803
WZ7TKijiCCkkpAASn3Laxsai2lLa4uzaw2T0559/dgeNS9jEukVKJtU8cOAAR+0hElIAaZTUznGO
zBt1vjSK9g0njueQIqQwqw4dOlQ1adIkpkHnv/zyi7tFKquTekq4vfbaa4GD1QkpJKQAEpfS2g+0
D2lbWSFVQjtJO1NbjJDCZHL+/PmqePHiatKkSRGXO3z4sPrwww9Vu3bt3FnNq1Wrpq644go1ZcqU
mLdKybn+5IjB7777jpBCQgogibCnPyhvhZSQ12Fmc0xCJVwkiHr06BFxTimZ7qBYsWIZZvuXIFq3
bl1M/6b8njZs2FCtXr2akEJCCoCQIqQwseeU+umnn9SaNWvC7qqTuJETHTsBp02SExjfddddMf2b
d955p7rgggvUr7/+SkghIQWQZCG1w+zW84fUZYQUpqrff/+9qlu3bthzUJ511lkxTaMgA9zlaD/Z
XUhIISEFkDycov1O+7S2tvmQ6KTtYgJrurYMIYXJqBy1t379erV3794M1y1fvlzVq1cvbEg1b948
5qP+OGoPCSmA5ERC6auAD4uZ8X7HCSk8GmXgd4kSJdT06dMzXCe/U127dg0bUvfdd1+65SMNPpfg
kl16/hnNCSkkpACSh6rai32WJaQwmZUTGcvA8Ztuuinw+oULF6qiRYu6Y6K8gMqdO7dq1KiRewJi
2U0np5vp2bOnO/6pf//+aunSpRnGXcl4rO7du7vTHxBSSEgBACGFSaFsRbr99tvV6aefHrh7T/zy
yy/Vtddeq1q2bKlatWrlDjKXwJJpEUaNGqUKFy6cbkuVnJT47bffTnc0oIRU06ZN1YMPPkhIISEF
AIQUJo9LlixRs2bNijhwXK7buHGj2rRpkxtI27Ztc7dEValSJXC3X4sWLdJNjyDn95PLhgwZQkgh
IQUAhBTiK6+8Enb8VKFChdzQ8pbdtWuXGjZsmHr55ZcJKSSkAICQwtRWBo3L1qVwIZU3b141Z84c
jtpDQgogSZGTEV8Qg+UJKUxmZeuRjJNatGhR1IPUZYJNGQ8VFFIyg/mqVasIKSSkAJKUpuG+SYeR
CTkxqZU5owoUKKCmTp0a01apgQMHqvz586f7eylYsKAaN26cOnjwYNqyO3bscHcFyoSchBQSUgCJ
Tz5tOWNj7QrtYOsyzzHaz7WVCClMZn/77Td15plnqnvvvTemI/62bt2qnn76adWsWTNVv3591aZN
G/eIPf+cUjJVgizz6KOPElJISAEkGfa59vxwrj2Ma+UIuh9//FFNmzZNzZ8/X/31119Zuh05Km/G
jBnqq6++inqdefPmuUf8yX2QqRNkd1+4f19mT5eQChdqhBQSUgCEFCGFx1WZKfyOO+5QlStXVsWL
F1elSpVSF154ofriiy+O24DzaE8RI9MlSCiNGDGCkEJCCiDJaGV27V0UcF1P7ffauoQUxtuWqMGD
BweO6ZNB4xImWb3dY/G7JOOlZOuV7OIjpJCQAkg+WpiY+sHncu3J8XzHCanUVIKkWrVqgSGVJ08e
NXny5Jhvc/fu3apbt27qgQceyHCKlyD37dunPvroI/Xzzz8f9eMhpJCQAkiOLVMP+qwd73eakEpN
ZY6msmXLBoaUnAtPTuMS623Kbjo5SXG/fv3cqMps+e3bt6tnn33WPf1LtFulZHdkUKQRUkhIASQu
12jfSdQ7T0il7mldTj755LBbpMaMGZOl25XZx88555x0p3fJLkeOHKl69OgRuNvRC6lLL72U1xcJ
KYAEI9Jgc0IK41I5yq5Lly6BIVWhQgW1Zs2aLN3u+++/726VijakZEyVTJ0QzbJyxF7jxo0Db9sL
qe7du/P6IiEFkGDcoV2rLURIYSK5dOlS1ahRo7QJMWVLlESUTIZ5NEfiydxQhw8fjiqiZMqFaGdD
l/mm6tSpoxYvXhw2pK655hpeWySkABKMM7QbtbPNbr4gTyWkMB6VcUoSKFdffbW655573KiJZqB4
Tvjtt9+6p5VZvXo1IYWEFEAScbf2QCZeSUhhKihbouS8exI9saxztPFGSCEhBQCEFCa8crTeGWec
oW688caolpcZy+X3L2grk3ckoJxnT3YDElJISAGkJs21ZxNSmArKGKmLLrpIderUKarl5bQwMpO6
rOcfPzV79mx34Lqcf693797uKWhmzZrlhpfMQRVrSMkAexlEH+1s6oiEFMDxQ3bdHQ6jjJ9qRUhh
qhwNeN1116lLLrnkqGYxf/DBB1WRIkUyzG8lg+NLly6dYQqESCEl48Dk1DJyezKgvkSJEurWW291
56TiNUNCCiDnuVQrv/QztWu0H0ufaF8wHwBT2bWHqXTqGTmq7vPPP496HTlRsZw4WQJKfpatRuXK
lQucmkHMmzeve2RgNCElW59kEH2hQoUyRJkMXD9w4ACvGxJSADmMzCO1XltQ+6x2urakNp92tHau
thwhhRjsl19+qVatWpX280svvRQ2osQWLVq4JzGOJqRk1vSCBQsG3s5JJ52kPvnkE14DJKQA4iCk
vAk5y5s36fPNz3nNz10JKcTolHmsIoXU448/nuEov3AhNW3atLC3ky9fPjVhwgSecySkAHKYftrV
2lOskLrJXFeXkMJUUybZ7Ny5s9q0aVO0HxruYHNvEs+vv/46w/goTxkf9Z///Cfqo/bmzp0bNqRO
OOEENWXKFF4zJKQA4oDF2m+0dZzQefcOah82Y6aWaGsRUpgqTpw4URUtWjTD7rdwypgoGa/kjXuS
MVPXX3+9u8XIHz8ykF0CbfLkye75AjMLKTn9TNWqVQNDqnbt2mr58uW8ZkhIAcQBTUwwNdAW104y
P38Xz+OjCCk8FoPNH3roIVW8ePFM536yB5tv3Lgx3bQEMneU3E716tXdsUxyapi77rpL/f777+7U
BzVr1lRDhw5NWydcSMl9ePXVV1WVKlXSAipXrlyqbNmy6pVXXonqVDaIhBQAEFJ4vD4A1GeffabG
jh2bLbclW6lkV59s3bLHRcn8UmeffbYbVplNfyCxJEcR3nDDDapDhw7q5ptvVnPmzIk69BAJKYDs
53TtshhsS0ghhg+mlStXqhUrVkS9zuuvv+5uqVq3bl3UE3LKli/Z0iX/5XlHQgogZzlZ+5Dlr2aM
1EM+ZYzUSrPLj5BCDDMBp0xDEMsEmbKFaubMmWm/t5wiBgkpgMTlaufIUXt+ZPD5Du0FhBSmyhgp
2bUnJy6Odb2j+XcJKSSkABIXex4pP8wjhSml7DaT8UutW7eOaT2ZYVx20/nPuZdZfK1du1bt2rWL
kEJCCiCBGaxd64RmNvdTTHtI25mQwlRQfo8konr06BHTel999ZUaOHCgO04q2pMKL1u2TJ133nnq
zTffdAedE1JISAEkLo9pZzmhyTltF2n7x/MdJ6QwO927d6+69tprYzpqT6Y+kKkO2rdvr1q2bOnO
KSXn3stsd59sxZIj99q1a+eeCoaQQkIKIHEprJ1gtj7Z3hfvd5yQwuw+Ak+OjJNdbdEsv3PnTtWp
UyeVP3/+dCcUlq1a0UyWOX78eFWiRAk1Y8YMQgoJKQAgpDC1BqY/+uijqkCBAoEzj3fr1i3T25CZ
yyWitmzZQkghIQUAhBSm1niqXr16hT0XXqVKlThqDwkpgBShixM6v144rySkMBXcvn27atCggZo9
e3ZUu/WuuuqqsCElp3GJ5t/cv3+/e3Lic889l5BCQgogAemglV96GWx+dRhPJaQwFVywYIE64YQT
1EcffZTpsnLqFjlfXp48eQJDqm3btlH9m7/88otq0qSJKly4MCGFhBRAAiLzSK3XFmLXHqa6jz/+
uHuC4R9++CGq5Tds2KCaNWvmnkjYsU4qLCcrlvPjRTvA/cYbb3TX7devH68DElIACRhSPzFGCvF/
avHixWrKlCnubrto15GTEssknmXKlFHFihVz54aSLVoyvUG0tzFv3jxVqFAhd1chrwMSUgCJRVHt
m9pntCcQUsiHwN8xLy8zmssuOjn6To7Ei/U25Dx9bdq0YYsUElIACUgb7XNmt8Sr2tEBctJixEyU
kxfL7jyZjDPWdTlqDwkpgMTleu33mXgxIYXJ7tatW9XEiRPV+vXrs7wlS3YJyvn6shpSPXv2dHcv
xrJrEZGQAgBCCnPc9957T1WuXDmqqQ+yWy+kzjnnHFWhQgU36HhNkJACSBzyOaEpDoLspW1LSGGy
z1IuR+zJgHEZ65TV29m8ebOaNm1azGOkvJDq3LmzuuSSS9zpEGTcFa8NElIAicGtTphJBbU/as8g
pDCZPXTokHrppZdU7969j2qQ+vz589WECRPc8VJZCamrr75avfXWW6pq1ao5smUMkZACiJ1+2t3a
57XLtG9rW2jv0R7QTmXXHqaCMrZJjrjLiX/bHmy+e/dud9D677//zuuChBRAAmDPIzVMO09byfx8
o/ZbbTVCCjE6Zf6oWH8fOWoPCSmA5Aip8mZ33vnm57zm566EFCaze/fudSfFlP8e7RQIL7zwgtq0
adNRh5TMSTVz5kxeHySkAOKcy8w4qCZWSI00151PSGEqOGfOHPcce9Ge1iXSoPUdO3Yc9TxSMmZr
5MiRqmLFimrjxo28RkhIAcQ5i7RrnNDEm89qD2mnaX/RzteeREhhMjtixAjVoEEDtWbNmhwfI+Vd
9tlnn7mDzkeNGsVrhIQUQJxTzgmdJqamtbtPfp4S73eckMLsmPrg4osvVr169cqWKQd++ukn9cYb
b8Q0WDwopOR+ycmMr7vuuixt5UIkpACODx21Y8Jcl0f7urY5IYXJHFKya09268U6/1OQy5Ytc8c2
xfI7GW6wucyyLrv25D7yWiEhBRA/lNC2M75qduG1C7ADY6QQc2bXHiIhBRC/lNHOcMJPwmm70AnN
cE5IIcZwFOD+/fuzLaTWrl2rPvnkE55bJKQA4ojC2pLaB7Trzf8HeQJjpDCZlekK5Bx32TUBpgTU
a6+9FtPRdpFCSualuuGGG9RZZ52lVq9ezWuGhBRAnNFU2ydR7zwhhUcbPQMGDHCP2Dt8+HDc7tr7
8ssvVeHChdWYMWOyZRwXIiEFkD1cot2orWt+lpMXDzWXif0JKUxm5ZQwcpJgiansvF2ZmDOWI+0y
CymZV0ruo5zHj4HnSEgBxAcXaVdohzih6Q+EQdovzWXiD9puhBQmq/v27VPTpk1TCxcuzLbblC1b
kydPVkOHDs3WweaxnggZkZACOHbU18ov+gzrslLaxdqnrcvGaf80W64IKcToPkTUhg0b3KkLjsVR
e3L77N5DQgog58dFyRF5NazLZGvUHic05YEH59pDjKPpD+T8ey+++KL6+eefed6QkAKIw5D6xbcc
IYVJ7Q8//OCeikWOjMvuST537doV9UmQ7ZCSrU3hduPJKWzKlCmjxo0bx1gpJKQA4iikimunE1KY
ag4ePFg1a9Ys208MLAH10UcfRb17zwuptm3bqrFjx7r3a/z48e7pZvzLtmvXTjVu3Fjt3r2b1xAJ
KYAcoqgTmtH8HW1Z7ZkmmK6xlimofUL7sROawJOQwqQ7NUzr1q1V7969s/33R7YqxbLFSI7wk6MH
CxUqpPLmzetOhlugQAHVpEkTd+oDe0zUW2+95U7XsG7dOl5HJKQAcpDLtW+YgNqtfU57mrmuvfZl
7d/af8bzgyCkMKvu3LlTde3aVT333HPHbNC5bDWKZmD40qVLVbly5QLPLiBbzGRmc/vovVhmTUck
pACOHTJr+YXaVr7L3zdeEGHd3Noilrlj/LcLaAsRUpiTW6Rk8LbMJXUsbv+ZZ55Ro0aNcqdYyGxZ
mQndCXOapvz586vp06cH3n+JKo7gQ0IKIDG50/eGPyCGdSto52gXEFKYrMYyhumBBx6IeM7LSZMm
ZVhn7ty57ha1bdu28XwjIQWQYMjuvv1m919H7RQnNHVC7yjX/9B8QBBSmCP+9ddf6vPPP49prqdj
qWxxChdRxYoVcweu+9eRkxiXLl1aTZ06ldcUCSmABEIGnstEnk/4Ln9e+64TOtFxJJpoN2h/IqQw
p5Sj4erUqaOGDx9+THcdLlq0SG3atCnTZeWoQRlA7o+oPHnyqJtvvjlw65ZMr9C9e3d3wLz8P68r
ElIAicE/zJt8Rd/l1czlzSKs28gE1EfaZ2IMqZO0d2vHGCdqXylRosSscB80iOH87rvvVJEiRQLH
HmVnSMm/s3379qimP7j88svdOaJkTJT8LRUtWlTddNNN7jiucOt98MEH6sknn+T3HwkpgBQJqeHa
ZdoTsxBSlbUPSTwZ79X+q2rVqmPvuecetkhhTL755puqfPnyatWqVXE1s3nfvn3dwe/Lli1zf6fl
ZMWZxRoTcyIhBZA6IXVY28f8f6whxa49zDYloN577724+b2J5Vx7kW6D1xYJKYDkDCkZVyUzp890
QhN9ElKYEtMryLQGgwYNOuYh9f7776uzzjpLffPNNzz3SEgBJGFIdTXXyfioJ4xLtVvM/5ckpDAZ
lRnLoznf3tGGlEzYWatWLdW/f3/+FpCQAohz5HQy27UtfZfLxJ5yrr56AevIdd/6lNvYY/6/IiGF
x0vZetOvX7/A89jJ5Jk5McFlduzae+KJJ1TFihXVwoULeZ2RkAKIc8ZpNztHZkSXrVS/OqHB4NHC
rj3MiTd4dd9996m6deuqzZs3pxszNXr0aPXPf/7TvX7BggXZNimnzAGV2VF12RFSv/76q3rqqacC
AxGRkAKIL4Zq15t4WqH9zURRWWsZmZ5gJCGF8TbbeI8ePdT555+fdsTbzJkzVb169dJOFixzN8mW
nRdffFEdOHDgqP49+b2UOaIyO/ouO0Iq1hMlIxJSADnLydpRluV911+j7RRh/Uu11xNSeDyVXXcy
E7g3f5ScXqVFixaBM4pXqlRJzZs3L2F27dmTjc6ZM8edvZ3XHAkpACCk8Jj57bffuluggkIqV65c
asSIEdmyOzGz38/sDKkxY8aoxo0bq9WrV/MaIyEFAIQUHjtnzZoV8WTB0UxdkJk7d+5US5YsiTiI
PTtDSmZCf/vtt6M6WhCRkAIgpAgpzLI//vijKlmyZGBE5cuXT02cOPGo/439+/dneiRgdoYUIiEF
AIQUHhdlHNGwYcNUwYIFM+zW69y5c8Tz3MXrGClEQgoACCk8bspJhYcPH+6eMLhAgQKqePHiqnfv
3mrdunUJNY8UIiEFAIQU5pgHDx5U69evd4/sS8QJOREJKQAgpDAlJaSQkAIAQgqRkEIkpAAIKURC
CpGQAiCkEAkpREIKAAgpJKQQCSkAIKQQCSkkpACAkEIkpBAJKQBCCpGQQiSkAAgp3sCQkEIkpACA
kEJCCpGQAgBCCpGQQkIKAAgpREIKkZACIKQQCSlEQgoACCkkpBAJKQAgpJCQIqSQkAIAQgqRkEJC
ipACIKQQCSlEQgqAkEIkpBAJKQAI4qqrrmo1cuRItWfPHt7AMGHdsWOHat++PSGFhBQAHF9at27d
6sEHH1R//fUXb2CYsG7btk2de+65hBQSUgBASCESUkhIAQAhhUhIIRJSAIQUIiGFSEgBACGFhBQi
IQUAhBQiIYWEFAAQUoiEFCIhBUBIIRJSiIQUACGFSEghElIAQEghIYVISAEAIYVISCEhBQCEFCIh
hUhIARBSiIQUIiEFQEgRUkhIIRJSAEBIISHF84GEFAAQUoiEFBJSAEBIIRJSiIQUACGFSEghElIA
QEghIYVISAEAIYVISCEhBQCEFCIhhUhIARBSiIQUIiEFQEghElJJ7+HDh1X16tUjun79+hy9j3v2
7FEPP/yw+vXXX7N8G2+++aZ6+eWXs/V+zZ49W40ZM4aQAiCkCCkkpFLVQ4cOKf02oDp16qSGDRsW
6I4dO3L0Ps6fP1899thjR3UbpUqVyvbokciU54eQAiCkCCkkpFI8pF5//fWolv/jjz/U2rVrXWVL
kfx379696ZaRLUf+ZQ4ePBh4G+vWrUu37i+//OIqr6e3zKeffqoqVqyotmzZEngb4vbt2wPvr9w3
ub5EiRJq6NChatOmTWnX/f7772nrB2118+67p/fv79+/3/25SpUqasCAAernn392L5fbDnc/CCkA
QgqRkErxkJJ4ueSSS9zlxd69e7v/ff/999OWWbNmjWrSpEmGZSQ8vHhp165d2vWFCxdWs2bNSlu/
c+fO6vTTT1eNGzdOW+arr75SgwYNcteVZWQLWdu2bdOuF5s1a5YhysQZM2akW07um1wuwXPRRRel
XV60aFH14Ycf2iGjevXqlW7d0047TS1atEh9+eWXGS6XdeQ+3HjjjYQUACGFSEilWkg9++yzauvW
rRmUrTKy3J9//qk6duyoevTooRYsWODapk2bdCEloVW3bl11zz33pC0jkeGFlNyG7EIsX768O15J
rpeIkl1kH3zwQVpIFShQQI0aNSrtNuytWeLll1+uihQpoiZNmpS2zPDhw9XFF18cGH9yffHixdUt
t9yilixZonbv3q0uvfRS9368+uqr7vXy79eoUcMd9yTr3XHHHapgwYLqoYceSvs3nnvuOdW8eXN3
65X8fPLJJ6t+/fqpb7/91l1n6dKlacFISAEQUoiEVAqFVDglJGQ5CRWJkXfeeSddpNgh1aVLF3d3
1xdffJG2zOeff54WUrJrTWLFfx/Gjx/vRosXUhJKke5z7dq13S1SsQw+t8dI3XXXXW7w+Zd55pln
3C1T8v8SWg0bNlSrV69mjBQAEFJISGHkkLr77rvdXVt+vbFDElLVqlXLsLXHH1IdOnRIt4w/pGRX
3vnnn59OCaNYQuqNN95wt1o1bdrUXV+2cslWJnks0YaUbNHy349atWqlhZTswitUqJC7m9G7XsZI
HThwgJACAEIKCSmMbYxUdoVUsWLF3HFTfq+99tqoQ0qcPn26u96ZZ56ZtvXszjvvjDqkZPB50P24
/vrr09b5+uuv3cu8XZhiz5490wbXE1IAQEghIUVIxRRS//3vfyOGVPv27d2B2pF27dm34Q3slvms
og0pWd+7DRncPm3aNNW/f393K1Msu/bs++m/H/a/IUcRyr9x//33u4/FO/KPkAIAQgoJKUIqqpCa
OnWqO0ZKxg799ttv7mUyQNsOKZnrKVeuXO6Ra94A8UceeSQtpKZMmeJukZJQ8uamkl1lshXovPPO
i2mMlOzO847ik+kIrrvuuqhD6rXXXnN34cm/JTEol8n7n2wVu/DCC9PGSMlReN7UBuLIkSMJKQAg
pJCQwowh1aJFC9WtW7dAZYuMLPvSSy+5y15wwQXu5eXKlcsw/YEc7SaXXXHFFe4yMvbJsaY/eOGF
F9yfJVjkegki+dk+ai+zkJLB6bKOTF9g34YcLRgppBo1apS2jBylKOvIoHW5DTkiUX72pkCQuav8
z0v+/PlVnz591L59+9JCSsZQydGA8rNscZPniJACIKQQCakUOkWMzOsUyc2bN6ft+po8eXLa5R99
9FGGkJLdYXI6F2+Zd999N11IyW3I1i/v+iuvvNJ97/F2o8m0ByNGjMgsMtxpC+z7+MQTT2TYZWgr
g8dlOS965DZk+gRvfQkl+36IH3/8cbp/Y/DgwWm7/sRVq1a5l3u/c7fddpt6+umnCSkAQgqRkMKM
g7uHDBkScbC5bOV58sknww4253kkpAAIKURCKiWdOHGiO77p6quvdnd7ifq9Q3Xv3j1tPJQMSJfd
XzJuyFumcuXK6r777ou4tQgJKQBCCpGQSnplsLZjTdZ50003pTutiiiDvu1l5Eg3b+ZvJKQACClE
QiqlB6Zv3LgxTTlazr+MDMS2l7HHFCEhBUBIIRJSiIQUABBSSEghElIAQEghElJJp8wkLtMgiC+/
/HKmy8s4LG95W//592Scl3edDIYnpACAkEIkpJJKmQG9ZMmS6pRTTlFVqlRxjxYcO3Zs2JMSyzgs
mX9KJgiV5W299zUJrYYNG6pTTz017To5SbGc0oaQAgBCCgkpQippzJ07tzvjuJw+Rn6WKRf0W5Va
v3594PLbt293r585c2bY2xw0aJD7++GdEkacPXu2G1Nz584lpACAkEJCipDKWeUUKbfeequ69957
VcuWLV1//PFHtXfvXvf6PXv2uK9TkF40ySlcZH4qucy73V27dqmrrrpK9ejRI2JIzZgxI+32du7c
mW6ZmjVrqueffz7DurKVauDAgYQUABBSSEgRUjlrly5d3KCR10FORCwWLlzYPXGxF1qONceUbWbn
2pPTr8i58iKFlPx73u1JIMkpXDK7z4QUABBSiIRU3IRUs2bN0s7NJ8pYpBo1aqgtW7ao1atXq1mz
ZgUqMZTVkBowYIDKly+fGj16dNrt/fvf/3YjSbZmBa0jM63LCYbr1aunVq5cSUgBACGFhBQhlfMh
1aFDh6M6115WQkpmT3/xxRczXC67AmWsVdA648aNcyMq3LgrQgoACCkkpDCuQur11193IylI7zQy
WQmpcIYLqUmTJqk6deqo5cuXM/0BABBSiIRUYoTU5MmTVadOnQJdtGhRlkNKjrrz1s8spJ588klV
t27ddLsfCSkAIKSQkCKk4jKkvAHo0e7amzdvnqpcubKaP39+2mUyhkmmKXjllVcC12nVqpV7suSg
kLKnRJD1Tz/9dPX9998zszkAEFKIhFT8hVSePHnU4MGD3akIOnbsqE488UR3l54Og5jmkcqfP796
99133dspW7asG1LelAgyjYJc7g0k//XXX1WDBg3UAw884F4uDh8+3B1s7k2rIFui8ubNqyZMmJC2
jCeDzQGAkEJCipCKi5CqX7++at68edo0BDIeKdbbGT9+vHv0n3cb1apVU0uXLk27fsWKFe7lCxcu
TLtMxjvJLjvHmv5AjhL0ri9VqlTYqReY/gAACCkkpAipuNm19+eff7rTGYgyzUBWbmv37t1pt+Gf
XFNOCSOX+08ZI1uovHX80x7s2LEj7Tq/soWLkAIAQgoJKUIq7sZIISEFQEghElJISBFSAEBIISGF
x863335bTZ06leeCkAIgpBAJKURCCgAIKSSkEAkpACCkEAkpJKQAgJBCJKQQCSkAQgqRkEIkpAAI
KUIKCSlEQgoACCkkpAgpJKQAgJBCJKSQkAIAQgqRkEIkpAAIKURCCpGQAgBCCgkpREIKAAgpREIK
CSkAIKQQCSlEQgqAkEIkpBAJKQBCCpGQQiSkAICQQkIKkZACAEIKkZBCQgoACClEQgqRkAIgpBAJ
KURCCiBnyK+tZJkvyvVKWuuUJaQQCSkkpABSkRFaZXlXFOvcrP3aWmedtiEhhYQUIYWEFEAqcYt2
n/YJ7bnaZ7V7tNdHWGe49qD232YdcaN2rbYCIYWEFCGFhBRAKlBR+4l2pO/yx7UzI+yue0M73XfZ
adoXtKUJKSSkCCkkpABSgX+Y3XIVfZdXM5c3C+od7VZtUzOWqoAxVwz/bk3teO27toUKFZp/++23
q3379vEGhoQUIiEFkJQh1dVcd4p2njVG6gZtrSj/3eLay7T9bMuXL//AyJEj2SKFhBQiIQWQ9CG1
QDtO28W4SzvoaO4Mu/aQkEIkpABSJaSG+nbntdT+ra1KSCEhRUghIQVASEUOqby+y1uYywkpJKQI
KSSkAFKCM7SbtG19l3fSbtDWDljnPO02bSNCCpGQQkIKINUZZ8LoAvPzJdod2ocirCPTH6z3bbF6
Wfu2thghhYQUIYWEFECqIAPEl2n/1P7ihCbjlDmkilrLvOWE5pbyKKH9wQkNMP/F+Iq2yNHcEUIK
CSlEQgogEZHZyG+3LOO7/krtRQHjqOx1Ch/tnSCkkJBCJKQAIIu0aNGi1cCBA9XXX3+tFi9ejJiQ
fvzxx6pJkyaqY8eOPB/H2BUrVqg1a9YcE+W2V69efcxuP6ddtWqVWrlyZTTL/eGEJl0GgHinTp06
lUuXLi3n8cvMldrno1guUX1d+5X2viR+jFvM7uBkfXxy6qVnk/jxyRhKObfmwzl5P0466aR3a9Wq
9fWxsFSpUr9XqVJl/bG6/Zy2cuXKK8uUKbO7Ro0a30ZarmbNmrOdozj1FwDEJ9O0Zybx45NZ3192
QqfgSVa+1Z6fxI9vmBOaXiRZkd3/8gFbLofvx4lOaPqWY+F72sHH8PZzWplIeZETOiNFpOXKOQBA
SCUYl2o/dJJ7c3qyh5RMWNs/yUPqcyd0qqhkZar2uiR+fOdol2tL8pECkHpMN9+mCKnE5TvtFYRU
QofUUid4rrlk4TUntGWRkAKApAyp3kkeUvO1BZP4MS52QrPkJ3NI3ZnkIfW9tk4SP8ZJ2lFJ/Pha
a1dpS/GRApB6yK69nkn8+GRS1CXaQkn8GGWL1FVJ/Pju1T6RxI9PBh+vdjKe4SCZkIMh7k/ix3e2
dp2TcbobAEgBrndCAySTlbraAU7G8xkmEzIRbDJvzZDTLl2UxI/vBCe0xa1CEj/GXk5o91eyUsW8
hkUcAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAASH5aOKHTa5wVwzrnmHXESnH++E6x7murKNepbq1z
VoK8jrnM/S0bxbKFrccnnhiHj6e87z7mjmKdytbyrRPob7Cl9uQolsvje07i/XQi1az72izKdepY
68T7dA+FrPtaI8p1ivtew5w6iq+V734U9l3f2FwebgLRWgHv/818t5mIf4sAMXGa9intn1ql/cP8
nNkbeh/tYbOOOD9OP4iFu7VfWPd1v3mMdTN5XhZb68jz0iEBXs985v5GM1/UQ9bjE/8vzh6LzDL/
ke8+3pzJOjLX0ufW8gedxJn/bLv21iiWu9X3nMx24vcckTK55nfWfd1p/vYineamvvZHa52t2vPi
9PFd7IQmEfXu6zLtI1Gs95LvNRx7nO93HfM67Pfdj0d9y3l/S28E3Ia8fy431w+wLl/tu81E/FsE
iIlrtBu0DZzQyTKbajeaN79wtNP+pX3OrHOB9hftrDh8fPJN6QcnNHeLd0JQ+db4UyYfWivN83KG
Wec/JjYbxOnrKFspZKvZ9ChD6nbzeLzn5VrzIfdoHD2mydrftB3NfXzY/N51j7DOx+aD9x9mnRe1
+8zvaLwi57CcqP07ipDqaR7PaPP4Opvn6LU4fFxVzd/QDdbfXhPz/hLpA1Uez1rtqWYd+RK0y4m/
rd6y9WaCEzq1lPf4rjF/R49HWO8B83j6m3UGmr/Fu4/jff+XE5oY1D558h1O6HycY5wjW8i8kNoT
5nNAhQmpx52MJ2L2/hZv4mMXko2bzZubfwvOhjDLy66jd82HnD15ZRsTH+fG2eO7zwmdksHPtebb
WBAdzTct+3kpZUJxbBy/jsr6dhwppGRCxwVO6JQqNlc7oXO5xcPEq83MVolLfJeP1850Mu6CEM4P
+B3Mb75NvxGnr5u8Toe0b2v3ZhJSRczWp2d9l7c3z1XTOHtsz5jfMz93aTdFCMXvnfRbiyWgZIv3
vXH2+GR28sFOxt3oH5stTkFUM19S/eeElNv5yolu1252IEHzz4DL65j3j0ZWSH1pvoxeGfBF503z
5cYfUvcF3HYB83d4iI9dSHYKmFiYHyGk5A+tR8B1G82bZDwhAXRKjCElH1SfBVwugflznL5uE8w3
yRJRhFQDs0w93+UnmsvbxcHjuSGTb8FBYzbkZLc/BVze1wntho5HRpn4lTEzme3aK2Me+4UB1/1l
fqfjibJO8FakSCH1lvmi5ke2cCxKgPdPeb+RLWgjwlzfxryG5X2XVzeXH68Yli8c/3ZCW/0c3xeP
6s6Rk7d/bt4PZavbK75l5f1TtsD9EWVICcW0c+L4CynAUVHBfBA9ZSKiYpKEVBAyOHR6wBtDIoeU
RzRjpAip+CTZQipcaMi4t8eSLKRamN8/GQIwPsJy8RJSbc2/t8Hcb7FlwHJeSMnvlpyLtKa5vJN2
hRPachVLSAnvaafykQvJyOnmQ+gn823lvCQNKfnmL4OqnzffjggpQoqQOj6UNKEhg7ELJ1lI/dN6
//zaCX9S4ngJqaLmfWCxuc+bndDYwvd9f1teSJ1g7t9l5vLXtR+Y/yekICWQsUy3+7wik29N4WIq
XkOqbcBjLB7w5iFv0i9lclvxGFIVAh7fOYQUIZUgISW7+WRL1MOZLJfou/YEGcj9jRM68jdeQ8pP
JRO4L5nXqRwhBZCegk7oqDrbKdYbXNAcJnL0xhMJFFJjAh6jPTZKHqMc2SRHjhRLwJBqFPD4hhFS
hFQChFRR86Er7yeFkyik8pogyuu7vLh5ndrHaUgNc8IfVRg02FzeD+WoYBn3tcJ8wf7NOXIEcywh
JcMq5ICJ5/lYhmRiu3nzKhpDSMnRaxN9byCyf/3HMG/yOU0J8+Y8IcrluzmhI4ca+CJjegK8AUQT
UvLtc6ETOtzZ/7jljbJuHDwOmShwjfngsXlS+2mY+JfIki2pLazLZPCsDOZ+PwlCSrYKzA34EJSj
FWW6gLPj8DFJMMjg4gejXF52kcnuJntiS9kaK0fCjYqzx1bP/K3dGUNI1TTvLX19l0uIyNF8VY7D
/ZZ/e6mJpmhDSujthKbouMIsUzALISX/NkftQdIh3/wPmg/PYsZ+5g+thvXhbIdWZ+fI5G2yvByq
Lluj5sXh45OjT+Qw3XdMQBSzLOr71mxPavirE5o24TSz7FTzPDVM0JAq6IsPeaOTQ6BvNI+vq/Z3
7bg4eizyzXWrCYVi5pu0vAZ9fHGR3/pZPoQ3OKG5mWSdseaN++IEDakC5jF6XK/9rxOaCqCY+eIi
WyffjsPHI79zcrTXy05oV5H9t3eC9cWsmO9LmXxYy+H2Zc11ElFyhNjJcfb45DGMN8FvP7ax5otb
aWsrTCFrvaed0DxSPc3yEo+7nci7w7KbHeZL00nW/e5vwulF673RDilv2pSlJmpzRwip0b7nRJQD
DJYEhCdAUiBbIvY46WfnreJ7895r/dzEvDn+11pHBliWjMPHdp8TPMuuN8O5/ebd27flY7m17C4T
kPFOuJCSN+8vrJ87mri0n494+zCWcWCf+e7j7b5lNvnemGX3w0JreYmoaxPk7zAopO5x0s/pJrtV
XvM9J/N8MRkvPBPhb8+b/qCk+dkOXdnavdZaVr7UXBTHr9sTvsfm3zUpX8Les37u5YR2ddrrHO8t
3fXMe/gB3/3wf5GyQ0qYZpbrZl0WFFLhZjZPlL9FgCwhMz9faqztu06i6pKAddpb65wap4+rlnUf
/dqb3i8N+MZ7urXsPxLkdcxt7u9JvsvltBv+cwwW8T0fpePw8Zzsu4/+c+3JFpnqvsuqWcu3S6C/
wbYBf0c1nIyzsufxPSfxep7L+hH+9rwhAPnNz/5JLRtZy7aM89cts78j+eLpP1dnSd86xXLwd86+
Hyf4rm9pXkePpgHvLxf7fm/bhHnNE+lvEQAAAAAAAAAAAADCIpuW24WxOk/PcaOKEz8n9m0U4/Ky
+7ZVnD2fRSL8Xovl+ZXLMrL7qeZR3kZR8zoU4+kEgETHP9jR9t88PccNGSz6RxzcD4m5ZTGuI0cI
fR9nz2fNCL/XYmd+5bKMHAhytFMh1DWvQ0OeTgBIhpCSD/GSARbi6TluyKHqJ8bB/bjNCR2llSwh
1SbM73Z+fuWyzApCCgAgfUhdHcVy3vwsnvakkXL48VkB68i8Q22tnwdZ63f1LSszo/tnFZYpArxJ
K4c4oaP8bjfrP2Auz++7X2Oj+JAs6Vve202R27rMP1uyHNYv8ynJ/EFylMxgs9z9Yf6NvtZt3eS7
bqh5Xu4y18tttzZB4tHYXCf3qaf5f3vCx+HmMv8uqiK+x2ZPalrLXFbEPLfeMt7pKOS5nu+EZuke
a5YXcvlus3kChdSZUSxby/f47GlE5Oi2fwesc6ZZ1qOO7zZKWNdd5GScBb+gWU6OTD3Deq289Vub
5S713e5lUTyeHtbyQROMnm9d75+oU94LvEPkHzbL3GJ+rmR+lvnOvjHPy7kmqlpYt2kfZfaodfk5
hBQApGJIFTBvlBvMm6e4zglNQuidy0pms5b5ovJY68lh86vNm3JBEz57zPpyqgmZF+s6a3n/PFKC
fVoKmVNKJs1bbG5DJhqUU3bISVh3WPdNnO6EP2lpRSc0qd0v1vISAd7hw13M7dW1AlLmmJFJRYua
xyT34zuzrsxAL3PytLSiQz68ZLLNhWaZJSaevAlH1/puQx6Df9deN/NBM8Dcvx/N9fIh+LR5XraY
/3qH30sQyXm6tluPTSYrrGZ9oCvzwbjcXL/F3E+5DZmBXE7Bc8hc18LE1Sbr9laZ+9EkCUJKtgC+
Zl4P7/Ftc0Jz91Q0y/Qz11e21sttQna1+flU8zyut25DgrSCFc7rAr6YKBNKXcz/2/dDLrtS+6cT
moDRu3y5uTwcN5q/rUVmefn/kebv2AvDXdbrL/8v80Z558WUsyzMNc/LQus2RphA+saEtjze98zv
+t/m98K7j+ea51ZOTr7TXLbS/H9rQgoAkjGkPjDfTG29b6GnmTc8+2Sn9c0bo3e+wA5mGXvg6CMm
ehznyKSco61v4zL5pJx/7aoYQuoT68PJMSF2yPz7jm/L1xkBj1XmypHJE2WMhz0vVR8TAt4pG143
H2oSC+eZ++7N2yIfnnOcI/PuVDDXv2RtiVpqtjZ5cy5V0X7pHJnMcq0JHjv2woXUcrPVoqr2K3PZ
f8wHn3wo/Woitbi5zeed9JMrdjIfcg2tkFpnBcY5JrxGmp/tXXveiVInWbd3mvlg/DRBQurlgN/t
q6wtnrJML2u9NuYD/27rsm+d9KeFKWLWu9y8NstN6DawtvjsMs9R6RhCyr+VVmJlppN+l69s+b05
zGPuZv6O3rTC6VFz2xJ7F5jXeq71d3Stuf7/rJCSn2USy/zW36Fc5p070961d6sJLXvLcy7z922f
E7SyCdStJrQIKQBIqpCSN+wffHqzA+czH0p1zJtfU/OhsccKqXPNh4+3FaewCQtvNmH5kB3vHDk3
lGM++Odab+DRhJR/XEYX8419vPm361rfrIPwzmN1hbW895jsM6tXMLEz1HyISlzktULKPpVEXvPz
LvPze+bDr65P2aL1hRVS/l094ULKnqT0WfN82B+sy01InWyW7x3wb8vlPa2Qqu/7t1eGCancvte+
rnktdyVQSP0U8Ls92grFmtZju8L8bh/yhZT8LbziHDnhby3z+y7R5Z2u6TTfv3+ZubxGDCHl3yX9
lQmfNub+ZXYUrcTPx76/gULmMeYzW5XWO+knrJStyLK7er8VUh/5vhS1zCSktvvuh3di9dvN/9tf
ZCSkhhBSAJBsIZXZGCkZE7PROXJal/tNUEyxlplottQILaxvwV5IjQ643Q+OMqSEa5z0R2O96aQ/
fUJQSIXTHn/Szlz2ie82gk4IepMvpMLdflZCKo8vpD73recPqXDaIVU6ypDytj6usG5Htuh8l0Ah
ldkYKXnND5plfza/27t8IXWKud7bfTvb2krnhZT/wIwzsyGk5DVdYD33v5voOSlCSE2P8FhHmK2T
fq71hZT/FCtZDakeAf/WRkIKAFItpGTszGbzgd3Q2prxvi+k5E1Wxh1daYJBBqAXOA4hldvcr4bm
2/Z680HYKUJIdbPWsbW/yffV/mbCpViMITU7zO3XOA4hdU2Yf7tkFkJKtsBsMK+rdzvyfE9IkpA6
z8TJNPPYvC0+G3whJYHzqNlC1Nk8P6cch5ASKpr7Ntr8bv8e8DtASAEAxHFIeWOkmlmX1TUf4FN8
y8oA6hvNB699clv5kJVdDvYRZvXMG3K4kJJv3XMzCan6TvqTdXrIQO9/Rgip4b7L5QNsoHNk94xs
jTpsokTiRk4ufEKYkJLxMm/7Qmqxk3HCQtk90/U4hNQjAY9bHlvtLISUN0bqcmtZb6xWMoSUN0aq
iHXZueZ1uNu37G0mGPwnEPdCyj8A/P5MQqpHFCF1XcD9l8H/WyKE1A9O+iNqK5rXv7gJqe1O+nPn
FTTrHYuQkgHreX3P7U5CCgBSLaSqOKHxUBI1Zc0HqXd2cX9I3WwiYZGTfvfDJeY2Pja3Ibv81pg3
YC84/jDfliubZT42QRQppHqZD4BRZp2yJirkqKKeAY9FtrCMMfdlsLXOc05oXFNJsxXtHfNzOfNt
/S/nyED01eZbdVOz7qvm+uusQJSglLE2FcwyMvh4q9kCcqxCSu73g+Y5G249NtmSIgPsy8QQUr+Z
dU80j2W5dXuLzW0kQ0i1M78/z5jHdo6JFBUQUhIk35rf21usy0uZ+JAtRd3N7QwxsfWY2VI10PzO
3WGu72W2emUWUivMVqj6Zr365ucVER6z3I9/Wa/XPPNvn2L+tmS3rByFeba5/kXz+3tTjCE1xjz2
oJASBpnn9mnz75xnnls56KISIQUAqRRSghwyvc288R004SEDvBc66QfZ1jLfiIcH3MZFZkuHN95D
3oxPt64/w4SUd718i49m195tTsbxQLdl8nge9C0vR8H1Nd+knzeXFbCWf9JsUTjDhJR8oO4wy+1z
Mh5t1cTEknf7m81zVvwYhpTHPb7HNttsRXGiDKk2ZouiMq97M/Ph7d3eBPNYllmvXyKPkeprtj4q
E7vPmZiY5mScIPVe83zXCbidab7n3T+/2Gjruh+cIwc4RAqpqla4ei4xl4ejvol4b/lfTMh7lHOO
HP2pzN+//aUjmpB6wjkypixcSAn9rOdWXGA9p4QUACQN5zvhB6/anGU+WL1pA3Kbn/0TQtb2RUjQ
bVzopN/94HG6dX1+82Ho7VKUAexBRy3lsdbxzJPJYynkW76UuTyXdVluXyBeaG2Nk117zc1l50T4
QPNuq0nAB5P/KK/K1hYrxzyvFzrpj3qq7WSctNT/vOTzPbZyvq0nFzpH5rPykK0T1ayfm/qelzMC
npfznCNzK1U39yOeKGLub/Eolm1jlvWiq5j5uYhvufxhIsoxcWo/7wUj/M7J65jX/H8Z8xr5f+c8
avhut0YUj8f+O2oacH1V6/rzfNc1cDJOHVLCLFvI99y2NnF1bibvL96/Zc/FdYK5rChvwQAAqUXQ
YHMAAAAAIKQAAAAAjh1POUdmxgYAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAABIGP4fA/avjDBRcuUAAAAASUVO
RK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2009-07-17 07:49:27 -0400" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-001.04" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of 3 trials comparing patients experiencing any adverse event between any transcutaneous electrostimulation and control (sham or no intervention). Values on x-axis denote risks ratios. The risk ratio in one TENS trial could not be estimated because no adverse event occurred in either group. The plot is stratified according to type of electrostimulation.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAssAAAFgCAMAAAB65cRZAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAdrUlEQVR42u1dTcslt5VWv7k9p02cpPHbJsEOBGNoCORH5Adol0Vg
9tkH8heyN8xfyHpgFvoDWWWTzTAGQ4ND4hgbuvPGw+B4WsTYubdKpW+ppLr1oVv1PN33rQ9JRyrp
qVNHqlPSI2IAsAvcoQoAcBkAwGUAWACnRsrBu78iFyEXKIqiObmJtJAKSTNeusnQ3nOrhYv1ynVz
RT41c1eJ6cG8uinO9etRt1rIvJd+Lo7IhOXuQRS5OS4bljHR/x8qovtrzjoh/cn+5i+ttE6AYBEh
Vn5bXfuQtafLVB10ZRTNcLqtIrdqL3fkPNeBqgRhzrohl6OOmWclISp1ayiE9WeqJc3IDZW1z4vu
6lQZtyxhy0VuRy/3nOVccSppaIi46XFNTYkWLl0zIDQ/BWuGui0XuR29LC738fD011WWrI8ghDdi
SU66dNvSdM13IZq8uhaL3JqNwd1OWE/wNPV3QWXrqSJE2FtSNhWKfGNcNibsBM1c1QqcN0hprgnQ
nFFxA0W+a6hSbHp1fV9h1VRAR+7ayqKCnSp1KCQie1UtF89a9H1eU8ZNSth+kR816Vt02wYDcHS9
DAB71MsAAL0MgMsAAC4DALgMAHPC9sdQA4GeI29ufGxIMR5zDDn/ZS7KEyY8mWvFF0rtX3kJ63To
0euI1y/IdGiyYGP1Lobq52o41w6aZ1Dztkprc5krx1Neca2Oq+p1EHm2ppPZNcFnEl8qdTwbP63g
XDhNP6EKjf+1GPgRBs3TKLdU2lOkEbXHqfYV1tcTcfAVzMTUUXuHYPNqyHVLHrk5TNoK72TjLZuO
Wy9+ROpw4/PIlbIhq7K2ssuk2eOcDKqOhw8O7jtnLYQmS+vYy+qlo2M1cK88nkMx9x/X3CSK+ALz
opf2Ee/kMffXPkKZJ3O5+BKpxnvX7HF9saWNpcXbVegUNFZ1fCOvkjZLe+c+HsPcRMbrKUghxh7o
uW/2uHazj0XnTBTewXHPjGvF1/h7KMEiaRQ5BozxDUlWYcqjuycPX5Ant1TaU2hfVF4pW8JeDq3M
ig6C/zSZR3xUarldn6/DAvGuFWtdUtdbr+nmXMvtVkt7ipW0/trmr7KYfqj4nG928TGpoldSygNs
8i0tOBd1XXmx4ae27Zb2zrOWAzWTGzWxUnBHNfGU1uIFt4aIlGYmh8GFxXNeoqKHHvUULd8n4tw1
erjruDrrA/yGSnvnWoTKGBqGAIWnrDwvVCuFGJ7VwklkPIWtCGl7OZqN9k4WY+asyHgyTxI/KjVW
NW6llTy4jLevfYJliyW84PWcr5stbZmfXFWG3ojkVDE3i/T1h/EmCd/sqhov7amIyXXmUTszkmxk
UBZdP6g8N+C/DAAAEMMvNsv5BL0MzIvNGAWfT2AvAJeBvcAdx4jPp6udoLTDnnGPcj2YAaARLvPM
nn5lZqbcZDN7MAPAXFyOvaAqecEIJgPN2cuRb4JGv8fgHJUINMdlUaRzlWODcdEFm4EG+36hWs6w
e5jzbsM3qwCQsDEs3Vvinqm2IDLQqF7manbook+9MSEn0LaNMUJf6+NwwQ/uFAe0A/jJAfNiu84T
3mED++77AQC4DADgMgCAywAALgPgMgCAywCwBpdlOpqUMtxkU8wNnWdZvNLopeIHoXLRS5Zercp4
HJlOu2aTtIayd9iSup+7WZfKQ55VJZ1NfH+ly19zWZnxrrbYxuiUj2Tml6+8hXVVHWiR1jYUk8vy
iKTbBjJ41sj+7PnP5a/zDJKyxRbZVC8X6zTZ1XytCrxFrEVlrw2oz8551qhz3QlG9jNI7R6jRQr1
Mg0aQna/sVZsrtJMY9/iXSMLrQsyLQXLI20vyyrOHLm3sQiZKWWtywRf5cQGPIqNUdIpkebRdxC1
vJGuN52AaDMEDXBQDX2X7LZfFIRWErE6JCJVa0eh8oZWhswPmQatcETVfAoq4Ny7COqz6zrT8JRz
H3aR6Au1cFF/tC+p2swufi0yD+Xpbkmv2v3bdGiAy7a5i1kT+K4EmBf4rgQAwGUAAJcBcBkAWkQw
z6e9rrtvy/NYoJogo0/MneXtzML1q/UHrNKIeeUOC/WJBcvurqYWrTWemINHT5N93MlK7pzaEOHK
ijy6a87o1em71E5NmqDVVrxVWVo5z3eLXC5QLH8nZqp7uFcxt86oXmaDThtu/X4F70H3clsNm+iu
orbUSXdKL7e6DgRbRHfyyGUu/XDhZr5286jpTnbNInQz6RbRD0t2zKmkHHvZXxG7NxeEUnP9rq27
vTWleanGuT2sRQ1uHi7CMNQ8aoS9LgHn/ZL0qkWUopn/oXSDXA7mUo7Px5yibF+BfJTVK5gZs2tQ
sZJaFqP2kxNVOC1yeMvjzmXjuAL1m1NVparms47gYtNavfE+UHSdjcHK4EUtctjZ3U8+MSupbMYw
WuHCglRe/gaJdiyEbhsuigp1UA19F72bKwYflNLQiU119zYH3w+VN7xD+eW/KFfp/PD2Mu8qTA8Q
C3XUU9XadW02rnqF9pKAxvwQK6sKtZwK57fZnMLUm148cTiyTsZ6MIJbBvQRVfN1fnKldYbp84+D
W/WTE7NHBIBtuFzKUVAZaJ7LAAAuAwC4DADgMgAuAwC4DACrwfLHUJNchBPIjc2bssq8KgvP+SAx
H9ueuNz07JALz1151Kkxd29jmLl/nYl87WmZ+wA1CXAQEwC21cuujiJ/dnn7wJnylybMQw8A6/b9
YhMiSpuzNBIbADbVyyzoDoYHMqQ4uAw0zGV3Zl/K6WDYGEDTNkaggKU1b/vhp/sF2tfLZp5fZ2pl
24zwTIou5rI2xsIZwEbaHZfJ+0vDf8uuoFiU5YlANy0eaMDGAABwGQDAZQAAlwFwGQDAZQBokcvS
+uvuFUJG3q2USowsxignFgMAl69GaiXnyckB4Fou+x7MtouylL0Ts+XBbEcz8Tt6ykCin3YQoXyj
LXFMh8A9GhhH1Lco9GA2u5f/zPNgNu7L5zQypmONxCDtsBnihbnisw+gmsuy7PFvL38dEuxCZ3u1
bEoKo6gICiIAQDWXST/px+ktC+3iGJlH7QV5ld0NgMsxbUtlHbUqDeq6RRdFgIYGpo9jyHElmVDN
niYmmZIeH3OTQQSoZmCyXnY8mLVZ2+8qn2bX4dc6UkSWXqCWyLSIbms2Q1wKIsC9GCjBpHnxR4YU
CkccQtYDO8B28+Kfqnk8ar2CnMBtcJlmiOHEA/OBhft+AAAuAwC4DADgMgDYXJY9vAjDC42qVxWh
I7P0JUh3Bz7OwLUonH/5ynE22xXuOtkY9QBqbAxpORErZ2XPlZklZmMOHY0HIZ4HdO/qrOgJH2dg
Zr1s60ntREyDW7LtVMwyszG7etbxhLb9nS+n4OMMrNf3o5FzwWzMhVzynOxkOgZ8nIEr9LJ6yFf4
80iW7LkVubrBxxlYiMs03hdMqdnA83jqzPnwcQZmsjFkoZqLzMac15cyGgc+zsAietk4KhuXY5bx
WGauk7PDSyeR5QHdyYWPMzAnHrXd/PBxvjls57+Md9jAzu3lVgAfZwB6GQCXAQBcBgBwGQDAZQAA
lwFwGQDAZQAAlwEAXAbAZQAAlwEAXAYAcBkAwGUAXAYAcBkAwGUAyML9Dpsz4e3x808MO0wHWzGj
yaMxEl81nk+PSUtFAYAEl3mwd2EQVxw8/+XXfGTL06fFeEowGajgcoRsIqotuVHVwtqIgHp2DH5R
r/2JyGn1n9k/5kVhQ2oBJQ2M2MtixBoIWH0hltlw57wfQ/TyuzPhaWVIcOHcUVzYUbRgLxYA+HpZ
pCibZLNwgkSGYGI8vQijJTgLpQyM9v0iajlmOmjq9oE8bRnn1KdOn9f90MDAFVweHuSuVhaheuS2
jRDTm1mqDumzVEYTAVPs5Z4/F7O0YyjnqcEyHdGkcZUw594e59GMKsc8AKCGywHjXBoKrUpFz0az
cc/HYiQShvraFqXNZpGlP3B0PMJUbcCswDyfAAAuAwC4DIDLAAAuAwC4DADgMnAUnFAFwDz4ui0u
h0vkRVcjG1YqU+vx2Ztucb8F3r8Uy3ULVZMDjYfGpZosmVcxhUvXGrG+qIuIWCjF06oWICaPuFzR
yW+w8qX0VGx3M7TE3CiV65am9mYZCY1L1WcpKIOkIiprsYEoRmGoUwr7wIpER1yB9uTrHpKkdSzZ
2kgO66WOLVS21MKSRXJpoazlaJaSZitH4kope85exXZZziQcv/4rHyxW5bKuCEkxZTGomjEVtiWV
l2FrGTmsR7+ME7zmIUGTEy1uX4irgtfjclch5DQh+Q1qmr3FtX2lMVoXkZ7Mkuwljy/mVrdidxWz
hjW9kxaSpHDhb8vEsKwQjGP0XQ2vxW7L9rJ4NLfST0mloafg3vXEaplldTpKzOvos+O4jo+nZG0l
jsYY0IiJUVsKWZRDtdSZ+2BrVvjt4c57wlnjbUnNLJu2MCY9SoiogKhyziwnjKlkqbz50/PUoxG9
rM0151maOpLKuO4TkWzi8bZoaeJS3SwlmWjK2CkUK+N1aULdCh/GmKQxqxpqhy2A70qaRubRV/Ju
ZwvguxKgztxYJtkO+35AO4My0/qhh3zaQi8DsJcBIMDXWz7yoZcB2BgA0G7fr+/8ajdFd1jHceAN
PHYX7cpnXIcz8esKNiI+65yt05o8ZZX/sp/Qkuj7L2sP5bDgJrRoVHvfXFb+A9EX+44Db+hmuySV
7ZzL49ffLyNjuUnnbJ1WumUo9l/2E9qloZSHcqTg1ubw/su6aqTWz9rpLFY5q4zHT3NpmNkRgsau
mea5xKHqx7R3pmRrvyRx6/k7yRBancs6X/2g7ndoyoN5ZhrVEIMWu7Pi9UAxSrLq7wfoGkNo8tdh
M7bP1+uyN8fljCuhd7dJh/M3j1EvhpwBmvDrnOC/PJJdvL49/2Vi8F+OdEESzaM3DV7P1A85xhiQ
c0OmROXV+y/ns6MSBXng9wWnOka0X2FySbUkqShnaWw02erdu0PcjdWKTBkYbTqwlDkiX9fBGcv5
6jLIitO+/7I8LpdPdlVpI5hZjswRs3IDV9mF8xoRnw12A22FUOi/HKRM+C8HjtIM/ss24I/RNOC/
PNHGAJo0/1dMth97GWjQ/B8bt6hOtyxev/P7X7/7GjYGcOt4fP/VK3b/8MMnf34CLgO3zOQfyL+p
3WffffjnplxWi+jpI+Hb8jwWqJYW7hNze3U+NqzNJ9brD1ilEfNKVWKFHyIimepFCUVJV4g7qYwY
PqxsKOxCeJfG/Sx1M6yMH3/1uX340y+/WJvNd06tiHDhSB7dNWcuqVQ1C289YRO02jqqKksr55nQ
XRwPpPJopsOeKL9R4mUX7pX07eMUwkssunKuT+TH73z/4zOV79XhefvRX3/+9k/WLYT/3k/0d/qw
aPvlDh90L7fVsInuqgdLe3enhFYUNwyu9aTHkvHLGlfL4aqz2UKMFmCDpWkfP/3eR2cCP7CH809v
//Bwf//mX7Yax/AWreZCLd3e3/T9rq27uZuYV7TYrbFZrfjtX+MctBHVhYgpk+3w6NmXn56pzB6C
38NnL9764yZcFj6bRbTiU5TtOc5HWb0olloyW93Avo0hxlXuaGWIYtUaKYRoQS1/c58O+/bjbfSy
EAUK1K+rYfl1MVh0XGyoLOY3lJm5uAk29qTKiNMxX4i0jlkc3/79rae8t5X937vvf/HLrexlUU1l
M4YBzGud11sqfBu1zNgn7IMP//HqYidfTAu9feONTzYbx/B7x0UU5dzVCqaz09sce+B51UXYkbmo
TxVl4zlYxXA3buh2z8Offf7y/cdq/6Ev01P5al0qs+8Yxfzi+Rnn+jhvxfPz38voQ3f04oUO6Hcv
gS+6FC+6VKJP3NXl+dTzPnQ4dzl6vlI1m5I+n7FlM1IvF+cGn8/EKiODroJ0qufs0g4vXNkm2KpU
P7FQh2azIn77f6//+3//Zzh69m//+R/frN4Jveq9Hy8eQm2gv70vYyOv8jeq8Ne/+82r8+btN/+0
xTvs63yLxOwRAX8gZBqVt8GTX718j/3ovZefbUFl+GMAc99/8F8GAHAZAMBlAFwGAHAZAMBlABiB
Mz9GB3s2VH8vjoW/XzfzwdJi4pk89OxVu+MytbySanzq49nES8JkVru0MaSUakKcbs87zUzAOU40
5vxqczH1r6fsBvakl+3mlUSS0jOwD/tdnCDmrFiWyiDxUfp+8UmFZWLu6xunBUyMHerlwJiMHMiQ
4lBxQMNclmSzlnI6ePG+09JqE2p53zZGoIClvWQay+hpWBhAC3p5sBcuvTprcS3bjPBMii7mTdsY
EgPMe+MyeX9p+G/ZFRSLsug838v2LGkH/VagxMYAAHAZAMBlAACXAXAZAMBlAGgF9picXs/dOa6A
v2Cu5xFtTnqCzdhudH1yPd6tMslKSPgj968wKSiv3os7SMdLJu3l/NKlkQyepFtx+WpQeCyjb7tD
Spn7KPC683zwKCsh448sE8vUM70mejRJpGRkx0uWpvsPKm9tY/gezLaLsuzXZ7U9mO1oJr4vz/g+
F7avoaV6/SjHJUSd+KJlqteYFL8TJPjasF4OPZjN7uU/8zyYjf6iYTVzSqhNvfC5jGryJHfIMmFy
Eow2dzyftSOJlYgSrE6UzLZQLrKKrgc034rLskwlkUybFT2dKZeajbM4X4gSCZ7protM2adA5n22
FijjpYpVROftjffjm3BZt5Ucp7dkZXdBSfACoLlTkMXPCol+dxhYu+9H4y1MFUSQYf+oxMYYeVjL
KaQtSJSNQlWpJElQbPtxjMzQnIybmWQZkynNLOsVJ6W+JaRqCpclorpbavKDAFiDy44HszYI+131
lHUdlq0jPQocWI7JB7RKfelP6Tys8bwC32g3gX9i1DBIjpzlSpah9VDgPh1YvhImzb8s6ZrgubKZ
UUJtTphOI43t5l+uflcii6zjG0PlKw3Q+Lbs5el24WwNTetJoHqx4HNrgG8RAC4DALgMAOAyABT1
/aLexsaVsurVBAX+Ov5Aq+1rxKo8mmt8jRmcLg/J5dyY6ZWMyHklVPgN67CiNGriDpD5yDaGtHyS
lbOy58rMErMxh/MwD0I8D+je1bnuTpnwlQtwUL3sKTj7EwrPlZllZmN2OeR4Qtv+zrYHcM7YsK2U
CEOzaYbXzuD0Ybk8ogpdRwtyP+QopA3FFGiFP/KIr7FZ3gQ8PjiXlbIrny1QRnfDYzndFqhxMR1c
mdC64DKN9wVTRAs8lStmzp/ijxxPAxaDy2UDD64KJF+5yqze9ectsP2eJxSfMooe9gW47Lrqakok
PZaZ6+TsuAo7iSwP6E6u+pg0Mlqc8htmE32NgSPg0c219BRfY2A9bOe/fHvvsCs/oQOVD4Mb9Meg
BWMD4DIAgMsAAC4DALgMgMsAAC4DALgMAOAyAC4DALgMAOAyAIDLAAAuA+AyAIDLAAAuAzeC1+/8
/tfvvt4m70fwVQdmw+P7r16x+4cfPvnzE3AZuGUm/0D+Te0+++7DP7fkMu/+6i8PzTeIXJ08n+F9
jC6q4Jd9Ha0POsfd6uNFPpTMbGaTzNTFBVLjmQ51YdfPSMFZKIa7efJoIbifpW6ZlfHjrz63D3/6
5Rdrs9myl4Xof3b7eS3KLxH6Ou1iuw0yVCXfiMqmFFZh5oDorjYmNZ7psCcq7pRo2YWbpxDCL4SX
WJV0dSI/fuf7H5+pfK8Oz9uP/vrzt3+ybiFO8bq93Nnc1wGBora0d3dKaK2wEZWDks6q9EU+03g6
UVXwTNlVpYuxAvANmPz0ex+dCfzAHs4/vf3Dw/39m3/ZdByjv8NF/3y0dIBTbZzziuZZBWu0IPeJ
ItYsuKp0pxCbTUZhmanPvvz0TGX2EPwePnvx1h+35LJTyynK9hzno6zejsrzqqdBKYoq/V9UP6JY
tarc7UKIFtTyN/fpsG8/boTLLFRDXNWmMt+4aEEzMNZCk8bM7En1Ey+7ENPUzuL49u9vPeW9rez/
3n3/i19uai/nKlVs1bPblsqr3hnTMlMts8k9/An74MN/vLrYyRfTQm/feOOTrcYxyuxFRwWYnk1v
c/B9Utm++qpYXNTLjpb9HKxiuBs3dLtH0c8+f/n+Y7X/0JfpqXy1LpUjXBZ956Ib4bGrTKgwoaM4
HT373HZ1qkvBF7DjRdj382pMjzWE9TOx7IHQRCFUy2yHJ59+8eG/66NnTz/4/9VfllS89+PF46Vt
mtA3h2xF5pm7URu8/t1vXp03b7/5py3eYVfYGGL2iMAom6dSeSPl/KuX77Efvffysy2oDH8MYO77
D/MvAwC4DADgMgAuAwC4DADgMgCMwPLHUOszDYN01uqTI+N2Cy/VpJYBZAuto6NWz8QqPXvicqPr
OpplguVy4iUWtdynjSGlVOuhdnveaWYCznGiMedXm4upfyUUNN6XXrabVxKpJbElOafd/S5OEHNW
LEtlkPgofb9IQ5O0SUU7ogVMjB3q5cCYjBzIkOJQcUDDXO4sh6jepYgKX1axLa02oZb3bWMECvii
fbXNzDJ6GhYG0IJeHuyFS6+uOwjNCM+k6GLetI0hMcC8Ny6T95eG/5ZdQbEoS/Jg4VEz2kG/FSix
MQAAXAYAcBkAwGXgyMC3q/vHxPHGm0hmp4NeBvaCU0DxKxzTlJOROe43rhgZnLHGdqX27qQgWImW
lJWQ8EfuX2FS6p7uhYZDc/GSWReZK41k8CTdistXg8JjGX3bHVLK3EeB153ng0dZCRl/5KAo0gki
Fk8SKRnZ8ZKl6f6Dyltzudc+XWsoRurdi7ZRfhp9gKVIL0dSxw8U1dDGpW8mrOcESVvRZSRI60Wl
lX1XYI9XVtQpt6pxhm3+TYvccbIxLocezGa3J7UXoPUXDQShhNrsPfnJ/lykiDtkmTA5CcRChqn7
0Hxr5b/rC268uLlhPRsksaLraUMt77rvl+CyLKsNW5+FJaDwwRpzc6bpTVIiwTPddZEpWymZ99la
oIyXKlYRbHhOAavbGLqt5Di9Zc0DYn03Opo7BVn8rJDod4eBte1lGm9hqiCCDPtHJTbGyCNITiFt
QaJsFKpKVW2SA0uMY2SG5mTczCTLmExpZlmvOCn1LSFVU7gsEU2y6hpWvrTjZHa6U5w+lgezNgj7
XfWUdR2WrSM9ChxYjskHNOlhDpOHNZ5X4BvtJvBPjBoGyZGzXMkytB4K3KdrgOXBMHne8JGxWVKW
7MQVz1HiRPTjT3qHLWn2q1lGjqRlcrqx6TSCYfJ8j9QZra9+Xzbh3pV6cH+MWXbEIH71O2x5xjpU
XvMpLFe+yRog9zIXOl0rXx+x+r0fzRBjYRNqggSqF3vLfKbFWoA2bCX4FgF7AbgMgMsAAC4DwBJI
z7/s9h3rhlqCN7cyGGi1fY1YlUdzja8xg9MliwyTl0bfopTFESk/vhx7Uzw+tD7O5YhXgh8eBKY8
mrW33FiaaUUHdmVjqLmUzTTM9hTLcvB2j83GHM7DPAixAwe5MnMLxW7HyksDiY9rY3gKzv6EwnNl
ZpnZmF0OOZ7Qtr+z7QGcMzZsKyXC0Gya4VEETh+WyyOq0HW0IHc25kLaRL/QqPBHHvE1NsubgMcH
57KsM8Udf06ZDkq5MRfxrcbFdHBlQuuCy+ZLiUK15n5tJJOso4I7orKTGU0DFjPGL3/mWmY9t167
CXNizZC/m+v4mvGnsoGItAokX7nKrN4NxxYkXcFAyij6g9sXYmNZYvUrvovxs/OEUxvNTXIc5Owj
a588JzonkRFMZkBEdp53MloEGRQm49KWSnNwSnPOeyXJ1b4+MGe8eOd/XJ/qj5k66QWEYq7IPyZ5
THpGL5NnYzBvpmUW/4CUnN3IpM3uJM1kdxQpo2/9NHkbIp/mqFQW5uls7/eH5ky/J7hQp6xAleRy
hvkBXRJf8MT8Y5JZXvqoXm4cR/M1vkohqye94BE2iKQtIFLxRDyamCV/EStAjaVyur1GogVj789e
zj6ezxxz4wmbcjzbr8yeqM9/oXEMYGc2Rpbwir0iZJ4o7dZlMinOf5m+H7AzOvv61rCLRyI6p4tV
M78+f37thUIv79zS4D09rSe6dco84/u9M+NE91Px4qrZC7j00kwm0/MXEclVhgjmEgdidsEtAjYG
sBdALwN7AfQyAC4DALgMAOAyAIDLALgMAOAyAIDLADAF/wLoOVRysKTmBgAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2009-08-04 09:20:16 -0400" MODIFIED_BY="Jenny Bellorini" NO="9" REF_ID="CMP-001.05" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of 4 trials comparing patients experiencing any serious adverse event between any transcutaneous electrostimulation and control (sham or no intervention). Values on x-axis denote risk ratios. Risk ratios could not be estimated in 3 trials, because no serious adverse event occurred in either group. The plot is stratified according to type of electrostimulation. Data relating to the 3 active intervention arms in <LINK REF="STD-Cheing-2003" TYPE="STUDY">Cheing 2003</LINK> were pooled.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAs0AAAFwCAMAAAB0LbaFAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAexElEQVR42u1dO6wkRxWtmTerekIstvVYvIttGQKcAQEOQEgQICGE
Sk4sgYRICCAmIoCMCCIyRIwICDACqQJLSAgnGCdIyBCAvBICdm3YXbFmDd7SvveG6e76f7qre/o3
0+fsvume+tyqrjp9+1b1naoVJQBwJFijCQCwGQDAZgAYDJuZ1IOVn7wuQV0kz0rmlMbTQlpI6vXi
TZH2mdswjI9ZswOr8mY29xXvHs1ad8WufT3ythbS98XvKsRr4uruQ1R5dmw2PCO8+q8aovw0oU5M
FVjd/rmNVgrgJCLEKm+6q1eFe/pMtkJZSz4bVs+rynO1m0t67tpANgI3oW5M8a3k5k5N8Jb6NRRC
qpDWknplhyzcZ0Z5fbKW09ZxvlWej26uWMuYZFXS3OBxA2SflpqHGarvWB6aoZzMhrxzrvJ8dDMv
7mRlA+gmS7ZHEMNmYk92vHjb4nQNec5neX1zrPLcLA3mDscqiqfJfyRktp4tnIfjJmlbocoHxmZj
ynbQzq16gbFZkpppCszOtDiAKq9n1Cg2wcpRMLdaKiAkc21m3oKfMncoJCJ7ZE0XL5xX419Ty4nq
OPcqr2bpdXToZgOwdN0MAMepmwEAuhkAmwEAbAYAsBkAhoHtpyGnBT1H37rZMpWjOWUT6vybGc/P
mPB0bis+T2oVUXmW6IjQ49cpQL8007HJqjW1PFcdwOT0rh3VzyTnYdXWZjOTbqmsxbU6jqz7gdfz
NZ3NbgnWk/hcqTkF+bk5Y9zp/A6NaDy0uWJIGNVPtxxSbTeRbtT+qNqXWF9PxAGYE5NSJ60chs3L
ItdtueH2MHlbeC8bX9p02vbiG6Wqm59FrpWowvJ6y66V5o8TGDQeCx8fzHfcGgizrK1jN8sXkY7t
wLz6eA7HzH9oM5Mp4ivMsl7lR7yXm5xjqwR5ns754vOkGu9ec8b05eZ2ly7AbkSnqrHGYxP5m8yz
tmv3ERmWxmv8oYIcvOmxXvfbPqYd8WPJGeGZ93DcY2Nf8bydnxKvuVy/Gsx4jSQbMeXzXdGHDciU
Q6rtJrQyWl4pGcJuDm3NFgMF/4nSj/io1DYWfn0rZhVgW7PWRZUj9zYDnn3ZPdfabmI1bX9t/TdZ
TEO0+Nlf7+LjUnmlqKR3WOfbmjPG2w3r+YQ/y51vbdee1RwomroZFCsHc5QTS+ktlnFz8EhtenIm
HFi8JZZlVKPhYctqSmDMNX6Y69ja62P8gGq7di1DaRKpCUHuKSzPR9XKwdUTmzuZjCexlSBtN0eL
0d7LvMms5TWezp3EN0qNN47bbDmPL+MNbAeQ2opxL3o89+zZ1jbPh65Vgd78ZFcxB4x0C4TpOgmf
7KpmXttNFpfbGUnzWcFkMsMyqwVA5r4B/2YAAIAUXpys5A10M9A3JuMUPEKB4wHYDBwP3DkNx4vV
9ddlZrROLMcp18MZAGbDZmc+3AvTr9HMcp2kZw9nAOiPzcxX0STv9Tq4DMzQbnbd/hqoqvw4GBoR
mCGbbd8CnvwFmHR4MA684DMwy1FgjungGiF9ejgDQI+WRitwo8YBYKZs3hkO0nbIMCFgZQCztzRY
jducNprLhRHY4h3mgPkAPnRA35huGIU32wBGgQBwIHYzAKRwPmcKQTcDsDQAAGwGALAZAMBmYElw
B6Si+oWicF6piNgLFpUydhgE2bKr6rauiqCdpDrhJloH0EbJ3tX5ogoR6djq3KQ1sYLQhbNZRNue
Jjp39xc9DEPmXNmiXXI3W2upItIaToCgWWSO5FQl0dpYzV8/loqF6+aygarWF5YKqPpE6ZqqFaM9
NAdlILr1YkO2VLTonTM0pylp/LmSk3dvL7FfZIhsv9DsIJaGvteppwJ0wNzveDpINtq9NEFHuIMn
IE6NyOn8NDZ5vaQDjDKKteEijbWam6B4lrVtFJm8IVecwSqTWGg3bPYwJmN3gQCdo8+51m3YqSmX
3v6burueTvsEPQaIYUZjduuHPbHYvlm7D8agJURCXcftDGBvmuZNsdC6R+lyFc3Gs/NsfUz96dXK
DqwaroyTKdzDUCZoG9nDVCUl1b1+QU3C6pxmChY02pRBrGx9h7VB7BLR+rcnsDDGNlU6dsVAHZXh
ETq3OY2axyDIPB869zqCP/o5jdgQHRh/WqRLd1CwGQAOmTDwoQOOB2AzADYDwLzZXDMMFkKEh1EH
zrrMvHS5yXPFK6Fi4EsWXruKeBqRzrvkl1h5Rn3Cj3lMMue6vXdztW5KL/Q8gRjhQpuB2aVsS6NU
QIKYvwZ3LjEjbUAH6W1DscFfHmm/DtkLInjiiCp091F8Ok8iIebYJ5Pq5vyfeWjHjmN/QTgemb1e
oJHfnFDL55w4jujaXW8JfZKpm6nSEaL8a+rH2TWaOGwf3wanO9fD0fnRCeyPTXo0kfv4hetc33Sm
Kbs95U4kOnbhUiyNnMGJMI+/hajmyfS9GQ5EOyLogoVq6XVyCE9LH0Oa7kZKqfnlO+yMoW0NUT+F
GvTD0n+zLecvjBezFRFxZzZtP8Kv3XMdlpXrL5mDP/ReF2uvbeI1vH+rqi7QrtR0oR7OWFsf6BtY
Wx8AhpnTAIAkrtz46YsX2/PtBVmdrDZkszp5nZ7C0gAOB8/+/IUdgS8vn3/1HiFn96pAc7y2/txv
/vfYyerk9qNpLQ2wGUhp4d9/Yfvvq4Uevpuf6QNf+8lKvPyl9ZuPpmaz3GpYf+O+Tc9ikXLDwCpz
uc+gTlZF7dKOd7dateF9S43vPM6s8kyxOgdvVlV+LhPAVLE8dXFWnZxY1vH6H77x0RuX3/jh5eX1
P+zXZGfr9Wpnhqx+8K0/n07BZtkt3CUsC/ntRLKKrzKEFcRV3SeDZaKRyMztSvUr1WsDTSceFqsC
7OZolp4Sk4p2OsOLbXX5V54kF9tH5HL7T9+I6ON4tt6Qk3ee+Bn95NAK2x8Fcq91mdG/zFbFJnnI
dIvMMpSPtYExJ1H92Y/UBJmbbgXec+2jD4cOl/7HL/79+td/dPnVl2/dFVTaw/LvXs/H4u/+53fH
j9/eDR0fPLH6F3k0OJu9vtppFmbudXla0N3w1VdSffTp3kbBqIOQfm9UWftuF5GT66F4/Mb2u98+
J8+/+hFC/vodQr5fBN8b6a8yX+4XlX1tZ4acnKx/+WKPlsjaveedXeB5VDGkNornpd5mpZAJ95Ln
0r7t2bgxT/N6RRkxids0h6y9uoj62vjnWZd+8ymyvXm52t68N+0Yk2/JdkV2dRlKN1d0bLbymKub
mPucK2xFRqbGIGTuYqIM0Rz1tamNLfXg9wr9SN/+2Pn2nBT/7py5hsZwf596bX1SDA7/RE8fVBX6
Mjkdhs1m3N6mqXgPC7YfCJkZ4bO7uIgln1nJx/TZ9rlXXrg8f/ry4kLauqVh0N/x2uorr/z3vY/f
2ohfBWX3CsvSsB6ILHOEo3JZ9ofR7ZWqH5fpjM1AM9vXnD9e2OVStWe1QtWtxeKZO1z66d8+cevN
O3fu3X/wzvbh6fs+9OOnrl9nRJkiHY/XNjc++MyzH379ubv0P2+/dPfdt/6xfTT0nEZsvlnPqjEz
xUHsUz3lxrg9cJFzdGY0ouebRx0EJmeG9xJKUrNe4Xyz1WJOczTVmUfmmyNCGXG6wJqesy99/xv6
yu/e+Ob24jO/vrzMf3tytv7sb0/evbra3J787clwSmsmj+iDA+s+TdRnkz+8+iQ5f/s95EK9UvHm
ld+/ITtr+KVPP/OX01Hnr3pmc27FGci8z4RdJzIPo0Cu3ChdjrYXd86efqsY0K1vbx6czqW34acB
9H4Pwr8ZAMBmAACbAbAZAMBmAACbAaAFLD8NuShGuPBc00oro6zEMvQKEdg57rjYPOt1JYde9RKL
6R2rpWFWDnaWAbaXda4i5BLCQcrDAzTzselmVw1Sf4V6+4uzYDDtsJb93AAyH/8oMLaUorBZS8EI
YN66OWVNihozkwqwGZg3m911gWmdHqawPYF5WxqBEhbWyu+LXywYOATdbFYJdpZmto0Jz7AoUw5r
acCUAdqymXqfVP23rAsaSzI80+iBywdmYGkAANgMAGAzAIDNAAA2A2AzAMydzcL6dM8yISJvW3Il
RjZ3FB2rAYDNPSC1P3Tn7ACwP5t9D2fbhVmIysnZ8nC2k5n0JUFFINHPq0RI32lLHNExh+4+DYyD
qNdR6OFsTov/xPNwNu7NuzwipmeNxCCvOqh0Yank4N2ngQnYLPKMAHtb7ZBiBaHtXbhpUhiNiqBB
AgDowGaqn/fNBBeZ9nGMzo1Wg9jL/gbA5rgqpnlDtlZa1HWbzkoALQ3sM6chmhVlQj172piKlPT4
DJwIEkA9A3voZsfDWZu31an0eXb9ja1vksrCi9QSiRZRHs1BpaVBAng3A3notH5zw/RC5uxDyHvg
KDDd+s2b1kxutGJBT+BQ2Ex7SOGkA/eBwUeBAAA2AwDYDABgMwDERoEiOipT82itRmu2I5HK7kkw
jkbRUlWIkJHCXlhaREeP9px0Kb0MwAzLMtlc56e2JydEDatoRLzxmZOstJzoBG3Ko94k2n57wFIt
DWE5GUtnZs/VmSRWcw4dkZUQz0O6coXOu1dAR6C9bvaUnK3aPFdnUrOas8s+x1Pa9ocugkLrImpA
0Jqv8TzC8VnF3bBkNntWQF2Y58uc/SokStAWpNMvJGlzOmDZbJYKL9/TR6T5k+EG10F3Zr1ad9aE
BJbKZto8KkyRK/BMbrH6fspq6JDHjBUBWBq1kxCERIxSaz+2Wt1rrO4gugv5aCIQPyQEm4ltYjgu
yaTGo5m4TtDO093JZHlIV0M1auZIaKwKgoZykoO6VB6QejlYHVxft2Un2Dw2pvNvPrw32y1HdiDz
gnCAfhp0wNQA2AwAYDMAgM0AADYDYDMAgM0AADYDANgMgM1oAgBsBgCwGQDAZgAAmwGwGQDAZgAA
mwEAbAYAsBk4Sri/2WaEy+MOXJ3pE3lqp4xmT6RI/PpxF9wkLZUEAJJsZuaUG0YxycLdJ9vn57gs
Hcybc4LLQCs2s1Ar8qjGZI7e1gcekM9OwQoVWwVEguV/Yv8RLwlRuTkUNdBoNxuKMMYydC0vqGUO
zAn3U/BKfhkSBktzgnFHhTNuJ9GCvVQAELLZ0nfc8KVGD5b0iuYPwHljfh6KKPgdE4Z+A5pHgRG2
xAwImYrJSJa2kOtUqM5fr/+hhYG92ByfWOAh6ZltKcTuhlqyqvxZpQNAO7tZmszq8c5YaupMRXOT
x1XExkAwsiIF8ZbzHwDQjs3KXOV6PMi8OO6kMgfu5w5SJDKGxXPHbuZqApxBWQM1WGGdNqBnYI1Q
AACbAQBsBsBmAACbAQBsBgCwGQCbAeCw4fpphJsRR7d0koFqQ0H7ENn8rx+02CeZJiveWfzAF5eu
fOwyUluTqm6hYLNqh/y2kKndg+T1IL2cVzVhffYlfuCLa1QfAfAGt9HSKBuy3I5PiPJTMUN9E9W3
hhadg27ouQ50vIvT2yGWre52gQkTqj+scLtvhBBLZPMm1nPC2ana+ib/j0mk9jwWA+qu8S6uanHq
dIETVvUEtZ6LxgRZ6jbj/iiwvKndfdyDXd3pXJg75k0y2qU27FVLnbNED8FuVg0iAuPwkB5aQ5GO
khHpTBODAZoaq4rGgKVaGupBlfjWRJ2p1bUYsgqTXRx1rMD6/lqwll77zzgz+5a81cWM7QxK6QBd
Oa6qi9saorYaIqjmEtXzxm9GOa9htWjqm6hmYWUmKgbVCNOKH7j0aHFqGp+a8p0wN3019hXKkBbL
VM/47QnQN/DbEwAAmwEAbAbAZgAAmwEAbAaANrDnm9XrUzlp585qSncW36V5tGnN3BlUt4a9iXcu
f8jLhH9zT2yWE/NRHxahG8ry2Rpxhj7XK8yvYU/iRatK7E/nJuAtQY6lUb3xFwUq9yNR08azfLM9
IcX6uQD4N/ejm21K6CdedUL3evofPCa4Svg3783mSAvQ6DNX/0Rufm2mfBXEQNKHV84078aCf3M9
m+sHH0S7t6jDTPWooJ6nVI9WAJ2GzvBv7m5ppDUuPRQlQA9Ian7B8G/OHwXGh3opM2OeCmDQqo10
wfBv7kE3C2MME8vR2W9nSkZyaSaRknPTta1aXvqxLhj+zR0B/2agb8C/GQDAZgAAmwGwGQDmDHu+
WW7Kp79x36ZnsUi5YXGVmdm7/RG11x8fb1xg1Yb3K1WK5cPWnjsb2EbbrWxznsi87P1v105r8HAr
ShY9NSFM7zBf5Pa36Fby2GhkLotkJHIle6G8ONa31MR9k25wdb9iD9BG3awVENfbwRfKVulfZqti
k9xV1pZCKYOq8wPf+l1rPTKW3rMa3HvglIFlx3DdUbpi+pE5Xk3nazd7m2EzLjeFr1RddWrrb1eR
MJarcw6Qz3InccbG4LHd4P4Dxzz/iu4p1YvuE6lsBng0HR6buc/n2N3NSapDqwZk4/R50iAYaCtu
yY7hScIb7SgnKXf6ZPH2x9rtsmYl6pNFbezOlXnJ+IStOoxWGtVMZdFHg7Q1WFafJBMuy27mrcls
5jOAfu4cltTYlVWR0ydL1dLr6P3cYiJCqg2d2TR3ZXkcA9NncBG7KjTbUGzp2tn2OjKzqtagWU5x
EPtUxlTUlXOwahhdjUTsoTWzp6BHmQwYZL6ZjzBVEGvwoHh3QsPpEztgQnOPz4HNHVu/x3TAMeBQ
feh47wkBYCo257IUZAYOgM0AADYDANgMAGAzADYDANgMAJPAWU+jhHqd0riMF8mN7wUDrxAhsIrb
cbF51utKDrzq5VIX1VyApWFWDnaWAZbBxETIJYSDlAAwtW529RT1V6i3vzgLBtMOa9kDwNijwAg9
qbBZSxtSA8DEupkEA8PwiwhJDjYDs2azuy4wrdPDsDSAmVsagRIW9gZspEZXA8A8dLNZJdjZGcE2
JjzDokw5rKUxcAGwlI6QzdT7pOq/ZV3QWJLhqUAPWjwwC0sDAMBmAACbAQBsBgCwGQCbAWDubBbW
p3uWCRF525IrMbK544w32QSOXzen9ofunB0A9mez7+FsuzCLas9X28PZTmbSlwQVgUQ/rxIhfact
cUTHwH0ayEHU6yj0cDanxX/ieTgb9+ZdHhHTs0ZikFcdVLqwVPw0BOjAZpFnBNi7mocUKwhN7W9J
YTQqggYJAKADm6l+3jcTXGTaxzE6N1oNYi/7GwCb46qY5g3ZWmlR1206KwG0NLDPnIZoVpQJ9exp
YypS0uMzcCJIAPUM7KGbHQ9nbd5Wp9Ln2XUItr5JKgsvUkskWkR5NAeVlgYJ4H4M5KHT2voN0wuZ
sw8h74GjwHRr629aM7nRigU9gUNhM+0hhZMO3AcGHwUCANgMAGAzAIDNABBjs6jgJVCvOFq9vAgd
nYUvQbgn8IEG9kfm+s17zrrZbnL7ycYMCNDO0hCWk7F0ZvZcnUliNefQEVkJ8TykK1doSVD4QAO9
62ZbV2onY6rclm2nY1KzmrOrax1PadsfugiCDzQw5iiQNoQFqzlnsslzwBPpFPCBBvbSzfJR38LT
R5DkGC7LDQ4+0MBgbKbNo8KUqg08k7uuvg8faKA3S0NkqrrIas71OlNE08AHGhhINxtHZuOSTGo8
monrBO0w08lkeUiXcuEDDfSL1bwJAB/oA8R0/s14sw0cvd08F8AHGoBuBsBmAACbAQBsBgCwGQDA
ZgBsBgCwGQDAZgAAmwGwGU0AgM0AADYDANgMAGAzsCBs0ARAG1y58dMXL7bn2wuyOlltyGZ18jo9
nUvlVnCEBxrx7M9f2BH48vL5V+8RcnavCjTHa+vP/eZ/j52sTm4/KgKm+yUV2AyktPDvv7D999VC
D9/Nz/SBr/1kJV7+0vrNRxOzmZWf+r4ydxiTgbsQVqUok3JWnOtkVdQu7VS3pqwmUxXkfYomSal2
eSaBag27hRqkR8phUkgi2u00J5Z1vP6Hb3z0xuU3fnh5ef0P+zXZ2Xq92pkhqx9868+nU7DZ0NY7
NzRhFV9lCCuIq/pKBstEk5C5qhRx6tjbfWJdfVhskEAF2C3UID1WjtfeiWpEY1td/pUnycX2Ebnc
/tM3Ivo4nq035OSdJ35GPzm0wt4kVAWzVbEEjzHdIrMM5WwiMkceML2Cp4utqxhvWwBvVw3ZG3mZ
Lfzxi3+//vUfXX715Vt3BZX2sPy71/Ox+Lv/+d3x47d3Q8cHT6z+RR6Nw+byxmbVPV48uAxfQ0W4
fwf2yDU2/L0Uuex+y7MfMH3ULrQkxOM3tt/99jl5/tWPEPLX7xDy/SL43kh/lflyv6jsazsz5ORk
/csXe7RE1vVagCX6ipd6u4hkbBJV3KjX+rR3ynbg+rKb9LWnutu0kCwgLCeqjr1zlav20m8+RbY3
L1fbm/cm7q8t2a7Iri4DWxpuqzFXETGXOYVhOA821/R3P3ZzlwfOQC1Uf3G1saUe/F6hH+nbHzvf
npPi350z19AY7u9Tr61PisHhn+jpg6pCXyanI7E5bBeeYykeG5lnfXGRYWnmpT+mz7bPvfLC5fnT
lxcX0tYtDYP+jtdWX3nlv+99/NZG/Coou1e0e7PNmGt/GH1VWR7sqMmce3l2unyNvsslM0bLMYFq
ionFM3e49NO/feLWm3fu3Lv/4J3tw9P3fejHT12/zogyRToer21ufPCZZz/8+nN36X/efunuu2/9
Y/to6DmNyAydnrfkel6Zq44xoxQ5R2eGHnq+eap3QdZ8c98zG+3mm5k1Scwypn6DXNZ8c0SoHu1y
f3rOiu3hhr7yuze+ub34zK8vL/PfnpytP/vbk3evrja3p3570pfCO+qn/IyeMfVKo89eeHj1SXL+
9nvIhXql4s0rv39DdtbwS59+5i+nk01ptWVzbi0ZyDzgjGA2mYfRKVdulC5H24s7Z0+/VQzo1rc3
D07nQgD4aQC934NYvxkAwGYAAJsBsBkAwGYAAJsBoAUsPw25z5+1OXtwFsco+58NvRsgNnE7LjbT
OXepGLh22AX2WC0NIcqNiYU884KJidiliaY8PEAzH5tudtVgsW+woxDtL+q8TBOkPECAzMc/Coz0
MRU2aykYAcxbN6esSVFjZmLLdmDubC7th6jupRE1DtsTmLOlESjhQgNr2xlTAsD8dbOyGorxXfkl
NCY8w6JMOaylAVMGaMtm6n1S9d+yLmgsyfBMowcuH5iBpQEAYDMAgM0AADYDAH7lugx0fBVwENns
fNDNwHFaGsL6dM9y75LI25ZciSKMFR2rAYDNPYDGOLpPdgBog01KUVJSessJ6YKhT4moXm7rCBmo
vgmdviSo9R5cSiReXiVCuYUYceobGf6XJ0dvOB9xtiY2hx7O5rSitReh3ZupkK/CaUpikFcdVLqw
VHLw7tOT46hHgQk2i7zWoKKumahWzI5yjgijURE0SAAAHXSzMgNyxm0i8yERo7NocbthJAjsaTfT
5kcU7f4kc92msxJASwP7zGmIZkWZUM+eNqYiJT0+AyeCBFDP05jNh5HNzreJWweWh7M2b6tT6fPs
+htb3wT1TXo7uRwqVhSXkxl6TkOfewng3dzLpIY3PVQ76BKxdVWGHM7Zk135Cf30nd5sN1Q382pC
3gODkVlPCun5ojreWHNIorUaER0Uj9C6rolbdsIgfeu3J2IH2vutCUxA72H0bHfNvH/CTf/WDW0n
CdyfsyVNB5PcKQ/tOAoEgOOZ0wAAsBkAwGYA2Bvp9ZvdUWS7aRfbkUhl9yQYR6NoqSpEyEhnAlRE
BwT25KPQs5GYYSkbS7kt5k3dm+RT1DI7Ia2fb475VDRPtTezWYSs8uODSGc1dHsCVMqqyyOI74UH
LNXSkGsxm2Wc7SWahXr1HFvNOVzHWQmxI5VcUXMT1d9iANBgaXhKznZJ9lydSc1qzi77HE9p2x+6
CAqti6gBQWu+xvMIx2cVd8OS2WzbJw1hni9z9jR4lKAtSCeIs4JYbTpg2WwW7UxyhzSijk+iL0si
69W6syYksFQ2m1fOmUSjrmWR5B3NuCdoK64n8lTZFm5hsOKjrw3c63aCN3FOqh7Kd0tt3o1+kzcp
kZ4qoT7pRK3uDadIxD6/m6KJQPyQsEcmd5XFR7/idYyhpZecPGh2Usd5zv5mnVPhu+pbAUYwNZMj
ovTKE9EqiIicpPGQyrN4UjPGKkXJ5Ln+YkK8dLt/TAdV34kM9CJCMXuUH5PcJL1GN1PP0iDeSs0k
/hNV6pxGFn12F3mm9pCR1uhcP0+9xeLXF955+vmsntH2efXVhFRnnHEZZEXKLEUI8SPKLL7gjuXH
JJN66Y26eeZoObJbsGquNFrFAs4ifOBJi4Cn0vF4Mt5L+TxWgTb2yubwOokOmPoY7ebah/SOZW46
bpOO1Y4wawPalz/QnAZwdJZGLeUlf3nIPZ47wKspJLv8YUaBwNER2te5hl8sktAJzlbPbP/y2b4X
Ct189PYGqwhqPdetIPOkr852nOPln0wXV89eRDFeM4V0L59HJLcyR7AaORC3Dg4RsDSA4wF0M3A8
gG4GwGYAAJsBAGwGALAZAJsBAGwGALAZAPrA/wGiPtaMGfLtjAAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-07-13 05:49:23 -0400" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2009-08-04 09:20:53 -0400" MODIFIED_BY="Jenny Bellorini">
<APPENDIX ID="APP-01" MODIFIED="2009-08-04 09:20:39 -0400" MODIFIED_BY="Jenny Bellorini" NO="1">
<TITLE MODIFIED="2009-08-04 09:20:27 -0400" MODIFIED_BY="Jenny Bellorini">MEDLINE, EMBASE and CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-08-04 09:20:39 -0400" MODIFIED_BY="Jenny Bellorini">
<TABLE COLS="3" ROWS="5">
<TR>
<TH VALIGN="TOP">
<P>
<B>OVID MEDLINE</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>OVID EMBASE</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>CINAHL through EBSCOhost</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>search terms for design </I>
</P>
<P>1. randomized controlled trial.pt.<BR/>2. controlled clinical trial.pt.<BR/>3. randomized controlled trial.sh.<BR/>4. random allocation.sh.<BR/>5. double blind method.sh.<BR/>6. single blind method.sh.<BR/>7. clinical trial.pt.<BR/>8. exp clinical trial/<BR/>9. (clin$ adj25 trial$).ti,ab.<BR/>10. ((singl$ or doubl$ or trebl$ or<BR/>tripl$) adj25 (blind$ or<BR/>mask$)).ti,ab.<BR/>11. placebos.sh.<BR/>12. placebo$.ti,ab.<BR/>13. random$.ti,ab.<BR/>14. research design.sh.<BR/>15. comparative study.sh.<BR/>16. exp evaluation studies/<BR/>17. follow up studies.sh.<BR/>18. prospective studies.sh.<BR/>19. (control$ or prospectiv$ or<BR/>volunteer$).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>search terms for design</I>
</P>
<P>1. randomized controlled trial.sh.<BR/>2. randomization.sh.<BR/>3. double blind procedure.sh.<BR/>4. single blind procedure.sh.<BR/>5. exp clinical trials/<BR/>6. (clin$ adj25 trial$).ti,ab.<BR/>7. ((singl$ or doubl$ or trebl$ or<BR/>tripl$) adj25<BR/>(blind$ or mask$)).ti,ab.<BR/>8. placebo.sh.<BR/>9. placebo$.ti,ab.<BR/>10. random$.ti,ab.<BR/>11. methodology.sh.<BR/>12. comparative study.sh.<BR/>13. exp evaluation studies/<BR/>14. follow up.sh.<BR/>15. prospective study.sh.<BR/>16. (control$ or prospectiv$ or<BR/>volunteer$).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Search terms for design</I>
</P>
<P>1. (MH "Clinical Trials+")<BR/>2. (MH "Random Assignment")<BR/>3. (MH "Double-Blind Studies")<BR/>or<BR/>(MH "Single-Blind Studies")<BR/>4. TX (clin$ n25 trial$)<BR/>5. TX (sing$ n25 blind$)<BR/>6. TX (sing$ n25 mask$)<BR/>7. TX (doubl$ n25 blind$)<BR/>8. TX (doubl$ n25 mask$)<BR/>9. TX (trebl$ n25 blind$)<BR/>10. TX (trebl$ n25 mask$)<BR/>11. TX (tripl$ n25 blind$)<BR/>12. TX (tripl$ n25 mask$)<BR/>13. (MH "Placebos")<BR/>14. TX placebo$<BR/>15. TX random$<BR/>16. (MH "Study Design+")<BR/>17. (MH "Comparative Studies")<BR/>18. (MH "Evaluation Research")<BR/>19. (MH "Prospective Studies+")<BR/>20. TX (control$ or prospectiv$ or<BR/>volunteer$)<BR/>21. S1 or S2 or (&#8230;&#8230;.) or S20</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Search terms for Osteoarthritis</I>
</P>
<P>20. osteoarthriti$.ti,ab,sh.<BR/>21. osteoarthro$.ti,ab,sh.<BR/>22. gonarthriti$.ti,ab,sh.<BR/>23. gonarthro$.ti,ab,sh.<BR/>24. coxarthriti$.ti,ab,sh.<BR/>25. coxarthro$.ti,ab,sh.<BR/>26. arthros$.ti,ab.<BR/>27. arthrot$.ti,ab.<BR/>28. ((knee$ or hip$ or joint$) adj3<BR/>(pain$ or ach$ or<BR/>discomfort$)).ti,ab.<BR/>29. ((knee$ or hip$ or joint$) adj3<BR/>stiff$).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Search terms for Osteoarthritis</I>
</P>
<P>17. osteoarthriti$.ti,ab,sh.<BR/>18. osteoarthro$.ti,ab,sh.<BR/>19. gonarthriti$.ti,ab,sh.<BR/>20. gonarthro$.ti,ab,sh.<BR/>21. coxarthriti$.ti,ab,sh.<BR/>22. coxarthro$.ti,ab,sh.<BR/>23. arthros$.ti,ab.<BR/>24. arthrot$.ti,ab.<BR/>25. ((knee$ or hip$ or joint$) adj3<BR/>(pain$ or ach$ or<BR/>discomfort$)).ti,ab.<BR/>26. ((knee$ or hip$ or joint$) adj3<BR/>stiff$).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Search terms for Osteoarthritis</I>
</P>
<P>22. osteoarthriti$<BR/>23. (MH "Osteoarthritis")<BR/>24. TX osteoarthro$<BR/>25. TX gonarthriti$<BR/>26. TX gonarthro$<BR/>27. TX coxarthriti$<BR/>28. TX coxarthro$<BR/>29. TX arthros$<BR/>30. TX arthrot$<BR/>31. TX knee$ n3 pain$<BR/>32. TX hip$ n3 pain$<BR/>33. TX joint$ n3 pain$<BR/>34. TX knee$ n3 ach$<BR/>35. TX hip$ n3 ach$<BR/>36. TX joint$ n3 ach$<BR/>37. TX knee$ n3 discomfort$<BR/>38. TX hip$ n3 discomfort$<BR/>39. TX joint$ n3 discomfort$<BR/>40. TX knee$ n3 stiff$<BR/>41. TX hip$ n3 stiff$<BR/>42. TX joint$ n3 stiff$<BR/>43. S22 or S23 or S24&#8230;.or S42</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Search terms for TENS</I>
</P>
<P>30. exp electric stimulation therapy/<BR/>31. (electric$ adj (nerve or<BR/>therapy)).tw.<BR/>32. (electric$ adj (stimulation or<BR/>muscle)).tw.<BR/>33. electrostimulation.tw.<BR/>34. electroanalgesia.tw.<BR/>35. (tens or altens).tw.<BR/>36. electroacupuncture.tw.<BR/>37. neuromusc$ electric$.tw.<BR/>38. high volt.tw.<BR/>39. pulsed.tw.<BR/>40. (electric$ adj25 current).tw.<BR/>41. (electromagnetic or<BR/>electrotherap$).tw.<BR/>42. iontophoresis.tw.<BR/>43. transcutaneous nerve<BR/>stimulation.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Search terms for TENS</I>
</P>
<P>27. exp electric stimulation therapy/<BR/>28. (electric$ adj (nerve or therapy).tw.<BR/>29. (electric$ adj (stimulation or muscle)).tw.<BR/>30. electrostimulation.tw.<BR/>31. electroanalgesia.tw.<BR/>32. (tens or altens).tw.<BR/>33. electroacupuncture.tw.<BR/>34. neuromusc$ electric$.tw.<BR/>35. high volt.tw.<BR/>36. pulsed.tw.<BR/>37. electric current.sh.<BR/>38. (electric$ adj25 current).tw<BR/>39. (electromagnetic or electrotherap$).tw.<BR/>40. iontophoresis.tw.<BR/>41. transcutaneous nerve stimulation.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Search terms for TENS</I>
</P>
<P>44. (MH "Electric Stimulation+")<BR/>45. TX (electric$ n1 nerve)<BR/>46. TX (electric$ n1 therapy)<BR/>47. TX (electric$ n1 stimulation)<BR/>48. TX (electric$ n1 muscle)<BR/>49. TX electrostimulation<BR/>50. TX electroanalgesia<BR/>51. TX tens<BR/>52. TX altens<BR/>53. TX electroacupuncture<BR/>54. TX neuromusc$ electric$<BR/>55. TX high volt<BR/>56. TX pulsed<BR/>57. TX (electric$ n25 current)<BR/>58. TX ( (electromagnetic or electrotherap$) )<BR/>59. TX iontophoresis<BR/>60. TX transcutaneous nerve stimulation<BR/>61. S44 or S45 or &#8230;. S60</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Combining terms</I>
</P>
<P>44. or/1-19<BR/>45. or/20-29<BR/>46. or/30-40<BR/>47. and/44-46<BR/>48. animal/<BR/>49. animal/ and human/<BR/>50. 48 not 49<BR/>51. 47 not 50</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Combining terms</I>
</P>
<P>42. or/1-16<BR/>43. or/17-26<BR/>44. or/27-37<BR/>45. and/42-44<BR/>46. animal/<BR/>47. animal/ and human/<BR/>48. 46 not 47<BR/>49. 45 not 48</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Combining terms</I>
</P>
<P>S21 and S43 and S61</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-08-04 09:20:53 -0400" MODIFIED_BY="Jenny Bellorini" NO="2">
<TITLE MODIFIED="2008-12-01 09:44:45 -0500" MODIFIED_BY="[Empty name]">CENTRAL and PEDro search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-08-04 09:20:53 -0400" MODIFIED_BY="Jenny Bellorini">
<TABLE COLS="2" ROWS="2">
<TR>
<TH VALIGN="TOP">
<P>
<B>CENTRAL</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>PEDro</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Search terms for Osteoarthritis</I>
</P>
<P>#1. (osteoarthritis* OR osteoarthro* OR gonarthriti* OR gonarthro*<BR/>OR coxarthriti* OR coxarthro* OR arthros* OR arthrot* OR<BR/>((knee* OR hip* OR joint*) near/3 (pain* OR ach* OR discomfort*))<BR/>OR ((knee* OR hip* OR joint*) near/3 stiff*)) in Clinical Trials<BR/>#2. MeSH descriptor Osteoarthritis explode all trees</P>
<P>
<I>Search terms for TENS</I>
</P>
<P>#3. MeSH descriptor Electric Stimulation Therapy explode all trees<BR/>#4. electric* near/ (nerve or therapy) in Clinical Trials<BR/>#5. electric* near/ (stimulation or muscle) in Clinical Trials<BR/>#6. electrostimulation in Clinical Trials<BR/>#7. electroanalgesia in Clinical Trials<BR/>#8. tens or altens in Clinical Trials<BR/>#9. electroacupuncture in Clinical Trials<BR/>#10. neuromusc* electric* in Clinical Trials<BR/>#11. high volt in Clinical Trials<BR/>#12. pulsed in Clinical Trials<BR/>#13. (electric* near/25 current) in Clinical Trials<BR/>#14. (electromagnetic or electrotherap*) in Clinical Trials<BR/>#15. iontophoresis in Clinical Trials<BR/>#16. transcutaneous nerve stimulation in Clinical Trials</P>
<P>Combining terms</P>
<P>#17. (#3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR<BR/>#11 OR #12 OR #13 OR #14 OR #15 OR #16)<BR/>#18. (#1 OR #2)<BR/>#19. (#17 AND #18) in Clinical Trials</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>1. Electro in title or abstract<BR/>2. Method: clinical trial<BR/>3. Body part: thigh or hip<BR/>4. Body part lower leg or knee</P>
<P>Combination 1. and 2. and 3.<BR/>Combination 1. and 2. and 4.</P>
<P>1. TENS in title or abstract<BR/>2. Method: clinical trial<BR/>3. Body part: thigh or hip<BR/>4. Body part lower leg or knee</P>
<P>Combination 1. and 2. and 3.<BR/>Combination 1. and 2. and 4.</P>
<P>Combine all</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2009-07-13 05:49:23 -0400" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>